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Abstract 
 Fatigue was recently reported to be the largest predictor of poor health-related 
quality of life (HRQOL) in children and adolescents with Duchenne muscular dystrophy 
(DMD). The objectives of this thesis were to describe fatigue from patients’ and parents’ 
perspectives and to explore associations of patient characteristics with fatigue in children 
and adolescents with DMD using a multicentre cross-sectional study design. Eligible 
patients and their parents were identified via the Canadian Neuromuscular Disease Registry 
and received mailed paper questionnaires. Children and adolescents with DMD 
experienced greater fatigue compared to healthy controls from published data. Fatigue was 
a significant issue in children and adolescents with DMD across all disease stages. Sleep 
disturbance symptoms, depressive symptoms and functional ability were associated with 
fatigue. Physical activity level was not associated with fatigue. These findings warrant 
future research aimed at understanding the determinants of fatigue and developing 
therapeutic strategies to reduce fatigue and improve HRQOL. 
Keywords: Duchenne muscular dystrophy, children, adolescents, fatigue  
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Chapter 1 
1 Introduction 
1.1 Thesis Overview 
Duchenne muscular dystrophy (DMD) is the most common and severe form of 
childhood muscular dystrophy, with an estimated incidence of 1 in 3600–6000 live male 
births. DMD is an X-linked recessive disease caused by the absence of or defect in the 
sarcolemmal protein dystrophin, ultimately resulting in progressive muscle degeneration 
and loss of independent ambulation by 13 years of age. Additional musculoskeletal, 
respiratory and cardiac complications emerge in patients as DMD advances. There is no 
cure for DMD. Current therapeutic strategies aim to improve quality of life [1]. In a recent 
study published by our group, fatigue was reported to be the largest predictor of poor 
health-related quality of life (HRQOL) in children and adolescents with DMD, from both 
patients’ and caregivers’ perspectives [2,3]. Fatigue is frequent and disabling in adults with 
neuromuscular disorders, but not well characterized in children and adolescents with 
neuromuscular disorders, including DMD [4]. Fatigue may be a modifiable factor, which 
makes it a particularly important construct to study fully [5]. However, the pathogenesis of 
fatigue in neuromuscular disorders is poorly understood and consequently, evidence 
regarding the efficacy of non-pharmacological and pharmacological interventions for the 
prevention and management of fatigue in patients with neuromuscular disorders is limited 
and inconsistent [6,7]. To our knowledge, no studies have explored factors associated with 
fatigue in children, adolescents or adults with DMD. Consequently, inferences from the 
study of fatigue in other neuromuscular disorders and childhood chronic health conditions, 
and a more clinically informed conceptualization of fatigue in DMD were required during 
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the formulation of the thesis objectives. Identifying fatigue when present and 
understanding the determinants of fatigue may facilitate the development of therapeutic 
strategies to effectively reduce fatigue, and subsequently improve HRQOL in children and 
adolescents with DMD. The aim of this thesis was to describe fatigue and to identify factors 
associated with fatigue in children and adolescents with DMD, using a multi-centre cross-
sectional survey study design. The current chapter provides background knowledge on 
fatigue and DMD, a proposed model of fatigue in children and adolescents with DMD, and 
objectives of this thesis. Subsequent chapters provide a comprehensive literature review on 
fatigue in DMD and related neuromuscular disorders (Chapter 2), followed by the methods 
(Chapter 3), results (Chapter 4), and discussion (Chapter 5). 
1.2 Fatigue  
The feeling of fatigue is a universal phenomenon and can be a normal response to 
physical and mental stress. However, fatigue is a frequent complaint secondary to physical 
or psychiatric illnesses, and is consistently associated with decreased quality of life and 
functioning across patient populations [8–11]. Fatigue may be acute and come on suddenly 
or be experienced more chronically. In the case of neuromuscular disorders, it is generally 
chronic, however, acute episodes of worsened fatigue may occur and be severely disabling 
[12]. Fatigue is among the most disabling symptoms in adult neuromuscular disorders, but 
not well studied in paediatric neuromuscular disorders [4,5]. This is worrisome because 
fatigue has different implications in children compared with adults. Fatigue may limit 
children’s participation in age-related recreational and school activities, and consequently 
delay physical, cognitive, language, social and emotional development, which are already 
problematic in children and adolescents with DMD [4,13]. In clinical practice, fatigue is 
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recognized as a common symptom of paediatric chronic health conditions, including 
neurologic disorders (cerebral palsy, multiple sclerosis, fibromyalgia, epilepsy and 
traumatic brain injury), cancer, postural orthostatic tachycardia syndrome, juvenile 
idiopathic arthritis, diabetes, inflammatory bowel disease and obesity [14]. However, data 
on the mechanisms and management of fatigue in paediatric chronic health conditions are 
limited, with most studies focusing on children with cancer [15].    
A major challenge in studying fatigue is the lack of a commonly accepted definition. 
Many studies fail to explicitly define fatigue, possibly due to the assumption that the term 
is known to all. Among studies that have defined fatigue, there is a considerable range of 
definitions [9,16]. Differences in reported prevalence of fatigue in neuromuscular disorders 
may be due to different definitions and assessment methods [17]. In 2011, an expert 
workshop was organized by the European Neuromuscular Centre (ENMC) to achieve a 
consensus on the definition of fatigue in neuromuscular disorders, and to discuss possible 
interventions. The definition of fatigue proposed by the ENMC workshop reads 
“Subjective or experienced fatigue is a lack of energy or the existence of weakness or 
exhaustion—mentally, physically or both.” [17]. In addition to subjective fatigue, the term 
physiological fatigue or fatigability often appears in the body of literature relating to fatigue 
in neuromuscular disorders. Physiological fatigue or fatigability refers to difficulty 
maintaining physical or mental activity at a desired level and, in the case of physical 
fatigability, appears to be related to muscle weakness. Physiological fatigability occurs in 
a short period of time, while subjective fatigue may persist over several days to weeks. 
Subjective fatigue and physiological fatigability are not necessarily correlated. Figure 1.1 
describes a conceptual model of fatigue in neuromuscular disorders. Subjective fatigue and 
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physiological fatigability both have a physical and mental component [16]. Subjective 
fatigue is assessed using self-reported or parent proxy-reported questionnaires, which can 
be unidimensional or multidimensional [8,14,16,17]. Physiological fatigability is assessed 
objectively in a laboratory setting, using exercise protocols for physical fatigability and 
reaction time protocols for mental fatigability [9,16]. Physical fatigability can originate at 
the level of the central nervous system (upper motor neuron) or peripheral nervous system 
(lower motor neuron, neuromuscular junction or muscle) [18,19].  
The focus of this thesis is subjective fatigue. Subjective fatigue often overlaps with 
sleep disturbance symptoms, such as excessive daytime sleepiness, or depressive 
symptoms. Fatigue, sleep disturbance symptoms and depressive symptoms can occur 
independently or co-exist and exacerbate one another in chronic health conditions. It is 
important to distinguish fatigue from these other entities, as clear definitions in the research 
and clinical realms are critical to accurately describe and measure these constructs, such 
that interventions can be more specifically targeted to achieve satisfactory outcomes [4,19]. 
Fatigue implies mental or physical exhaustion, independent of exertion or amount of sleep, 
whereas excessive daytime sleepiness implies a problem with the sleep-wake cycle [4]. 
Depression is characterized by a general lack of interest in daily activities that are normally 
enjoyed. However, this motivational component is unaffected in fatigue. Fatigue may be 
disease-related or induced by medical interventions [8]. Understanding the contributors to 
and factors associated with fatigue in paediatric DMD is essential for comprehending this 
complex symptom, and for ultimately developing effective therapeutic strategies for 
reducing fatigue. Additionally, it is important to differentiate between disease-related and 
treatment-induced fatigue. With the surge of novel therapeutics for DMD under 
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development and clinical investigation, it is important for fatigue to be assessed both as a 
potential marker of efficacy, given that an effective new therapy might reduce fatigue as it 
improves motor function, or as a possible adverse effect when documenting safety 
concerns. Moreover, the value of patient-reported outcomes in understanding the impact 
and efficacy of a treatment is increasingly being recognized by regulatory authorities, such 
as the U.S. Food and Drug Administration [20].  
 
Figure 1.1. A conceptual model of fatigue in neuromuscular disorders. Adapted from Lou. 
Phys Med Rehabil Clin N Am. 2012;23:11–22. 
1.3 Duchenne Muscular Dystrophy  
1.3.1 Epidemiology 
 DMD is the most common form of inherited muscle disease in childhood [21]. A 
systematic review and meta-analysis of population-based prevalence and incidence 
estimates of DMD was recently conducted [22]. The pooled prevalence of DMD was 4.78 
(95% CI: 1.94, 11.81) per 100,000 males worldwide. Among paediatric populations, the 
Fatigue
Subjective Fatigue
Assessed using unidimensional or 
multidimensional questionnaires
Subjective Physical 
Fatigue
Subjective Mental 
Fatigue
Physiological Fatigability
Assessed using laboratory testing
(exercise protocols and reaction-time 
protocols for physical and mental 
fatigability, respectively)
Physical Fatigability
Central Origin 
Upper motor neuron
Peripheral Origin 
Lower motor neuron, 
neuromuscular 
junction, muscle
Mental Fatigability
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prevalence was 12.57 (95% CI: 9.04, 17.46) per 100,000 males worldwide. Meta-analysis 
was not performed on incidence estimates due to limited data and study heterogeneity. The 
incidence of DMD ranged from 10.71 to 27.78 per 100,000 live born males per year 
worldwide between the years 1986–1997. Prevalence and incidence studies of DMD were 
limited to North American, European, African and Asian populations. However, the 
majority of data was collected from European populations [22]. The incidence rate in the 
Canadian population is estimated to be 1 per 3,600–4,700 live born males per year and has 
remained relatively stable over time between the years 1969–2008 [23,24].  
1.3.2 Pathogenesis  
 As an X-linked recessive disease, DMD primarily affects males. However, 
approximately 8% of female carriers present with muscle weakness to some extent and are 
designated as manifesting carriers [25]. DMD is caused by mutations in the DMD gene at 
locus Xp21.2, which codes for the sarcolemmal protein dystrophin [26]. The DMD gene 
contains 79 exons and seven promoters, which generate protein isoforms expressed in 
various tissues [27]. The majority of cases are caused by deletions (~68%), followed by 
small point mutations (~20%) and duplications (~11%), which disrupt the reading frame 
or generate a premature stop codon in the protein-coding region of the DMD gene [28,29]. 
Consequently, the production of non-functional or truncated protein leads to dystrophin 
deficiency in skeletal and cardiac muscle, as well as other tissues where dystrophin 
isoforms are expressed, such as smooth muscle, brain, retina and kidney [30]. Normally, 
dystrophin interacts with integral membrane proteins to form the dystrophin-glycoprotein 
complex, which connects the inner cytoskeleton of skeletal and cardiac muscle fibres to 
the extracellular matrix. The primary function of the dystrophin-glycoprotein complex is 
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to stabilize the plasma membrane, protecting the muscle fibre from contraction-induced 
damage. In addition to a structural role, the dystrophin-glycoprotein complex is 
hypothesized to have a role in cellular signal transduction. In DMD, the absence of or 
defect in dystrophin ultimately results in progressive muscle degeneration and additional 
clinical manifestations that may contribute to fatigue [27,30–32].  
1.3.3 Onset and Diagnosis 
 Children are typically diagnosed with DMD at 4–5 years of age, when their physical 
ability diverges noticeably from their peers [28]. However, the diagnosis may be suspected 
earlier due to delayed developmental motor or intellectual milestones [1,33]. Delayed 
speech development is reported in 50–70% of children with DMD and may precede 
concerns related to delayed motor development and muscle weakness. Although onset is 
before school age in most cases, occasionally, a diagnosis is not made until 8–9 years of 
age [34]. Weakness of pelvic girdle muscles results in a broad-based waddling gait, and 
difficulty standing from a supine or sitting position, climbing stairs, running and jumping 
[35,36]. Affected children also present with enlargement of the calf muscles during early 
stages of the disease. Muscle enlargement is primarily due to excess adipose and fibrous 
connective tissue and is therefore termed pseudohypertrophy [34]. In addition to abnormal 
muscle function discovered during the medical history and physical examination, suspicion 
of DMD may be triggered after the detection of elevated serum creatinine kinase or 
transaminases (amino and alanine aminotransferases), which are indicative of muscle 
damage [35,37].  
Confirmation of the diagnosis is dependent on genetic testing. Initial genetic testing 
aims to detect deletions and duplications, as these mutations account for most DMD cases. 
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If no deletions or duplications are detected, sequencing of the whole DMD gene should be 
performed to look for small point mutations [35]. In exceptional cases when no mutation 
is detected in patients with a clear DMD phenotype, a muscle biopsy can be performed to 
study dystrophin protein [28]. Establishing a genetic diagnosis is important for providing 
optimal care in accordance with disease progression predicted by genotype-phenotype 
associations, guiding genetic counselling for the family, and evaluating a patient’s 
eligibility for emerging mutation-specific therapies [28].  
1.3.4 Clinical Characteristics and Prognosis  
 In addition to progressive muscle degeneration, orthopaedic, respiratory and 
cardiac complications emerge in children as DMD advances [1]. Affected children and 
adolescents are also at increased risk for neurodevelopmental, emotional and behavioural 
problems [38–40]. Muscle weakness, immobility, reduced respiratory and cardiac function, 
and neuropsychiatric disturbances have all been reported to be associated with fatigue in 
chronic health conditions, including neuromuscular disorders [5,41–48]. Prior to routine 
glucocorticoid therapy and non-invasive ventilation (NIV), the mean age at death was 15 
years and in 90% of cases, death occurred before the age of 20 years due to respiratory or 
cardiac failure [49,50]. Improved medical management has prolonged survival with 
patients now having a possible life expectancy into their fourth or fifth decade [34,51]. In 
developed countries, mean age at death is now approximately 25 years [34,49,52]. 
Pulmonary infections and respiratory failure are the leading causes of death in DMD [53]. 
DMD is no longer considered purely a childhood disease, and fatigue experienced during 
childhood and adolescence may impact outcomes in adulthood. By limiting participation 
in age-related activities during childhood and adolescence, fatigue may impact 
  
9 
developmental milestones and consequently impact social, educational and occupational 
pursuits during adulthood [13,54].   
Musculoskeletal Complications  
Muscle weakness occurs bilaterally and symmetrically in DMD. During early 
stages of the disease, lower limb muscles are affected more than upper limb muscles, and 
proximal muscles more than distal muscles. Muscle weakness appears when skeletal 
muscle has degenerated and been replaced by adipose and fibrous connective tissue. In 
approximately 50% of affected children, walking is delayed until at least 18 months of age 
[34]. In most cases, children are unable to run or jump properly [33]. Affected boys report 
difficulty keeping up with their peers, and tenderness or stiffness after exercise, particularly 
in their calf muscles [34]. In addition to a waddling gait, toe-walking is a frequent 
complaint due to contractures of the Achilles tendon. During early stages of the disease, 
weakness of the pelvic girdle muscles results in an anterior pelvic tilt, and consequently 
progressive lumbar lordosis, an inward curvature of the lower spine, which can cause low 
backache [34]. Muscle weakness continues and loss of independent ambulation typically 
occurs by 13 years of age [55]. Initially, affected boys may only need to use a wheelchair 
part-time, before becoming permanently confined to a wheelchair. An earlier age at loss of 
ambulation is typically associated with poorer prognosis [34]. Transitioning to intermittent 
wheelchair use has been reported to be associated with fatigue in children and adolescents 
with DMD [3]. Upper extremity function declines during mid-teenage years and is 
followed by an inability of affected boys to independently feed or care for themselves [56]. 
Muscle weakness and reduced functional ability secondary to muscle weakness have been 
reported to be associated with fatigue in neuromuscular disorders, including 
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facioscapulohumeral dystrophy, myotonic dystrophy, and hereditary motor and sensory 
neuropathy type I [57]. In children and adolescents with DMD, objective measures of 
functional ability, such as timed motor function tests, were weakly associated with fatigue 
[58].    
Around the time of loss of ambulation, most children with DMD develop some 
degree of kyphoscoliosis—an abnormal spinal curvature in the coronal and sagittal planes. 
Following its onset, kyphoscoliosis progresses rapidly and can impair unsupported sitting 
ability, feeding and comfort, cause pain, and further deteriorate already compromised 
respiratory and cardiac function of affected boys. By contributing to immobility and 
respiratory and cardiac function decline, kyphoscoliosis may worsen fatigue [59–61]. 
Additionally, DMD is associated with reduced bone mineral density (osteopenia) 
secondary to reduced load and immobility, and increased bone fragility (osteoporosis) 
secondary to chronic glucocorticoid use. Poor bone health in DMD can further contribute 
to immobility by increasing affected boys’ risk for bone fractures [62–65].  
Respiratory Complications  
Onset of respiratory function decline occurs between 9–11 years of age due to 
progressive weakness of intercostal muscles and the diaphragm muscle [56]. Deterioration 
of respiratory function is exacerbated by kyphoscoliosis [66]. Forced vital capacity, a 
global index of respiratory function, is consistently above 70% in pre-adolescent ambulant 
boys and declines linearly with age during adolescent years [34,50]. Respiratory muscle 
weakness is associated with an ineffective cough, impaired airway clearance, pneumonia, 
atelectasis, sleep disordered breathing and ultimately nocturnal, followed by daytime, 
respiratory failure [50,64,67,68]. In neuromuscular disorders, fatigue may manifest as a 
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symptom of respiratory failure [69]. Onset of respiratory failure can be predicted by a 
forced vital capacity below 35% or an absolute forced vital capacity below 1 L. During 
sleep, intercostal muscles are less active and diaphragmatic breathing alone cannot 
sufficiently maintain normal gas exchange. Thus, early respiratory failure is characterized 
by nocturnal hypoventilation, resulting in oxygen desaturation (hypoxemia) and 
accumulation of carbon dioxide (hypercapnia), followed by restoration of normal blood 
gas tension upon arousal. The early respiratory failure phase can last for several months. 
However, when hypoxia and hypercapnia persist during the daytime, survival beyond 12 
months is unlikely without the initiation of NIV [34,50,70].  
Nocturnal and diurnal hypoventilation are frequently compounded with additional 
sleep-related breathing disorders, such as obstructive sleep apnea (OSA) secondary to 
oropharyngeal muscle weakness or weight gain associated with glucocorticoid therapy 
[71]. In young boys with DMD, OSA in the absence of clinically significant 
hypoventilation has also been reported. In affected boys, sleep-related breathing disorders 
may co-exist with additional sleep disturbance symptoms including difficulty initiating or 
maintaining sleep, sleep hyperhidrosis and excessive daytime sleepiness [72,73]. Bloetzer 
et al. reported the need to be turned by a caregiver during the night as a predictor of sleep 
disturbance symptoms in boys with DMD [72]. Muscle weakness and immobility may 
therefore contribute to sleep disturbance symptoms. Sleep disturbance symptoms, 
measured both subjectively by patient-report and objectively by polysomnography, have 
been reported to contribute to fatigue in patient populations, such as myotonic dystrophy, 
multiple sclerosis and cancer [7,74–82]. An association between sleep disturbance 
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symptoms and fatigue has also been reported in school age-children and paediatric patient 
populations [78,79]. 
Cardiac Complications 
 Improved respiratory management has unmasked cardiomyopathy as a major 
source of morbidity and mortality in DMD [83]. Premature death due to heart failure occurs 
in 15–20% of patients [34]. Onset of cardiomyopathy occurs at a mean age of 14–15 years 
and is a universal consequence by adulthood [84,85]. However, approximately 25% and 
59% of affected boys present with asymptomatic cardiomyopathy at 6 and 10 years of age, 
respectively [86]. Fibrosis caused by the degeneration of dystrophin-deficient 
cardiomyocytes proceeds to progressive cardiomyopathy, characterized by left ventricular 
systolic dysfunction with dilation [86–88]. Canadian Cardiovascular Society paediatric 
heart failure guidelines define left ventricular systolic dysfunction as left ventricular 
ejection fraction below 50% [89]. Because of physical activity limitations associated with 
musculoskeletal weakness, exertional signs and symptoms of heart failure are often absent 
despite myocardial disease progression [90]. Fibrosis of the conduction system, in addition 
to the myocardium, has been demonstrated. Arrhythmias are seen in DMD; sinus 
tachycardia is a common finding at disease onset [91]. In advanced cardiomyopathy, 
patients may experience atrial fibrillation or flutter, ventricular fibrillation and ventricular 
tachycardia [92]. Now that survival of patients with DMD is prolonged, the cause of death 
in DMD is increasingly cardiac-related [34]. Cardiac dysfunction may be directly 
associated with fatigue [43]. Evidence also suggests that cardiac dysfunction may 
contribute to sleep disordered breathing. Conversely, sleep disordered breathing may 
contribute to heart failure [93]. Cardiac dysfunction and sleep disordered breathing may 
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therefore exacerbate one another and further contribute to fatigue in DMD. However, 
because clinical manifestations of cardiomyopathy in DMD typically occur in young 
adulthood [94], cardiac dysfunction may have a greater role in fatigue in adults with DMD 
than in children or adolescents with DMD.    
Neuropsychiatric Complications  
 The role of dystrophin isoforms in the central nervous system remains unclear, 
however, it is recognized that DMD is associated with an increased risk for 
neuropsychiatric disturbances [38]. Approximately one third of affected boys experience 
learning difficulties [34]. Although there is considerable variability in intellectual ability 
among affected boys, overall mean intellectual quotient scores are about one standard 
deviation below the mean [95]. Working memory deficits have also been reported 
[38,40,95]. Cognitive impairment in DMD is not progressive and does not correlate with 
disease duration or severity [91]. Boys with DMD are reported to have a higher prevalence 
of neurodevelopmental disorders, including autism spectrum disorder and attention deficit 
hyperactivity disorder, than the general paediatric population [96,97]. Emotional and 
behavioural problems, including depression, anxiety, aggression and oppositional defiant 
disorder, are also frequently reported in affected boys [38,91]. Moreover, affected boys 
may experience emotional and behavior problems as adverse effects of glucocorticoid use, 
which is currently standard of care therapy in DMD [53]. An association between 
depression and fatigue has been widely reported across paediatric and adult patient 
populations, including neuromuscular disorders [12,44,47,98]. Depression has consistently 
been described as the strongest correlate of cancer-related fatigue. The association between 
depression and fatigue is hypothesized to be bidirectional, however, few longitudinal 
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studies have examined directionality [99–101]. Moreover, depressive symptoms often co-
exist with sleep disturbance symptoms, and may therefore exacerbate one another to 
contribute to fatigue [79,102,103].    
1.3.5 Management  
 With the characterization of the DMD gene and its protein product, novel disease-
modifying therapies are under development and investigation. Disease-modifying 
therapeutic strategies include agents to reduce muscle damage, promote muscle 
regeneration following injury, or increase expression of functional dystrophin protein using 
gene-therapy or RNA-based approaches [53,104,105]. To date, no disease-modifying 
agents are licenced for use in routine clinical practice in Canada. Current therapeutic 
strategies focus on prolonging ambulation, managing respiratory and cardiac 
complications, and ultimately improving quality of life. Psychological, educational and 
social needs of affected boys should also be considered at all stages of the disease [53]. 
International consensus-based recommendations on multidisciplinary standards of care in 
DMD were published in 2010 [1,64].      
Musculoskeletal Management  
 Glucocorticoids (prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day) are the 
only pharmacological therapy that slow the decline in muscle strength and function [1,105]. 
Although the exact mechanism is unclear, glucocorticoids are hypothesized to act primarily 
by reducing inflammation [105]. Glucocorticoid therapy is typically initiated between 5–8 
years of age when the child’s motor development reaches a plateau phase, and is continued 
indefinitely [1,26]. Long-term glucocorticoid use has been demonstrated to prolong 
independent ambulation by 2–5 years, reduce the risk of scoliosis and the need for spinal 
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fusion surgery, stabilize respiratory function and delay the need for NIV, stabilize cardiac 
function, and improve survival and quality of life [52]. Deflazacort is as effective as 
prednisone and associated with less weight gain, often making deflazacort the more 
desirable option in Canada [106]. In addition to weight gain secondary to increased 
appetite, adverse effects associated with chronic glucocorticoid use requiring proactive 
prevention and management include: immunosuppression, growth failure, pubertal delay, 
hirsutism, osteoporosis, hypertension, gastric ulceration, cataracts, and altered mood and 
behaviour [53,65].  
 In conjunction with a neurologist or neuromuscular specialist, musculoskeletal care 
should involve a physical therapist, physiatrist and orthopaedic surgeon. Active, active-
assisted and passive stretching is recommended to prolong walking, and to prevent or 
minimize contractures during ambulatory and non-ambulatory phases. Orthoses, standing 
frames and walkers can be used to prolong ambulation and aid in standing. Lower-limb 
contracture surgeries, and spinal fusion surgery to correct scoliosis and prevent further 
deformity are considered on a case-by-case basis [53,64]. In boys with DMD, physical 
activity level is largely related to musculoskeletal function. Physical activity level (over-
exertion or excessive rest) has been reported to be associated with fatigue, and exercise 
therapy has been proposed as a treatment for fatigue [44,107–109]. However, evidence 
supporting exercise therapy for the treatment of fatigue in neuromuscular disorders is 
lacking [110]. 
Respiratory Management  
 Respiratory assessment should be conducted annually during early stages of the 
disease, semi-annually following loss of ambulation, when forced vital capacity is below 
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80% and/or 12 years of age, and before any surgical procedure. To improve airway 
clearance and prevent pulmonary infections in patients with an ineffective cough, 
mechanical insufflation-exsufflation machines can be used to assist coughing [68]. NIV, 
particularly nocturnal nasal intermittent positive pressure ventilation, is the most effective 
way to attenuate the decline in respiratory function. When patients progress to daytime 
respiratory failure and require 24-hour ventilatory support, mouthpiece intermittent 
positive pressure ventilation may be introduced [53,68]. In a recent study, comparing 
respiratory management practices across Canada for children and adolescents with DMD, 
variations in the timing and choice of tests for respiratory function and sleep disordered 
breathing were reported. Polysomnography, overnight pulse oximetry or both were used to 
detect sleep disordered breathing either routinely, at a certain age, or due to abnormal 
pulmonary function tests [73]. However, the utility of overnight pulse oximetry alone for 
the detection of sleep disordered breathing in neuromuscular disorders is unclear. 
Moreover, the absence of abnormal pulmonary function tests and symptoms may not rule 
out sleep disordered breathing. Therefore, routine polysomnography may be the most 
effective screening practice for sleep disordered breathing and assisting in initiating NIV 
[71,111]. Effective detection and treatment of sleep disordered breathing may subsequently 
reduce fatigue.  
Cardiac Management  
Cardiac assessment should be conducted biannually until 10 years of age, annually 
after 10 years of age, and before any surgical procedure [64]. Data regarding optimal 
pharmacological regimens and when to initiate therapy to delay the onset of 
cardiomyopathy in DMD are lacking [112]. Initiation of therapy with an angiotensin-
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converting enzyme inhibitor or angiotensin receptor blocker by 10 years of age is 
recommended, however, it is unclear if earlier therapy is warranted. With further 
deterioration, beta-adrenergic blocking agents are added, followed by diuretic agents at the 
onset of symptomatic heart failure [92].  
Neuropsychiatric Management 
 Neuropsychiatric assessment should be conducted around the time of diagnosis, 
before entering school, and after a change in function. However, a brief evaluation of 
patients’ emotional and coping status is recommended at every clinic visit. Speech 
language therapy is necessary for younger boys with delayed speech development and 
older boys with impaired speech intelligibility due to deteriorating oral muscle strength. 
Development of an individual education plan is recommended for all boys with DMD to 
address learning difficulties, physical activity limitations and accessibility issues in school. 
Psychological and pharmacological therapies should be considered for moderate to severe 
psychiatric symptoms, and prescribed according to standard practices and guidelines [64]. 
Antidepressants have been proposed as a possible treatment for fatigue. Studies evaluating 
the efficacy of antidepressants to treat fatigue have reported conflicting results across 
different patient populations, suggesting that the association between depression and 
fatigue may be modified by disease-specific mechanisms [99,113–115]. 
1.4 A Proposed Model of Fatigue in Duchenne Muscular Dystrophy  
Figure 1.2 presents a hypothesized model of fatigue in children and adolescents 
with DMD. This model was developed based on the clinical characteristics and 
management of DMD, in conjunction with the literature relating to fatigue in other 
neuromuscular disorders and paediatric chronic health conditions. Sleep disturbance 
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symptoms may be overlooked in the management of DMD [71], and variations exist in the 
screening and management of sleep disordered breathing in children and adolescents with 
DMD across Canada, between centres and sub-specialists (neurologist and respirologists) 
[73]. Given the findings from the survey of respiratory management practices across 
Canada for DMD patients [73], and recognizing that sleep may be a modifiable factor, the 
need is clear for further study and consensus in this area to guide best clinical practices. In 
addition to musculoskeletal, respiratory and cardiac characteristics being potential 
predictors of fatigue in children and adolescents with DMD, we hypothesize that these 
clinical characteristics are also directly associated with physical activity level and 
functional ability related to activities of daily living. In turn, physical activity level and 
functional ability may be associated with fatigue in DMD, as has been reported in adult 
neuromuscular disorders [57,116]. Lastly, depression is the most commonly cited 
neuropsychiatric disturbance to be associated with fatigue across chronic health conditions 
[12,44,47,98], and may be associated with fatigue in boys with DMD.  
 
Figure 1.2. A hypothesized model of fatigue in children and adolescents with Duchenne 
muscular dystrophy.  
  
19 
1.5 Objectives  
 With the exception of the past finding by our group of an association between 
fatigue and poor health-related quality of life in children and adolescents with DMD [3], 
data on fatigue and factors associated with fatigue in this population are lacking. To 
facilitate the development of the best clinical practices to treat fatigue in children and 
adolescents with DMD, an understanding of fatigue from both patients’ and parents’ 
perspectives, as well as potential factors contributing to fatigue in this population is needed. 
The perspective of parents is important because it is typically the parents’ perceptions of 
their child’s health status that influences healthcare utilization—particularly when the child 
is too young, too cognitively impaired or too ill [117,118]. Therefore, the objectives of this 
thesis are: 
1. To describe subjective fatigue in a multicentre cross-sectional sample of 
children and adolescents with DMD from patients’ and parents’ perspectives.  
2. To explore associations of patient characteristics with child self-report and 
parent proxy-report measures of subjective fatigue in a multicentre cross-
sectional sample of children and adolescents with DMD.  
Hypothesis: Sleep disturbance symptoms, depressive symptoms, physical 
activity level, functional ability related to activities of daily living, 
musculoskeletal characteristics (ambulatory status, wheelchair use and 
scoliosis), respiratory characteristics (forced vital capacity, NIV status) and 
cardiac characteristics (left ventricular ejection fraction and cardiomyopathy 
status) are associated with fatigue.   
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Chapter 2 
2 Literature Review 
2.1 Background  
While fatigue has been established as a complaint in adult neurologic and 
neuromuscular disorders, the role of fatigue in paediatric neuromuscular disorders is not 
yet well defined or studied [4,14,17,19,119]. Moreover, data regarding the role of fatigue 
in Duchenne muscular dystrophy (DMD) are largely insufficient and lacking in both 
paediatric and adult populations [3,120]. The aim of this literature review was to 
summarize the current body of scientific literature relating to subjective fatigue in DMD, 
as well as diseases with similar clinical manifestations, particularly other muscular 
dystrophies and spinal muscular atrophy (SMA).  
Other muscular dystrophies of interest were Becker muscular dystrophy (BMD), 
Emery-Dreifuss muscular dystrophy (EDMD), limb girdle muscular dystrophies (LGMDs) 
and facioscapulohumeral dystrophy (FSHD). BMD is a dystrophinopathy characterized by 
later-onset and milder progressive muscle weakness and degeneration than DMD [36]. 
EDMD is characterized by joint contractures and slowly progressive muscle weakness and 
wasting in a humeroperoneal distribution that later extends to the scapular and pelvic girdle 
muscles [121]. DMD, BMD and EDMD are part of a larger group of LGMDs characterized 
by weakness and wasting of the scapular and pelvic girdle muscles [122]. FSHD is 
characterized by slowly progressive weakness of the facial muscles and the stabilizers of 
the scapula or the dorsiflexors of the foot [123]. In contrast to the myopathies, SMA is 
characterized by muscle weakness and atrophy caused by degeneration of lower motor 
neurons in the anterior horn of the spinal cord and brain stem nuclei. SMA is amongst the 
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most common childhood neuromuscular disorders, following DMD, and is classified into 
different phenotypes per age of onset, maximum motor milestone achieved, and life 
expectancy. Type I SMA is the most severe phenotype with onset before 6 months of age, 
and characterized by sitting with support only as the maximum motor milestone attained. 
Types II and III SMA are intermediate phenotypes with onset between 6–18 months and 
after 18 months of age, respectively. Type II and III SMA are characterized by independent 
sitting when placed and independent ambulation, respectively, as the maximum motor 
milestones attained. Type IV SMA is the mildest phenotype with adult onset and normal 
motor milestone attainment [124]. 
2.2 Search Strategy and Search Results  
 A literature search was conducted to identify quantitative, qualitative and mixed-
methods studies relating to subjective mental and/or physical fatigue, evaluated using 
unidimensional or multidimensional questionnaires, in paediatric and adult muscular 
dystrophies and spinal muscular atrophy. Studies assessing the relationship between 
physiological fatigue and subjective fatigue were also included. Studies that combined 
other disease populations with muscular dystrophies or SMA were included, so long as 
disease-type was controlled for in the analysis or subgroup analyses were conducted. Only 
studies published in English were included. Records were not excluded based on country 
or date of publication. Review articles, editorials, commentaries and case reports were 
excluded. The literature search was conducted using MEDLINE (Ovid), EMBASE, 
CINAHL and PsycINFO databases on October 22nd, 2016. A comprehensive search 
strategy was developed with guidance from a research librarian using terminology related 
to muscular dystrophies, SMA and fatigue. The search strategy employed database-specific 
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terminology and syntax, which are presented in Appendix A (Table A.1). Appropriate 
Boolean operators and database-specific limitations were used to optimize search results. 
A generic search strategy is presented below:  
1. Database-specific subject headings for ‘muscular dystrophies’ OR ‘spinal 
muscular atrophy’ 
2. Keywords: muscular dystroph* OR dystrophinopath* OR Duchenne muscular 
dystrophy OR Becker muscular dystrophy OR Emery Dreifuss muscular dystrophy 
OR facioscapulohumeral muscular dystrophy OR limb girdle muscular dystrophy 
OR spinal muscular atrophy OR spinal muscle atrophy 
3. (1) OR (2)  
4. Database-specific subject headings for ‘fatigue’ 
5. Keywords: fatigue OR fatigability OR tired* 
6. (4) OR (5) 
7. (3) AND (6) 
A total of 1,016 records were retrieved from databases (404 from MEDLINE (Ovid), 
356 from EMBASE, 47 from CINAHL and 209 from PsycINFO), and 1 additional record 
was retrieved through personal communication with the author. Duplicate records were 
removed and records were screened in three consecutive stages by title, abstract and full-
text. Of the 867 records remaining after duplicate records were removed, 50 records met 
eligibility criteria for full-text review and 27 records were ultimately included in this 
literature review [3,57,58,98,116,120,125–145]. Reference lists of included studies and 
excluded non-original studies were searched to ensure no records were omitted from the 
search strategy. A study selection flowchart is presented in Appendix B (Figure B.1).  
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2.3 Characteristics of Included Studies   
Three themes emerged from studies included in this literature review: (1) the 
burden of fatigue, (2) risk factors associated with fatigue, and (3) the management of 
fatigue in muscular dystrophies and SMA. Although the management of fatigue in 
muscular dystrophies and SMA is beyond the scope of the objectives of this thesis, these 
studies were included as data on the effectiveness of interventions to treat fatigue can 
provide insight on risk factors associated with fatigue. Study characteristics and findings 
are summarized in Table 2.1 and Table 2.2. Studies were published between the years 2005 
and 2016, underscoring the relative infancy of the study of subjective fatigue in muscular 
dystrophies and SMA. Studies were conducted in the Netherlands [57,116,120,128,131–
133,136,139,140,142,143], United States of America [98,129,137,141], Japan [138], 
Denmark [135,145], Canada [3,144], Italy [58,130], France [126,127], and Turkey 
[125,134]. The majority of studies evaluating the burden of fatigue and/or risk factors 
associated with fatigue used a hypotheses-generating, cross-sectional design 
[3,57,98,128,129,131–133,136,138,140,145], with the exception of three studies that 
prospectively followed patients for 12 to 18 months [58,116,144]. Studies assessing the 
management of fatigue were composed of randomized controlled trials (RCTs) 
[126,137,142,143], non-randomized trials [125,134], single-arm trials [127,135], and a 
prospective cohort study [130].  
Four studies focused on paediatric DMD patients [3,58,125,144] and one study 
focused on adult DMD patients [120], while the remaining studies primarily included 
adults with other muscular dystrophies or SMA. Although studies of adults with muscular 
dystrophies and SMA may have limited generalizability to fatigue in paediatric DMD, they 
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can offer preliminary guidance for this novel area of research, including the conceptual 
framework of this thesis. Moreover, studies of fatigue in DMD populations did not examine 
associations between potentially modifiable risk factors and fatigue, further justifying the 
need to turn to the scientific literature for other neuromuscular disorders.   
2.4 Definition of Fatigue  
 Fatigue was most often defined as “an overwhelming sense of tiredness, lack of 
energy and feeling of exhaustion” [57,116,120,131–133,136,139,142,145]. Werlauff et al. 
added that patients experience difficulties in initiating or sustaining activities mentally, 
physically or both [145]. Kalkman et al. differentiated fatigue from muscle weakness and 
muscle fatigability [133]. Schipper et al. defined fatigue as “a subjective, unpleasant 
symptom which incorporates total body feeling ranging from tiredness to exhaustion, 
creating an unrelenting overall condition which interferes with an individual’s ability to 
function to their normal capacity” [140]. In contrast, de Groot et al. referred to fatigue as a 
“physical complaint” [128], and Noto et al. defined fatigue as “activity-induced muscle 
weakness and fatigability” [138]. Fourteen studies did not offer a definition of fatigue 
[3,58,98,125–127,129,130,134,135,137,141,143,144].  
The lack of a commonly accepted definition of fatigue has previously been 
highlighted as a challenge in studying fatigue [16]. Different definitions of fatigue may 
result in differences in the reported prevalence and impact of fatigue in neuromuscular 
disorders [9,17]. In a clinical setting, both physicians and patients often discuss fatigue 
without explicitly defining the term [16]. In practice, the definition of fatigue may overlap 
with sleepiness, depression, or muscle weakness [4,16]. Additionally, children with 
neuromuscular disorders may not spontaneously report fatigue as a symptom or have the 
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ability to clearly articulate the chief complaint [4,146]. Thus, the lack of a commonly 
accepted definition of fatigue in research may translate to under-diagnosis or treatment 
plans with unsatisfactory outcomes in clinical practice [4,9]. Furthermore, studies have 
defined fatigue using different terms, yet employed the same instruments to measure 
fatigue, calling into question the appropriateness and construct validity of these instruments 
[120,138].  
2.5 The Burden of Fatigue in Muscular Dystrophies and Spinal Muscular Atrophy  
 Studies included in this literature review demonstrated that fatigue was prevalent, 
with far-reaching consequences on health-related quality of life (HRQOL) and patient 
functioning in patients with muscular dystrophies and SMA. Studies characterizing the 
burden of fatigue were limited to the patient populations of DMD, FSHD and SMA (Table 
2.1). 
2.5.1 Duchenne Muscular Dystrophy  
 In a Dutch cross-sectional study of adults with DMD (N=80), Pangalila et al. 
reported fatigue to be present in 40.5% (95% CI: 29.7, 51.3%) of patients, with 21.5% 
attributable to intermediate fatigue and 19.0% attributable to severe fatigue [120]. Fatigue 
was measured using the Dutch version of the Fatigue Severity Scale (FSS). The FSS is 
composed of nine items, each measured on a 7-point Likert scale from 1 (no signs of 
fatigue) to 7 (most disabling fatigue). The FSS score is the mean of all item scores. 
Intermediate fatigue was defined as a minimum score of 4 and severe fatigue was defined 
as a minimum score of 5 [120,147]. Severe fatigue was more frequent in adults with DMD 
(19.0%), compared to Dutch healthy controls from published data (5.0%) [120,148]. In 
adults with DMD, fatigue was concurrent with pain in 11.4% of patients, with affective 
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disorders (anxiety and depression) in 1.3% of patients, and with both pain and affective 
disorders in 22.8% of patients. Fatigue was more prevalent in adult DMD patients with 
poor quality of life (QOL) than in patients with good QOL. In multivariate logistic 
regression analysis, with dichotomized QOL (good/poor) outcomes, fatigue emerged as a 
determinant of overall QOL (OR=2.89; 95% CI: 1.71, 4.87; P<0.001), as well as QOL 
related to physical functioning (OR=6.77; 95% CI: 2.11, 21.75; P=0.001) and environment 
(OR=1.95; 95% CI: 1.16, 3.28; P=0.01), but not psychological functioning or social 
relationships [120].  
  In a prospective cohort study by our group of children with DMD (N=98), fatigue 
at baseline was significantly associated with worse overall, physical and psychosocial 
HRQOL at baseline, by child self-report and parent-proxy report [3]. Fatigue was measured 
using the Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional Fatigue 
Scale (MFS). The PedsQLTM MFS is an 18-item form composed of three domains: General 
Fatigue (six items), Sleep/Rest Fatigue (six items) and Cognitive Fatigue (six items) [117]. 
HRQOL was also assessed using the PedsQLTM measurement model with generic and 
disease-specific measures: Generic Core Scales, Neuromuscular Module and Duchenne 
Muscular Dystrophy Module [149,150]. Of the patient and family characteristics examined 
as independent variables in multivariable linear regression analysis, only fatigue was 
associated with all measures of HRQOL at baseline (=0.38 to =0.88; P<0.001 to 
P=0.02). Fatigue explained more of the variability in HRQOL than any other variable 
examined, as determined by backward elimination regression analysis. Other variables 
examined were age, wheelchair use, scoliosis, corticosteroid therapy, forced vital capacity, 
left ventricular ejection fraction, diagnosis with one or more neuropsychiatric disorder, 
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family stress, annual household income and parents’ highest educational attainment [2,3]. 
Patients were then followed for 18 months and the longitudinal relationship between 
fatigue and HRQOL was examined in children with DMD (N=49). Change in fatigue was 
significantly correlated with change in HRQOL over 18 months, by child self-report and 
parent proxy-report (r=0.50 to r=0.81; P<0.001 to P=0.003) [144]. Because fatigue and 
HRQOL were both assessed using the PedsQLTM measurement model, it is possible that 
their association was an artifact due to common method variance—shared variance among 
variables attributable to the measurement model rather than the constructs the measures 
represent [151]. Common method variance can inflate or deflate observed relationships 
between predictor and criterion variables, resulting in both Type I and Type II errors, 
respectively [151,152]. 
 In an Italian prospective cohort study, Messina et al. evaluated 12-month change in 
fatigue, also using the PedsQLTM MFS by child self-report and parent proxy-report, in 
ambulant children with DMD (N=98) [58]. At baseline and 12-months, children with DMD 
experienced greater fatigue than healthy controls from published data by child self-report 
and parent proxy-report [58,117,118]. No significant change in child self-reported fatigue 
was observed over 12 months, however parent proxy-reported fatigue significantly 
increased over 12 months (P=0.002) [58].  
2.5.2 Other Muscular Dystrophies 
  Severe fatigue (Checklist Individual Strength Fatigue subscale score 35 [153])  
was reported by 34–61% of adults with FSHD [57,142]. Adults with FSHD reported higher 
levels of current fatigue than healthy controls [139,142]. In a cross-sectional survey of 
FSHD patients, combined with myotonic dystrophy patients, fatigue was the most frequent 
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and severe symptom reported by patients, relative to imbalance, pain, memory loss and 
vision loss. Fatigue was most often reported to worsen or stay the same, rather than 
improve, since its onset and over the course of the past six months [141]. In adults with 
FSHD, fatigue has been reported to be associated with poor physical and psychological 
functioning, greater depressive symptoms and functional impairment [98,116,141]. 
Functional impairment was measured using the following subscales from the Sickness 
Impact Profile: body care and movement, home management, communication, work 
limitations, recreation and pastimes, and impairments with eating [116,154]. Despite a high 
prevalence of severe fatigue among FSHD patients, severe fatigue was not associated with 
employment status. Thus, fatigue can impair patient functioning, but is not related to 
participation in the workforce. However, types of occupations and number of hours worked 
have not been explored in this population [136]. In a qualitative study of fatigue in adults 
with FSHD using semi-structured interviews [140], respondents described fatigue as an 
overwhelming, unpredictable and capricious experience with physical and psychological 
components. The psychological component was described as a fear of becoming fatigued, 
which resulted in reluctance to participate in activities. Respondents indicated that fatigue 
negatively influenced activities of daily living, social participation and participation in 
work [140].   
2.5.3 Spinal Muscular Atrophy 
 Data regarding the burden of fatigue in SMA are sparse, inconclusive and limited 
to cross-section studies. Patient populations varied across studies with respect to SMA 
phenotype, limiting comparability of findings [128,129,138,145]. In a study of SMA and 
spinal and bulbar muscular atrophy (SBMA) patients, adults with SMA (unspecified type) 
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or SMBA reported significantly greater fatigue than healthy controls [138]. In a study by 
de Groot et al., fatigue was significantly more prevalent in Type III SMA patients (61%) 
than in Types I and II SMA patients (34%). Moreover, fatigue was one of the most 
frequently reported physical complaints among Type III SMA patients, preceded only by 
muscle weakness and cold hands or feet [128]. In a study of adults with Type II SMA, 
severe fatigue was reported by only 10% of patients, corroborating the finding by de Groot 
et al. that fatigue may not be a common feature in Type II SMA [128,145]. Data regarding 
the burden of fatigue in children with SMA were limited to a published abstract [129]. 
Fatigue was assessed in children with Type II or III SMA using the PedsQLTM MFS. 
Children with SMA reported greater fatigue than healthy controls from published data 
[117,118,129]. However, fatigue was not associated with quality of life or function in Type 
II or III SMA patients [129].  
2.6 Factors Associated with Fatigue in Muscular Dystrophies and Spinal Muscular 
Atrophy 
2.6.1 Duchenne Muscular Dystrophy  
In the prospective cohort study conducted by our group, children with DMD using 
a wheelchair intermittently reported significantly greater fatigue than children not using a 
wheelchair, indicating that the transition into wheelchair use may be associated with 
fatigue. This association was not present by parent proxy-report [3]. Messina et al. assessed 
whether 12-month change in functional ability was associated with 12-month change in 
fatigue in ambulant children with DMD [58]. Functional ability was assessed using 
measures commonly used in therapeutic trials and clinical practice, including the six-
minute walk test (6MWT), North Start Ambulatory Assessment (NSAA), 10-metre 
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walk/run test, and time to rise from the floor (Gowers’ test) [155–157]. The NSAA is a 17-
item scale that assesses abilities necessary to remain functionally ambulant in children with 
DMD [157]. Few associations between functional ability and fatigue were observed by 
Messina et al., suggesting that functional ability, a proxy for disease severity in DMD, may 
be weakly related to fatigue. At baseline, shorter 6MWT distance was weakly associated 
with greater fatigue, by child self-report (r=0.23; P=0.02) and parent proxy-report (r=0.27; 
P=0.006). Greater time to rise from the floor was weakly associated with greater fatigue, 
by child self-report (r=-0.21; P=0.04). Over 12 months, change in 10-metre walk test was 
weakly associated with change in fatigue, by child self-report (r=-0.22; P=0.03). Because 
a significant 12-month decline in functional ability was observed in children >7 years of 
age, a subgroup analysis was conducted for this age group. In children >7 years of age, 12-
month change in 6MWT was weakly associated with change in fatigue, by child self-report 
(r=0.24; P=0.01) and parent proxy-report (r=0.25; P=0.03). NSAA and age were not 
associated with fatigue in ambulant children with DMD [58]. However, the correlation 
analyses using cross-sectional data by our group [3] and Messina et al. [58] do not allow 
for causal conclusions regarding the relationship of physical functioning with fatigue in 
children with DMD. No additional studies have explored factors associated with fatigue in 
children with DMD.  
2.6.2 Other Muscular Dystrophies  
Eight studies conducted in the Netherlands examined factors associated with 
fatigue in adults with FSHD [57,116,131–133,139,140,142]. All studies, except one [140], 
recruited patients from the Neuromuscular Centre at Radboud University Nijmegen 
Medical Centre and the Dutch Neuromuscular Diseases Association (Vereniging 
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Spierziekten Nederland). A common patient source across studies may limit the 
generalizability of findings [57,116,131–133,139,142]. Using a prospective cohort study 
design and structural equation modelling, Kalkman et al. aimed to identify predictors of 
fatigue and to develop a model of fatigue in adults with FSHD. Model testing revealed that 
sleep disturbances, pain, physical activity level and muscle strength were significantly 
associated with fatigue. Sleep disturbances, pain and physical activity level had a direct 
causal effect on fatigue, while muscle strength had an indirect effect on fatigue mediated 
by physical activity level [116]. The associations of pain and physical activity level (over-
exertion or excessive rest) with fatigue reported by Kalkman et al. [116] corroborate 
previous findings [57,140,142]. However, van der Kooi et al. did not observe a difference 
in physical activity level between FSHD patients with and without severe fatigue [142]. 
Kalkman et al. did not observe an association between neuropsychological functioning 
(concentration, alertness, information-processing speed and motor speed) and fatigue 
[116]. However, it was previously reported that severely fatigued patients have more 
concentration problems and reduced motivation compared with less fatigued patients [57]. 
Data regarding the relationship between mental health and fatigue in FSHD are 
inconclusive. No difference in fatigue severity was observed between FSHD patients with 
and without current or lifetime psychiatric disorders evaluated using the Structured 
Clinical Interview for DSM-IV Axis I Disorders [131,158]. Self-reported mental health 
and depressive symptoms have been statistically analyzed as both determinants and 
outcomes of fatigue. Reports of significant associations of mental health and depressive 
symptoms with fatigue are inconsistent across studies [57,98,116,131,141,142]. Thus, the 
strength and directionality of associations of mental health and depressive symptoms with 
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fatigue in FSHD remain unclear. Similarly, physical functioning has been statistically 
analyzed as both a determinant and an outcome of fatigue in FSHD, and has consistently 
been reported to be associated with fatigue [57,98,142]. Kalkman et al. did not observe an 
association between social functioning or social support and fatigue [116]. However, a 
study assessing the influence of relatives on fatigue experienced by FSHD patients 
demonstrated that receiving higher levels of sympathetic or empathic support from 
relatives was associated with greater fatigue experienced by patients. Moreover, fatigue 
severity experienced by relatives was significantly associated with fatigue severity 
experienced by patients [132]. Age and sex were not associated with fatigue in FSHD 
[57,142]. In a qualitative study by Schipper et al. [140], coping and stress were identified 
as risk factors for fatigue in FSHD. Semi-structured interviews with adults with FSHD 
ultimately demonstrated that the source of fatigue may be a complex network of factors. 
However, patients are often unaware of the causes of fatigue, making it difficult to manage 
[140].    
The relationship between physiological fatigue and subjective fatigue in FSHD has 
been examined by two studies [133,139]. Physiological fatigue—the inability to maintain 
the desired muscle force during sustained or repeated exercise—can originate at the level 
of the central nervous system (upper motor neuron) or peripheral nervous system (lower 
motor neuron, neuromuscular junction or muscle) [16]. Peripheral and central aspects of 
physiological fatigue are measured in a laboratory setting using electrophysiological 
protocols such as intermittent submaximal exercise protocol, sustained maximal force 
exercise protocol, twitch interpolation or transcranial magnetic stimulation [16,159]. Using 
a twitch interpolation technique [159], Schillings et al. [139] and Kalkman et al. [133] 
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demonstrated that total physiological fatigue, peripheral physiological fatigue, and central 
physiological fatigue were not correlated with subjective fatigue measures in adults with 
FSHD. This finding suggests that physiological and subjective fatigue are separate types 
of fatigue. The mechanisms and determinants of physiological and subjective fatigue may 
differ, requiring targeted interventions [133].  
2.6.3 Spinal Muscular Atrophy  
 Two studies examined factors associated with fatigue in SMA and did not observe 
any significant associations [129,138]. Age, SMA phenotype, ambulatory status, disease 
duration and degree of disability were not associated with fatigue [129,138]. Physiological 
fatigue, determined by the decrement in distance from the first to sixth minute during the 
6MWT [155], was not associated with subjective fatigue in ambulant Type II or II SMA 
patients [129]. Physiological fatigue, determined by activity-dependent conduction blocks 
during simulated-single fibre electromyography [160], was not associated with subjective 
fatigue in SMA (unspecified type) or SBMA patients [138].   
2.7 The Management of Fatigue in Muscular Dystrophies and Spinal Muscular 
Atrophy 
2.7.1 Duchenne muscular dystrophy  
  In a non-randomized trial, Alemdaroğlu et al. [125] aimed to assess the acute 
effects of various exercise protocols on fatigue in ambulant children with DMD (N=30). 
Patients were assigned to one of the following exercise protocols per session: (1) 3 minutes 
of 5-step stair-climbing, (2) 40 minutes of stationary cycling, or (3) a 40-minute physical 
therapy program of stretching the gastrocnemius, hamstring and hip flexor muscles, 
strengthening upper and lower extremities and aerobic activity. Fatigue was evaluated on 
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the same day following each exercise protocol using the Pictorial Variant of the Children’s 
Effect Rating Scale Table scale—an illustrated visual analog scale of 0–10 with a present-
state recall period [161]. Telephone-interviews were conducted the second day following 
exercise protocols to evaluate whether post-exercise fatigue affected patients’ activities of 
daily living. A significant increase in fatigue was reported immediately following each 
exercise protocol compared to baseline, however post-exercise fatigue did not influence 
activities of daily living on the same day of exercise [125]. No studies have evaluated the 
effects of exercise therapy or other interventions on long-term fatigue in paediatric or adult 
DMD.  
2.7.2 Other Muscular Dystrophies   
 The effects of exercise therapy, neuromuscular electrical stimulation therapy, 
pharmacological therapy with salbutamol, and cognitive behaviour therapy (CBT) on 
fatigue have been assessed in adults with FSHD or LGMD [126,127,134,142,143]. No 
significant changes in fatigue were observed following 8–26 weeks of exercise therapy 
consisting of strength training only in FSHD or LGMD patients [134,142]. However, a 
significant reduction in fatigue was observed following 16–24 weeks of aerobic exercise 
therapy alone or in combination with strength training [126,143]. A decrease in subjective 
fatigue, following combined aerobic and strength training, was associated with a decrease 
in physiological fatigue and an improvement in mental health [126]. Neuromuscular 
electrical stimulation therapy is a passive muscular training technique used to prevent 
muscular atrophy, which demonstrated safety and efficacy in stabilizing or improving 
muscular weakness in DMD patients [162–166]. Although no significant changes in fatigue 
were observed following neuromuscular electrical stimulation therapy in FSHD and 
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LGMD patients, an improvement in the impact of fatigue on activities of daily living was 
reported by FSHD patients [127,134]. The 2-adrenergic receptor agonist salbutamol has 
previously been reported to increase muscle mass and strength in FSHD patients, however 
the anabolic effect diminished with prolonged use [167,168]. No significant changes in 
fatigue were observed following 26 weeks of therapy with salbutamol alone or in 
combination with strength training [142].  
In contrast to therapies that target physical components of fatigue, CBT facilitates 
the identification of maladaptive thoughts, beliefs and attitudes. CBT challenges these 
cognitions through collaborative hypothesis-testing, using behavioural tasks of diary-
keeping and validity-testing of beliefs between sessions, combined with the development 
of coping strategies within sessions [169]. Studies have demonstrated that CBT can reduce 
fatigue in patients with chronic fatigue syndrome and multiple sclerosis [169,170]. In an 
evaluator-blind RCT by Voet et al. [143], CBT significantly reduced fatigue severity in 
adults with FSHD compared to usual care. CBT and aerobic exercise therapy produced 
quantitatively similar beneficial effects on fatigue. However, CBT improved all fatigue-
perpetuating factors, except pain, in the model described by Kalkman et al. [116], whereas 
physical activity level was the only fatigue-perpetuating factor modified by aerobic 
exercise therapy [143] 
2.7.3 Spinal Muscular Atrophy  
 The effects of exercise therapy and pharmacological therapy with salbutamol on 
fatigue have been assessed in SMA. Following 12–24 weeks of aerobic exercise therapy 
(stationary cycling) alone or in combination with strength training, Type III SMA patients 
reported no change in fatigue or worsened fatigue [135,137]. In contrast, training-induced 
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fatigue was not observed in studies evaluating aerobic exercise therapy in muscular 
dystrophies [126,143], suggesting alternative underlying mechanisms of fatigue in 
muscular dystrophies and anterior horn cell disease, which may require disease-specific 
therapies [135].  
SMA is caused by a deficit of survival motor neuron (SMN) protein encoded by the 
SMN1 and SMN2 genes. Patients have homozygous pathogenic variants of the SMN1 gene 
and retain at least one copy of the SMN2 gene. However, the SMN2 gene produces 
insufficient levels of functional protein due to the exclusion of exon 7 in most transcripts 
caused by alternative splicing [171]. Studies have demonstrated that treatment with the 2-
adrenergic receptor agonist salbutamol increase expression of full-length SMN2 
transcripts, and may increase motor function in SMA patients [172–175]. Giovannetti et 
al. assessed the perceived effects of salbutamol on fatigue in adults with Type II, III or IV 
SMA. A significant reduction in fatigue was reported by patients following treatment with 
salbutamol [130].  
2.8 Conclusions  
This literature review highlights the need for additional studies to characterize the 
prevalence of and factors associated with fatigue in children and adolescents with DMD. 
Understanding the determinants of fatigue in paediatric DMD is necessary for the 
development of treatment strategies that produce positive clinical outcomes. This review 
demonstrated fatigue to be frequent and disabling in patients with DMD, FSHD and SMA, 
and likely caused by multiple, dynamic factors. Much of the data presented in this review 
focused on adults with slowly progressive forms of muscular dystrophies or mild 
phenotypes of SMA. The clinical presentations of FSHD, LGMD, and Type III and IV 
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SMA are uncharacteristic of DMD. Although findings presented in this literature review 
are hypothesis-generating for this thesis, they may be unrelated to phenomena in children 
or adults with DMD. Contrasting results across patient populations, with respect to 
determinants of and therapeutic interventions for fatigue, further underscore the role of 
disease-specific mechanisms of fatigue. Data regarding the management of fatigue in both 
children and adults with muscular dystrophies and SMA are largely insufficient. However, 
the assessment of therapeutic interventions to modify fatigue is ultimately dependent on 
understanding disease-specific mechanisms of fatigue in these patient populations. 
Prospective cohort studies with larger, representative sample sizes are needed to 
characterize fatigue in both paediatric and adult muscular dystrophies and SMA. However, 
an initial cross-sectional study of factors associated with fatigue in paediatric DMD can 
inform the design of future longitudinal studies.  
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Table 2.1. Studies on the frequency of and factors associated with fatigue in muscular dystrophies and spinal muscular atrophy 
Author, Year, 
Country 
[publication] 
Study Design 
(Follow-up) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in 
Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
Pangalila, 
2015, 
Netherlands 
[120] 
Cross-
sectional 
study  
DMD (80) 
 
Four Centres for Home 
Ventilation in the Netherlands; 
Dutch rehabilitation centres; 
Dutch patient organization for 
neuromuscular diseases 
28.2  6.3 
(20–44) 
FSS (recall-period not 
reported) 
Fatigue present in 40.5% of adult DMD patients. Univariate 
logistic regression analysis demonstrated fatigue 
significantly associated with poor overall QOL and domains 
of physical health, psychological functioning and 
environment, but not social relationships. Multivariate 
logistic regression analysis demonstrated fatigue 
significantly associated with poor overall QOL and domains 
of physical health and environment.   
 
Wei, 2015, 
Canada [144]a 
Prospective 
cohort study 
(18 months)  
DMD (49) 
 
Canadian Neuromuscular Disease 
Registry 
12.2 (5–19) PedsQLTM MFS, 
patient- and parent 
proxy-report (4-week 
recall period) 
 
Change in fatigue significantly correlated with changes in 
child self- and parent proxy-reported HRQOL over 18 
months.  
Wei, 2016, 
Canada [3] 
Cross-
sectional 
study  
DMD (98) 
 
Canadian Neuromuscular Disease 
Registry 
10.7  3.7 PedsQLTM MFS, 
patient- and parent 
proxy-report (4-week 
recall period) 
Multivariable linear regression analysis revealed fatigue 
significantly associated with child self- and parent proxy-
reported overall, physical and psychosocial HRQOL. 
Fatigue explained more variability in HRQOL than any 
other patient or family characteristic.  
 
Messina, 
2016, Italy 
[58] 
Prospective 
cohort study 
(12 months)  
DMD (98) 
 
Ten tertiary neuromuscular 
centres in Italy 
8.4  2.29 PedsQLTM MFS, 
patient- and parent 
proxy-report 
Included DMD patients were ambulant. Parent proxy-, but 
not child self-reported, fatigue significantly increased over 
12 months. Baseline child self-reported fatigue significantly 
correlated with time to rise from floor and 6MWT. Baseline 
parent proxy-reported fatigue significantly correlated with 
6MWT. 12-month change in patient-reported fatigue 
significantly correlated with change in 10-meter timed 
walk/run test. In children 7 years of age, 12-month change 
in child self- and parent proxy-reported fatigue significantly 
correlated with change in 6MWT.  
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Author, Year, 
Country 
[publication] 
Study Design 
(Follow-up) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in 
Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
Kalkman, 
2007, 
Netherlands 
[131] 
Cross-
sectional 
study  
FSHD (65) 
 
Neuromuscular Centre, Radboud 
University Nijmegen Medical 
Centre; Dutch patient organization 
for neuromuscular diseases 
 
43.1  10.3 CIS-Fatigue (2-week 
recall period) 
Current and lifetime psychiatric disorders not associated 
with fatigue.  
Schillings, 
2007, 
Netherlands 
[139] 
Cross-
Sectional 
study  
FSHD (65) 
 
Neuromuscular Centre, Radboud 
University Nijmegen Medical 
Centre; Dutch patient organization 
for neuromuscular diseases 
43.1  10.3 
(22.5–60.9) 
SFQ (Present-state 
recall period) 
Patients reported greater subjective fatigue than healthy 
controls. Total, peripheral and central physiological fatigue 
not correlated with subjective fatigue. FSHD patients 
experienced greater central activation failure than controls; 
central activation failure not significantly correlated with 
subjective fatigue. 
 
Kalkman, 
2007, 
Netherlands 
[116] 
Prospective 
Cohort Study 
(18 months) 
FSHD (60) 
 
Neuromuscular Centre, Radboud 
University Nijmegen Medical 
Centre; Dutch patient organization 
for neuromuscular diseases 
44.3  9.9 CIS-Fatigue (2-week 
recall period) 
Physical activity, depressive symptoms, sleep disturbances, 
pain and muscle strength correlated with fatigue. 
Neuropsychological impairment, social functioning and 
social support not correlated with fatigue.  
 
Structural equation modelling demonstrated sleep 
disturbances at baseline had direct effect on fatigue at 
follow-up. Pain at baseline had direct effect on physical 
activity at baseline and fatigue at follow-up. Muscle strength 
at baseline had indirect effect on fatigue at follow-up via 
physical activity at baseline. Fatigue at follow-up has direct 
effect on functional impairment at follow-up. 
 
Kalkman, 
2008, 
Netherlands 
[133] 
Cross-
sectional 
study 
FSHD (65) 
 
Neuromuscular Centre, Radboud 
University Nijmegen Medical 
Centre; Dutch patient organization 
for neuromuscular diseases 
 
43.1  10.3 CIS-Fatigue (2-week 
recall period) 
Peripheral and central physiological fatigue did not correlate 
with subjective fatigue, suggesting that these are separate 
types of fatigue. 
Minis, 2010, 
Netherlands 
[136] 
Cross-
sectional 
study  
FSHD (138) 
 
43.7  10.1 CIS-Fatigue (2-week 
recall period) 
Bivariate analysis demonstrated employed patients reported 
significantly less fatigue than unemployed patients. 
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Author, Year, 
Country 
[publication] 
Study Design 
(Follow-up) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in 
Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
Neuromuscular Centre, Radboud 
University Nijmegen Medical 
Centre; Dutch patient organization 
for neuromuscular diseases 
 
However, multivariate regression analysis demonstrated 
fatigue not associated with employment status.  
Alschuler, 
2012, USA 
[98] 
Cross-
sectional 
study 
FSHD (139) 
 
Previous study participants; 
Individuals responding to 
advertisements through Muscular 
Dystrophy Foundation, 
publications and clinics 
 
53.6  13.8 
(22–89) 
NRS of 0–10 with a 1-
week recall period 
Hierarchal linear regression analyses demonstrated greater 
fatigue significantly associated with poor physical 
functioning and greater depressive symptoms, independent 
of pain and age. Fatigue explained more variability in 
depressive symptoms than physical functioning.  
 
Noto, 2013, 
Japan [138] 
Cross-
sectional 
study  
SMA (5)  
SBMA (17) 
 
Chiba University Hospital 
59 (37–75) FSS (recall-period not 
reported) 
SMA/SBMA patients reported significantly greater fatigue 
than healthy controls and other patient populations (multiple 
sclerosis, myasthenia gravis, chronic inflammatory 
demyelinating polyneuropathy and axonal neuropathy), 
although differences not significant. Fatigue not correlated 
with age, disease duration, degree of disability or 
conduction blocks during stimulated-single fibre EMG. 
 
Werlauff, 
2014, 
Denmark 
[145] 
Mixed 
methods 
cross-
sectional 
study 
SMA II (29) 
 
Danish National Rehabilitation 
Center for Neuromuscular 
Diseases 
 
30.6  10.5 
(19–55) 
FSS (2-week recall 
period) 
 
Three patients (10%) patients reported severe fatigue, 
indicating fatigue may not be common in SMA II. Fatigue 
not associated with age or sex.  
Dunaway, 
2014, USA 
[129]a 
 
Cross-
sectional 
study  
SMA II (7); 
SMA III (25) 
 
- 
(5–49) PedsQLTM MFS; FSS 
(recall periods not 
reported) 
All patients reported subjective fatigue. Fatigue not 
associated with age, SMA type, ambulatory status, function 
or QOL in all patients, or with physiological fatigue in 
ambulatory patients.   
 
Smith, 2014, 
USA [141] 
Cross-
sectional 
study  
FSHD (90) 
 
National Registry of DM and 
FSHD; University of Washington 
Muscular Dystrophy Association 
51.9  13.1 
(21–90)a 
NRS of 0–10 
(severity); patients 
asked to indicate 
whether fatigue had 
become worse, become 
Fatigue was the most common and severe symptom, relative 
to imbalance, pain, memory impairment and vison loss. 
Fatigue most often worsened or stayed the same since onset 
and during past 6 months. Bivariate analysis demonstrated 
fatigue significantly correlated with psychological 
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Author, Year, 
Country 
[publication] 
Study Design 
(Follow-up) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in 
Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
clinic roster; Previous study 
participants; Individuals 
independently contacting 
researchers 
better or stayed the 
same since its onset, 
and during the past 6 
months (symptom 
course) 
functioning, social integration, home competency and 
productive activity. When controlling for other symptoms, 
age, sex and disease duration, multivariable linear 
regression analyses revealed fatigue only significantly 
associated with psychological functioning.b 
 
Schipper, 
2016, 
Netherlands 
[140] 
Qualitative 
Cross-
Sectional 
study  
FSHD (25) 
 
Previous study participants; 
Computer Registry of All 
Myopathies and 
Polyneuropathies; patient support 
organizations 
53.8  12.4 
(24–77) 
Semi-structured 
interviews [Patients 
previously reported 
severe fatigue (CIS-
Fatigue scores 35)] 
Four themes identified: (1) fatigue is overwhelming and 
unpredictable with physical and mental component; (2) 
fatigue caused by combination of factors (weak muscles, 
physical overachieving or underachieving, stress). Causes 
unknown most of time, making fatigue difficult to deal with; 
(3) fatigue influences participation, social contacts and 
activities of daily of living; (4) managing fatigue requires 
adaption to changing situations of progressive disease, 
making it more difficult. 
Abbreviations: DMD, Duchenne muscular dystrophy; QOL, quality of life; HRQOL, health-related quality of life; 6MWT, six-minute walk test; FSS, Fatigue Severity Scale; 
PedsQLTM MFS, Pediatric Quality of Life InventoryTM Multidimensional Fatigue Scale; FSHD, facioscapulohumeral dystrophy; CIS-Fatigue, Checklist Individual Strength 
Fatigue subscale; SFQ, Shortened Fatigue Questionnaire; NRS, numerical rating scale; SMA, spinal muscular atrophy; SBMA, spinal and bulbar muscular atrophy; VAS, visual 
analog scale. 
 
aMeeting abstract 
bStatistical analysis combined FSHD and myotonic dystrophy type 1 patients, however dystrophy type did not moderate associations between fatigue and criterion variables. 
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Table 2.2. Studies on the management of fatigue in muscular dystrophies and spinal muscular atrophy  
Author, Year, 
Country 
[publication] 
Study Design (Follow-
up) 
Intervention(s) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
Alemdaroğlu, 
2012, Turkey 
[125] 
 
Open-label, non-
randomized trial (1 day)  
3-minute stair 
climbing; 40-minute 
cycling; 40-minute 
stretching-
strengthening with 
aerobic exercises for 
extremities  
 
DMD (30) 
 
Physical Therapy 
Department, Hacettepe 
University 
7.87  1.45 
(6–11) 
Pictorial Variant of 
the Children’s 
Effort Rating Scale 
(VAS of 0–10; 
present state recall 
period) 
Significant increase in fatigue 
observed immediately following 
exercise compared to baseline. 
Post-exercise fatigue did not affect 
performance of daily activities on 
same day of exercise. 
 
van der Kooi, 
2007, 
Netherlands 
[142] 
Evaluator-blind RCT of 
training/non-training, 
followed by double-
blind RCT of 
salbutamol/placebo (52 
weeks) 
Strength training of 
elbow flexors and 
ankle dorsiflexes or 
non-training (26 
weeks), followed by 
salbutamol (sustained-
release 8 mg BID) or 
placebo (26 weeks)  
FSHD (65) 
 
Neuromuscular Centre, 
Radboud University 
Nijmegen Medical 
Centre; Dutch patient 
organization for 
neuromuscular diseases 
38  10 CIS-Fatigue (2-
week recall period)  
Twenty-two patients (34%) had 
severe fatigue at baseline. Patients 
reported greater fatigue compared 
to healthy controls from published 
data. Severely fatigued patients 
experienced significantly more 
pain, functional disability, 
psychological distress and 
depressive feelings. Age, sex and 
self-reported daily activity not 
associated with severe fatigue. 
Strength training and salbutamol, 
alone or in combination, did not 
affect fatigue.  
 
Colson, 2010, 
France [127] 
Single-arm trial (5 
months)  
5-month strength 
training with 
neuromuscular 
electrical stimulation 
(5 20-minute sessions 
weekly)  
FSHD (9) 
 
Neuromuscular Disease 
Centre of Nice, France 
55.2 (39–69) VAS of 0–10 
(present state recall 
period); Patients 
rated changes in 
fatigue related to 
daily living as 
worse, unchanged 
or improved at the 
end of the study 
period 
 
No significant change in fatigue 
observed following training with 
electrical stimulation. Seven 
patients (78%) reported improved 
fatigue related to daily living. 
  
43 
Author, Year, 
Country 
[publication] 
Study Design (Follow-
up) 
Intervention(s) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
Voet, 2014, 
Netherlands 
[143] 
Evaluator-blind RCT 
(28 weeks) 
Aerobic exercise 
training (38-minute 
cycling 3 times 
weekly for 16 weeks); 
CBT (minimum 3 50-
minute sessions over 
16 weeks); usual care  
FSHD I (57) 
 
Previous study 
participants; Dutch 
neuromuscular database, 
Computer Registry of 
All Myopathies and 
Polyneuropathies; 
patient support 
organizations 
(20–79) CIS-Fatigue (2-
week recall period) 
All patients severely fatigued. 
Fatigue significantly reduced 
following 16 weeks of aerobic 
exercise or CBT compared to usual 
care. Beneficial effects remained at 
12-week follow-up without 
supervised treatment. Post-
treatment, 76% in CBT group and 
50% in the aerobic exercise group 
no longer severely fatigued. 
Aerobic exercise and CBT 
produced similar effects on fatigue, 
despite fewer CBT sessions.    
 
Madsen, 2015, 
Denmark 
[135] 
Single-arm trial (12 
weeks) 
Home-based aerobic 
exercise training (30-
minute cycling 2–4 
times weekly, totaling 
42 sessions)  
SMA III (6) 
 
- 
32.5  16.49 Patients rated 
changes in fatigue 
as worse, 
unchanged or 
improved at the end 
of the study period 
 
All patients reported worsened or 
no change in fatigue following 
training. One patient dropped out 
due to excessive fatigue.   
Montes, 2015, 
USA [137] 
Evaluator-blind RCT (6 
months)  
Home-based exercise 
training (30-minute 
cycling 5 times 
weekly, 30-minute 
strength training 3 
times weekly); usual 
care (control) 
 
SMA III (12) 
 
SMA Clinical Research 
Center, Columbia 
University Medical 
Center; Pediatric 
Neuromuscular Clinical 
Research Network; 
ClinicalTrials.gov 
 
27.0  14.6 
(10–43; 
exercise); 26.7 
 17.7 (10–
48; control) 
PedsQLTM MFS; 
FSS (recall periods 
not reported) 
No significant changes in fatigue, 
between or within, the exercise and 
control groups were observed.  
Kilinç, 2015, 
Turkey [134] 
 
Open-label, non-
randomized trial (8 
weeks) 
Electrical stimulation 
(high voltage pulsed 
galvanic stimulation 3 
days weekly); exercise 
therapy (moderate 
intensity progressive 
LGMD (24)  
 
Physical Therapy 
Department, Hacettepe 
University 
31.62  16.92 
(electrical 
stimulation); 
30.14  11.04 
(exercise 
therapy) 
VAS of 0–10 
(present state recall 
period) 
Fatigue did not increase after 
electrical stimulation applications 
or exercise therapy. 
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Author, Year, 
Country 
[publication] 
Study Design (Follow-
up) 
Intervention(s) 
Disease  
(Sample Size) 
 
Patient Source(s) 
Age in Years 
Mean  SD 
(Range) 
Subjective Fatigue 
Assessment 
Summary of Findings  
resistance exercises 3 
days weekly)   
 
Bankolé, 
2016, France 
[126] 
Open-label RCT (24 
weeks), followed by 
single-arm trial for 
patients initially 
assigned to control 
group (24 weeks)  
Home-based exercise 
training (35-minute 
cycling 3 times 
weekly); usual care 
(control) 
FSHD (16) 
 
Centre Hospitalier 
Universitaire de Saint-
Etienne; entre 
Hospitalier Universitaire 
de Grenoble 
40  13 
(training);  
41  9 
(control) 
FSS (recall period 
not reported)  
Subjective Fatigue significantly 
decreased over 24-weeks in patients 
in exercise group compared to 
controls. Decreased subjective 
fatigue significantly correlated with 
decreased physiological fatigue 
(increases in VO2 max, MAP, 
MVC, muscle endurance and 
6MWT) and improved mental 
health. 
Giovannetti, 
2016, Italy 
[130] 
Mixed methods; 
Prospective cohort 
study (1 year) 
Salbutamol SMA II (1) 
SMA III (6) 
SMA IV (3) 
 
- 
41.3  11.2 FSS (recall period 
not reported); Semi-
structured 
interviews 
Patients treated with salbutamol for 
30  20.2 months before study. At 
initial evaluation, patients reported 
significantly less fatigue after 
salbutamol treatment. One year 
after initial evaluation, patients 
reported stability of fatigue, not 
improvement. 
Abbreviations: DMD, Duchenne muscular dystrophy; VAS, visual analog scale; RCT, randomized controlled trial; FSHD, facioscapulohumeral dystrophy; CIS-Fatigue, 
Checklist Individual Strength Fatigue subscale; CBT, cognitive behavioural therapy; SMA, spinal muscular atrophy; PedsQLTM MFS, Pediatric Quality of Life InventoryTM 
Multidimensional Fatigue Scale; LGMD, limb girdle muscular dystrophies; VO2 max, maximal oxygen consumption; MAP, maximal aerobic power; MVC, isometric maximal 
voluntary contractions; 6MWT, six-minute walk test; FSS, Fatigue Severity Scale. 
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Chapter 3 
3 Methods 
3.1 Study Design  
The study described in this thesis is a cross-sectional survey study of children and 
adolescents with Duchenne muscular dystrophy (DMD) identified via the Canadian 
Neuromuscular Disease Registry (CNDR). Eligible patients, and their parent or primary 
caregiver, were sent paper questionnaires by mail between July 2016 and November 2016. 
Approval of the study was obtained from the Health Sciences Research Ethics Board at 
The University of Western Ontario (Western University) and the CNDR Advisory 
Committee. Approval Notices from the Health Sciences Research Ethics Board at Western 
University are presented in Appendix C.  
3.2 Study Population  
3.2.1 Patient Source  
 Eligible patients were recruited through the CNDR. The CNDR is a multicentre 
clinic-based registry that was established in June 2011 to facilitate national and 
international research opportunities between researchers and patients, and clinical 
knowledge translation to allow for uniform standards of care across Canada. Paediatric and 
adult patients with any neuromuscular disorder who are residents in Canada are eligible for 
enrollment in the CNDR. The CNDR is administered and supported centrally at the 
National Office at the University of Calgary in Alberta, Canada. The CNDR employs a 
blended recruitment model in which patients are actively recruited at participating 
neuromuscular clinics in combination with self-registration by contacting the CNDR 
National Office for patients unable to attend affiliated neuromuscular clinics. Any 
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physician in Canada can refer a patient to the CNDR for enrollment, by completing 
registration forms available via the National Office or guiding patients to self-register. This 
recruitment model provides access to patients across Canada, including those in remote 
regions with limited access to specialized neuromuscular care. The CNDR includes 
patients recruited from nine paediatric neuromuscular clinics across Canada located in 
British Columbia, Alberta, Ontario, Quebec and Nova Scotia. Clinics enroll patients and 
collect medical and demographic information at routine clinic visits. Each neuromuscular 
clinic is affiliated with an academic institution and has a site principal investigator (Table 
D.1, Appendix D). All patients provide voluntary, informed consent for enrollment, 
updating of demographic and medical information at future routine clinic visits, and 
notification of research studies for which they may be eligible. Patients who are minors can 
be registered by a parent or legal guardian, and are asked to provide assent when possible. 
Upon reaching the age of majority in their province of residence, patients are asked for 
their consent to remain in the registry [176].   
3.2.2 Patient Inclusion and Exclusion Criteria  
 Patients were identified by the CNDR National Office staff for inclusion in the 
study reported here according to the following inclusion and exclusion criteria:  
Inclusion Criteria  
1. Patients are enrolled in the CNDR. To be enrolled in the CNDR, subjects must:  
a. Consent to have clinical information submitted by a physician licensed and 
practicing in Canada.  
b. Be residents in Canada.  
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2. Patients have consented, or a parent or legal guardian has consented on their behalf, 
to be notified by the CNDR of research studies they may be eligible to participate 
in. 
3. Patients with a diagnosis of DMD confirmed by genetic testing or a muscle biopsy 
demonstrating an absence of dystrophin protein, and a physician confirmed clinical 
presentation consistent with DMD. 
4. Patients are males.  
5. Patients are between 5–17 years of age.     
6. Patients have a parent available to complete a parent questionnaire.  
Exclusion Criteria  
1. Both patient and parent are unable to adhere to the study protocol (e.g. inability to 
complete questionnaires, even with assistance, due to limited literacy, a 
communication disorder or cognitive impairment). 
2. Patient has a serious health condition or comorbidity unrelated to DMD, which may 
influence study outcomes.   
3.3 Data Collection Procedures  
Data were collected using two sources: mailed paper questionnaires and registry data 
collected during patients’ routine clinic visits. All data were de-identified. In accordance 
with the CNDR protocol, all contacts with eligible patients were facilitated through the 
CNDR National Office. No direct contacts were made with eligible patients or their parents 
by research personnel to avoid unintended identification of patients or their parents. 
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3.3.1 Mailed Questionnaires  
Paper questionnaires were designed and mailed to eligible patients and their parent 
in accordance with the Tailored Design Method, which was formulated using social 
exchange theory as a rationale. Applied to questionnaire design and implementation, social 
exchange theory assumes that the probability of responding to a questionnaire, and doing 
so accurately, is greater when the respondent trusts that the perceived benefits outweigh 
the perceived costs of responding [177]. In accordance with the Tailored Design Method, 
a four-contact mailing strategy was used to maximize response rate. The four-contact 
mailing strategy was executed between July 2016 and November 2016. Eligible patient-
parent pairs received (1) an initial questionnaire package, (2) a thank-you postcard one 
week after the initial invitation (Appendix G), (3) a follow-up reminder letter (Appendix 
H) with a replacement questionnaire package four weeks after the postcard, and (4) a final 
reminder letter with replacement questionnaire package four weeks after the follow-up 
reminder. Each questionnaire package included a letter of information (Appendix E), assent 
letter (Appendix F), a postage-paid return envelope to minimize the cost of responding, 
and two questionnaire booklets: one to be completed by the patient and one to be completed 
by a parent. Three sets of questionnaires were designed using age-appropriate language 
and instructions according to the following age groups: young children (5–7 years), older 
children (8–12 years) and adolescents (13–17 years). Children and parents were instructed 
to complete their respective questionnaires independently. If a patient was unable to 
independently complete his questionnaire, the parent was instructed to read the questions 
to the patient verbatim without providing interpretation, and to indicate the patient’s 
answers in the questionnaire without providing guidance on how to respond. Parents of 
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young children were instructed to act as interviewers for their child. A Tim Hortons gift 
card valued at $5 CAD was included in the initial questionnaire package as a token of 
appreciation for patient-parent pairs. Implied consent was assumed for patients and parents 
who completed and returned questionnaires.  
Questionnaire packages and thank-you postcards were compiled at Children’s 
Hospital, London Health Sciences Centre in London, Ontario and forwarded to the CNDR 
National Office. Unique identification numbers were generated for eligible patient-parent 
pairs and used to label questionnaires by the CNDR National Office staff. Envelopes of 
questionnaire packages and thank-you postcards were labeled with patient mailing 
addresses and shipped to eligible patient-parent pairs by the CNDR National Office staff. 
Completed questionnaires were initially returned by patient-parent pairs to the CNDR 
National Office, and were then forwarded to Children’s Hospital, London Health Sciences 
Centre by the CNDR National Office staff. If a questionnaire package was returned to 
sender, an effort was made by the CNDR National Office staff to contact the patient’s clinic 
to verify or obtain an updated mailing address for the patient.     
3.3.2 Registry Data  
Patient medical histories were retrieved from the CNDR database. Patient data included 
in the CNDR database are collected prospectively at routine clinic visits through 
standardized data collection forms completed by the physician or data-entry staff reviewing 
patient medical records, followed by direct entry into the registry via a secure online entry 
system. Patients without access to a participating neuromuscular clinic are required to sign 
consent, assent and release of information forms to have their data submitted by their 
healthcare provider. All data entry personnel are trained by the CNDR National Office 
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staff. All data are encrypted and stored at the University of Calgary, and subject to 
regulations for the protection of personal health information. Data entry is reviewed weekly 
at the CNDR National Office to ensure data standard compliance; detected errors are 
logged and reported to the site data-entry personnel for correction. Local data collection 
forms are maintained as source documents and reviewed during annual audit visits by the 
CNDR National Office staff. Participating individuals may withdraw their data from the 
CNDR at any time [176].  
Following data submission, patient-identifying information is separated from medical 
information for de-identification. A unique identifier code is assigned and is the only link 
between the two sets of information. The code is stored on a separate secure server and 
accessible only by the site principal investigator and CNDR National Office staff. A dataset 
of de-identified medical information, described below, was obtained for participating 
patients who completed and returned questionnaires and non-participating patients who did 
not complete and return questionnaires allowing for the assessment of whether clinical 
characteristics of non-participating patients differed from participating patients [176].  
3.4 Data Management  
All completed questionnaires were securely stored at Children’s Hospital, London 
Health Sciences Centre, where data were also cleaned and coded by the author using Stata® 
13.0 Data Analysis and Statistical Software. Data from patient and parent questionnaires 
were merged with registry data into a single Stata® 13.0 file in preparation for analysis 
[178].  
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3.5 Measures  
Several measures for fatigue, physical activity level and depressive symptoms were 
reviewed during selection of measures to be included in the patient and parent 
questionnaires. Measures were selected based on validity, reliability and previous 
administration in children and adolescents with DMD, neuromuscular disorders or physical 
disabilities; appropriateness of measures for DMD patients according to clinical expertise; 
factors associated with ease of administration and low participation burden, such as length 
and use of developmentally appropriate language; and suitability for use in a mail-out 
questionnaire and completion in an unsupervised setting.  
3.5.1 Fatigue   
 Fatigue was measured using the Pediatric Quality of Life Inventory (PedsQLTM) 
Multidimensional Fatigue Scale (MFS) [179]. The PedsQLTM Measurement Model was 
developed to integrate generic and disease-specific modules to measure paediatric health-
related quality of life (HRQOL). The generic module enables comparison of HRQOL 
across patient and healthy populations, while disease-specific modules enhance sensitivity 
for detecting and quantifying minimal clinically important differences [180,181]. The 
PedsQLTM MFS was designed as a generic module to measure patient and parent 
perceptions of fatigue in paediatric patients [179]. The PedsQLTM MFS was developed and 
validated in paediatric oncology patients, and has since been validated in paediatric 
hematology, rheumatology and endocrinology patients [117,118,179,182,183]. In addition, 
the PedsQLTM MFS has been administered to paediatric nephrology, psychiatry and 
neurology patients, including children and adolescents with DMD [3,14,58]. A recently 
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published systematic review of instruments to assess fatigue in paediatric chronic health 
conditions identified the PedsQLTM MFS as the most commonly used instrument [14].  
  The PedsQLTM MFS is available in child self-report formats for ages 5–17 and 
parent proxy-report formats for ages 2–18 years. Parent proxy-report forms are parallel to 
child self-report forms, and designed to assess parents’ perceptions of their child’s fatigue. 
In this study, child self-report and parent proxy-report forms for ages 5–7 years (young 
children), 8–12 years (older children) and 13–18 years (adolescents) were used. Items for 
each form are essentially identical, differing only in developmentally appropriate language 
for each age group, and first or third person as appropriate for child self-report and parent 
proxy-report forms [117,118,179].  
 The PedsQLTM MFS is an 18-item form composed of three domains: General 
Fatigue (six items), Sleep/Rest Fatigue (six items) and Cognitive Fatigue (six items). Items 
include statements such as “I feel too tired to do things that I like to do” (General Fatigue), 
“I feel tired when I wake up in the morning” (Sleep/Rest Fatigue) and “It is hard for me to 
keep my attention on things” (Cognitive Fatigue). The instructions ask the respondent to 
indicate how much of a problem each item has been in the past one month (Standard 
Version) or seven days (Acute Version). The PedsQLTM MFS Standard Version (one-
month recall period) was used in the current study. A 5-point Likert scale is utilized across 
child self-report forms for ages 8–18 years and parent proxy-report forms (0=never, 
1=almost never, 2=sometimes, 3=often, and 4=almost always). To increase ease for young 
children of ages 5–7 years, response options are simplified to a 3-point Likert scale (0=not 
at all, 2=sometimes, and 4=a lot) anchored to a faces scale (0=happy face, 2=neutral face, 
and 4=sad face). Items are reverse scored and linearly transformed to a scale of 0–100 
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(0=100, 1=75, 2=50, 3=25, and 4=0), such that higher scores indicate fewer problems or 
symptoms. Scores by domain are computed as the sum of items divided by the number of 
items answered within the domain. In accordance with scoring instructions, if more than 
50% of items in a domain is missing, the domain score was not computed. A total score is 
computed as the sum of all items divided by the number of items answered on all domains. 
For a total score to be computed, completion of 50% or more items is required 
[117,118,179]. The PedsQLTM MFS child self-report and parent proxy-report forms are 
presented in Appendices I and J, respectively. 
3.5.2 Physical Activity Level 
Physical activity measures may be broadly classified as objective or subjective. 
Objective measures aim to quantify physiological and biomechanical parameters, and 
estimate physical activity outcomes using methods such as accelerometry, pedometry or 
heart rate monitoring. Subjective measures include survey measures, interviews and 
activity diaries or logs [184,185]. A child self-report measure was used in the current study 
because of low cost, ease of administration and low participation burden.  
The Physical Activity Questionnaire for Children (PAQ-C) and Physical Activity 
Questionnaire for Adolescents (PAQ-A) were used to measure physical activity level 
(Appendix K) [186]. Reliability and validity have been reported as acceptable to good in 
Canadian children and adolescents [187–189]. The PAQ-A has been previously 
administered to adolescents with physical disability secondary to a neurologic disorder—
cerebral palsy [190]. The PAQ-C and PAQ-A measure physical activity level during the 
past seven days [186]. The PAQ-C was designed for use in children in grades 4–8 
(approximately 8–14 years of age) and the PAQ-A was designed for adolescents in grades 
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9–12 (approximately 14–19 years of age). Questions in the PAQ-C were deemed applicable 
for young children (5–7 years of age) in our study based on clinical paediatric expertise. 
The PAQ-C was included in the patient questionnaire for young children and older 
children, and the PAQ-A was included in the patient questionnaire for adolescents.  
The PAQ-C is composed of nine items scored on a 5-point Likert scale. The first 
item asks respondents to rate the frequency of participation in 22 common leisure and sport 
activities and two “other” fill-in choices during the past seven days. This item is scored as 
a mean of all activities. The remaining items ask respondents to rate their physical activity 
level according to time-of-day or day-of-the-week. The PAQ-C summary score is the mean 
of all nine items, with a score of 1 indicating low physical activity and score of 5 indicating 
high physical activity. In the case of missing items, a summary score was not computed in 
accordance with scoring instructions. The PAQ-A is composed of eight items and is 
identical to the PAQ-C, except that the PAQ-A does not include an item concerning 
physical activity during recess at school [186].  
To improve applicability to DMD patients at all stages of the disease, modifications 
were made to the PAQ-C and PAQ-A with permission from the developers. Items 3 and 4 
in the original PAQ-C, and item 3 in the original PAQ-A provide the following response 
options for rating physical activity during recess or lunch at school: 1=sat down (talking, 
reading, doing school work), 2=stood around or walked around, 3=ran or played a little bit, 
4=ran around and played quite a bit, and 5=ran and played hard most of the time. To 
accommodate non-ambulatory children and adolescents, option 4 was modified to “ran 
around or played quite a bit” and option 5 was modified to “ran or played hard most of the 
time”. The mobility and strength of DMD patients may be limited, preventing participation 
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in physical activity to the same extent as their healthy peers. Therefore, respondents were 
instructed to consider any activity that causes them to sweat, breathe hard, or causes their 
legs or arms to feel tired.  
3.5.3 Functional Ability   
 Functional ability was assessed using the DMD Functional Ability Self-Assessment 
Tool (DMDSAT; Appendix L), a patient- or parent-reported survey measure designed and 
validated for assessing physical and respiratory functioning at all stages of disease 
progression in patients with DMD. The DMDSAT is fit for measuring functional ability 
from the early ambulatory to late non-ambulatory stage. The DMDSAT is composed of 
eight items in four domains: arm function (one item), mobility (one item), transfers (five 
items) and ventilatory support (one item). Each item asks respondents to rate their current 
level of functioning related to common activities of daily living, upper and lower 
extremities, or ventilation status. Item 1 is scored from 0–6, item 2 is scored from 0–5, and 
items 3–8 are scored from 0–2. Higher scores indicating higher functional ability. A total 
score is computed as the sum of all items, ranging from 0 (low functional ability) to 23 
(high functional ability) [191]. In the case of missing items, a total score was computed by 
dividing the sum of completed items by the maximum possible score of completed items, 
and multiplying this fraction by the maximum possible score of all items, as advised by the 
developer (Landfeldt, E., Personal Communication, May 2nd 2017). The DMDSAT was 
included in the parent questionnaire; parents were instructed to complete the measure with 
their child.  
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3.5.4 Depressive Symptoms 
Depressive symptoms were assessed using the Center for Epidemiological Studies 
Depression Scale for Children (CES-DC; Appendix M)—a modified version of the Center 
for Epidemiological Studies Depression Scale [192,193]. The CES-DC is a 20-item scale 
comprising six symptom domains: depressive mood, feelings of guilt or worthlessness, 
sense of helplessness or hopelessness, psychomotor retardation, loss of appetite and sleep 
disturbance. Respondents are asked to indicate how strongly they experienced certain 
feelings during the past week, using a 4-point Likert scale. Negatively phrased items are 
scored as: 0=not at all, 1=a little, 2=some, and 3=a lot. Positively phrased items are reverse 
scored as: 3=not at all, 2=a little, 1=some, and 0=a lot. A total score is computed as the 
sum of all items and ranges from 0–60, with higher scores indicating greater depressive 
symptoms [192,193]. In the case of missing items, a total score was computed after 
imputing the mean of completed items as the response for missing items, as advised by the 
developers (Fendrich, M. and Weissman, M., Personal Communication, April 27th, 2017). 
The CES-DC has been validated for youth of ages 6–23 years, and is widely implemented 
in research and clinical settings as a screening tool for depression [194]. Questions in the 
CES-DC were deemed applicable for 5-year-old children with DMD included in our study 
based on clinical paediatric expertise. The CES-DC has been previously used in children 
and adolescents with physical disability secondary to a neurologic disorder—multiple 
sclerosis [195]. The CESD-DC was included in the patient questionnaire. A child self-
report, rather than a parent proxy-report, measure of depressive symptoms was selected 
because previous studies have demonstrated poor to moderate agreement between child 
self-reported and parent proxy-reported internalizing problems, such as depressive 
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symptoms [196–198]. Child self-reports of depressive symptoms are often more consistent 
with formal psychiatric diagnoses of depression than parent proxy-reports [199,200].  
3.5.5 Sleep Disturbance Symptoms   
Sleep disturbance symptoms were assessed using the Sleep Disturbance Scale for 
Children (SDSC; Appendix N). The SDSC is a 26-item parent proxy-report measure 
encompassing six domains: disorders of initiating and maintaining sleep (seven items), 
sleep-related breathing disorders (three items), disorders of arousal (three items), sleep-
wake transition disorders (six items), disorders of excessive somnolence (five items), and 
sleep hyperhidrosis (two items). In answering questions, respondents are asked to consider 
their child’s sleep behaviour during the past six months. Using a 5-point Likert scale, 
respondents indicate how frequently certain behaviours are exhibited by their child: 
1=never, 2=occasionally (once or twice per month or less), 3=sometimes (once or twice 
per week), 4=often (3 or 5 times per week), and 5=always (daily). Respondents are also 
asked to provide estimates of sleep quantity and sleep onset latency. Domain scores are 
computed as the sum of items within each domain. A total score is computed as the sum of 
domain scores, and ranges from 26–130. Higher scores indicate greater sleep disturbance 
symptoms. In the case of missing items, the domain score and total score were not 
computed as advised by the developer (Bruni, O., Personal Communication, April 27th, 
2017). The SDSC was designed for use in research and clinical settings, and has been 
validated in healthy and patient populations of ages 6–15 years [201]. The SDSC has 
previously been used in children and adolescents with DMD of ages 4–18 years [72]. The 
SDSC was included in the parent questionnaire.  
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3.5.6 Patient Medical Information   
Patient medical histories were retrieved from the CNDR for both participating and 
non-participating patients. The patient’s age (years) as of June 13th, 2016 was obtained 
from the CNDR. Musculoskeletal characteristics retrieved from the CNDR included: 
unsupported ambulatory status (ambulant, non-ambulant), unsupported sitting ability status 
(yes, no), wheelchair use (never, intermittent or permanent), scoliosis status (none, 
surgically corrected, or uncorrected), corticosteroid therapy status (never, past, or current), 
and corticosteroid type (deflazacort or prednisone). Respiratory characteristics retrieved 
from the CNDR included: forced vital capacity (%), non-invasive ventilatory status (never, 
part-time, or full-time) and invasive ventilatory status (never, part-time, or full-time). 
Cardiac characteristics retrieved from the CNDR included: left ventricular ejection fraction 
(%), cardiomyopathy status (yes, no) and use of cardiac medications (yes, no).   
In addition to patient medical histories retrieved from the CNDR, a patient medical 
information section was included in the parent questionnaire (Appendix O). The patient 
medical information questionnaire was adapted from the Health-Related Quality of Life in 
Children with Epilepsy Study (HERQULES), with permission from the principal 
investigator [202]. Parents reported the presence of serious health conditions or co-
morbidities unrelated to DMD, such as cystic fibrosis, diabetes, cerebral palsy, epilepsy 
and cancer. Parents reported whether their child had been formally diagnosed with any of 
the following neuropsychiatric disorders: developmental delay, learning disability, 
attention deficit disorder, attention hyperactivity deficit disorder, autism spectrum disorder, 
oppositional defiant disorder, conduct disorder, depression and anxiety. To evaluate the 
relationship between neuropsychiatric disorders and fatigue, a single binary variable was 
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used: diagnosis with one or more neuropsychiatric disorder. Parents reported whether their 
child has ever needed and ever received: pharmacological or psychotherapy for behavioural 
or emotional problems, speech language therapy, occupational therapy, and special 
education. Lastly, parents reported their child’s ambulatory status (ambulant, non-
ambulant) and if applicable, time since loss of ambulation (less than one year ago, or one 
year ago or more). Parent-reported non-invasive ventilatory status was also extracted from 
DMDSAT. Where possible medical information of participating patients retrieved from the 
CNDR was cross-referenced with parent-report medical information (ambulatory status 
and non-invasive ventilatory status). In the case of discrepancies between registry and 
parent-reported medical information, the most recently dated information available was 
used, which was parent-reported information in all cases. Discrepant information was 
reviewed by a paediatric neurologist to ensure the most recently dated information was 
reflective of the progressive functional decline of the disease and interpreted in the context 
of other clinical characteristics.  
3.5.7 Sociodemographic Information   
 A sociodemographic information section was included in the parent questionnaire 
(Appendix P). Parents reported their age, sex, relationship to the patient, highest 
educational attainment, employment status and marital status. If applicable, parents 
reported the highest educational attainment and employment status of their spouse or 
partner. Lastly, household size and annual household income before taxes (CAD) were 
collected by parent-report. 
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3.6 Statistical Analyses  
All statistical analysis was performed using Stata® 13.0 [178]. A two-sided level of 
significance at =0.05 was assumed.  
3.6.1 Sample Characteristics 
Descriptive statistics were computed for patient medical information and 
sociodemographic information. Mean  standard deviation or median (interquartile range), 
minimum and maximum were computed for continuous variables. Frequencies and 
percentages were computed for categorical variables. To assess differences between 
participating and non-participating patients, unpaired two-sample t-tests were used for 
continuous variables, and 2 tests of independence or Fisher’s exact tests were used for 
categorical variables. Fisher’s exact tests were used in place of 2 tests of independence 
when an expected frequency in a response category was less than 5.  
3.6.2 Objective 1: To describe subjective fatigue in children and adolescents with DMD 
from patients’ and parents’ perspectives.  
 Distributions of child self-report and parent proxy-report PedsQLTM MFS scores 
were assessed using graphical methods (normal quantile-quantile plots, box-and-whisker 
plots and histograms) and statistical methods (Shapiro-Wilk test of normality). Descriptive 
statistics were computed for child self-report and parent proxy-report PedsQLTM MFS 
scores for the total sample and for subgroups according to age (young children, 5–7 years; 
older children, 8–12 years; and adolescents, 13–17 years) and ambulatory status (ambulant 
and non-ambulant). Mean  standard deviation, median (interquartile range), minimum and 
maximum were computed for total fatigue, general fatigue, sleep/rest fatigue and cognitive 
fatigue scores. PedsQLTM MFS scores of DMD patients in the current study were compared 
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with PedsQLTM MFS scores of healthy children and adolescents from published data 
[117,118]. Agreement between child self-reports and parent proxy-reports of PedsQLTM 
MFS scores were examined using pairwise correlation analyses with Pearson’s correlation 
coefficient (r), or Spearman’s rank correlation coefficient (ρ) if non-normality of data was 
observed. 
3.6.3 Objective 2: To explore associations of patient characteristics with child self-report 
and parent proxy-report measures of subjective fatigue in children and adolescents 
with DMD.  
 Bivariate analyses were conducted to explore associations of patient characteristics 
with child self-reported and parent proxy-reported fatigue. For dichotomous variables 
(ambulatory status, time since loss of ambulation, current glucocorticoid use, 
cardiomyopathy, diagnoses with one or more neuropsychiatric disorder), unpaired two-
sample t-tests or non-parametric Wilcoxin Rank Sum tests were used to assess differences 
in PedsQLTM MFS scores between categories. Wilcoxin Rank Sum tests were used in place 
of unpaired two-sample t-tests when n<30 in one or more category or normality of the 
PedsQLTM MFS score was violated. For categorical variables of more than two categories 
(age group, wheelchair use, scoliosis and non-invasive ventilatory status), one-way 
analysis of variance (ANOVA) or non-parametric Kruskal-Wallis tests were used to assess 
differences in PedsQLTM MFS scores between categories. Kruskal-Wallis tests were used 
in place of one-way ANOVA when n<30 in one or more category or normality of the 
PedsQLTM MFS score was violated.   
Distributions of continuous variables were assessed using graphical methods 
(normal quantile-quantile plots, box-and-whisker plots and histograms) and statistical 
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methods (Shapiro-Wilk test of normality). Relationships of continuous variables (age, 
physical activity level, functional ability, depressive symptoms, sleep disturbance 
symptoms, forced vital capacity and left ventricular ejection fraction) with PedsQLTM MFS 
scores were visually inspected using scatter plots. Associations of continuous variables 
with PedsQLTM MFS scores were examined using pairwise correlation analyses with 
Pearson’s correlation coefficient (r), or Spearman’s rank correlation coefficient (ρ) if non-
normality of the data was observed. 
 Multivariable linear regression analyses were used to further explore the 
association between total sleep disturbance symptoms with child self-reported and parent 
proxy-reported fatigue, while adjusting for additional patient characteristics. Given the 
exploratory nature of this thesis, bivariate analyses and clinical expertise were used to guide 
selection of patient characteristics to be adjusted for in the linear regression analyses, as 
described in Chapter 4 (Results). Linear regression analyses were initially performed with 
complete case analysis (listwise deletion), followed by linear regression analyses with 
multiple imputation using chained equations as a sensitivity analysis for examining the 
impact of missing data. Normally distributed continuous variables were imputed using 
linear regression. Non-normally distributed continuous variables were imputed using 
predictive mean matching [203,204].  
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Chapter 4  
4 Results  
4.1 Sample Characteristics  
 A total of 193 eligible participants, composed of 26 young children (13.5%; ages 
5–7 years), 75 older children (38.9%; ages 8–12 years) and 92 adolescents (47.7%; ages 
13–17 years), were identified through the Canadian Neuromuscular Disease Registry 
(CNDR) and received mailed paper questionnaires. An overall response rate of 36.8% was 
achieved, with N=71 eligible patient-parent pairs returning completed questionnaires. 
Questionnaire packages were returned to sender for seven patients for whom mailing 
addresses could not be corrected by contacting their clinic. Participating patients included 
12 young children (16.9%), 25 older children (35.2%) and 34 adolescents (47.9%). Both 
patient and parent questionnaires were completed by 64 patient-parent pairs, while for five 
participants only the parent questionnaire was completed and for two participants only the 
patient questionnaire was completed. No patients were excluded due to a parent-reported 
comorbidity unrelated to Duchenne muscular dystrophy (DMD). One parent answered 
“Yes” to their child having all comorbidities: asthma, cystic fibrosis, diabetes, cerebral 
palsy, epilepsy and cancer. Based on clinical judgement, however, this was assumed to be 
a response error and the patient was included. Three additional patients were reported to 
have asthma. These patients were included under the assumption that their asthma was 
well-managed due to routine clinical respiratory care typically received by DMD patients. 
Additionally, asthma may be an adverse effect of medications used in the cardiac 
management of DMD, such as angiotensin-converting enzyme inhibitors or beta-
adrenergic blocking agents [205].  
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4.1.1 Comparison of Participating and Non-Participating Patients   
 Patient medical histories were retrieved from the CNDR for both participating and 
non-participating patients, and are summarized in Table 4.1. No statistically significant 
differences were observed between participating and non-participating patients with 
respect to any clinical characteristic examined: age, genetic mutation, musculoskeletal 
characteristics (unsupported ambulation, unsupported sitting ability, wheelchair use, 
scoliosis and corticosteroid use), respiratory characteristics (forced vital capacity and non-
invasive and invasive ventilatory support) and cardiac characteristics (left ventricular 
ejection fraction, cardiomyopathy status and cardiac medications), and clinical trial 
participation. Additionally, no statistically significant difference was observed between 
participating and non-participating patients with respect to geographic region in Canada 
(Table 4.1).  
4.1.2 Patient Medical Information  
 In addition to patient medical histories from the CNDR, parents of participating 
patients completed a patient medical information questionnaire as summarized in Table 
4.2. On average, participating patients were 11.6  3.6 years of age (mean  standard 
deviation), and ranged from 5–17 years of age. Most patients had a deletion (60.6%) in the 
DMD gene, followed by a duplication (16.9%) or point mutation (16.9%). More than half 
of patients were ambulant (59.2%). Among non-ambulant patients, the majority lost 
ambulation more than one year ago (74.1%). Most patients did not have scoliosis (64.8%). 
Most patients were currently receiving corticosteroid therapy (73.2%). Of patients 
currently receiving corticosteroid therapy, most were receiving deflazacort (90.2%). On 
average, forced vital capacity of patients was 85.2  18.3% (mean  standard deviation), 
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and ranged from 50–127%. Four patients (5.6%) were receiving non-invasive ventilatory 
support either part-time (N=2) or full-time (N=2). No patients were receiving invasive 
ventilatory support. On average, left ventricular ejection fraction of patients was 63.3  
7.0% (mean  standard deviation), and ranged from 48–76%. Five patients (7%) were 
diagnosed with cardiomyopathy. More than half of children have been diagnosed with at 
least one neuropsychiatric disorder (53.5%). A learning disability was the most commonly 
reported neuropsychiatric disorder (33.8%), followed by developmental delay (22.5%), 
attention deficit disorder or attention deficit hyperactivity disorder (15.5%) and anxiety 
(12.7%).  
4.1.3 Sociodemographic Information  
 A sociodemographic information questionnaire was completed by parents as 
summarized in Table 4.3. On average, parents of participating patients were 44.6  6.3 
years of age (mean  standard deviation), and ranged from 29–56 years of age. Of the 
primary caregivers who completed the parent questionnaire, 84.5% were female and 94.4% 
were the child’s biological parent. Most parents completed post-secondary education 
(70.4%), and more than half were employed either part-time or full-time (60.6%). Most 
parents were married or living common law (71.8%). Median annual household income 
before taxes was $75,000 to $99,999 CAD, which is consistent with the national median 
household income [206].     
4.2 Objective 1: To describe subjective fatigue in children and adolescents with 
DMD from patients’ and parents’ perspectives.  
Descriptive statistics for child-self report and parent proxy-report Pediatric Quality 
of Life Inventory InventoryTM (PedsQLTM) Multidimensional Fatigue Scale (MFS) scores 
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are summarized in Tables 4.4–4.6 for all respondents, by age group, and by ambulatory 
status, respectively. Possible PedsQLTM MFS scores range from 0–100 for total fatigue, 
general fatigue, sleep/rest fatigue and cognitive fatigue, with higher scores indicating less 
fatigue [118]. For reference, data from the current study were compared to PedsQLTM MFS 
scores of healthy children and adolescents from published data (Table 4.4). On average, 
healthy children and adolescents were 13.7  2.2 years of age (mean  standard deviation), 
and ranged from 10–17 years of age. The healthy sample included 74 males (47.1%) and 
83 females (52.9%) [118]. PedsQLTM MFS scores were also compared to published data 
from a second healthy sample, which included younger children of ages 8.9  11.0 years 
(mean  standard deviation) ranging from 2–18 years. The healthy sample was composed 
of 69 males (67.6%) and 33 females (32.4%) who were administered the PedsQLTM MFS 
Acute Version (seven-day recall period) [117].  
4.2.1 PedsQLTM Multidimensional Fatigue Scale by Child Self-Report  
Children and adolescents with DMD reported greater fatigue (lower scores) 
compared with healthy children and adolescents from published data across all domains, 
irrespective of age group or ambulatory status [117,118]. The average fatigue score by 
child self-report was 71.6  15.2 (mean  standard deviation). Median general fatigue score 
by child self-report was 70.8, with an interquartile range of 58.3–83.3. Median sleep/rest 
fatigue score by child self-report was 75 with an interquartile range of 64.6–87.5. Median 
cognitive fatigue score by child self-report was 70.8, with an interquartile range of 54.2–
91.7. The trajectory of child self-reported fatigue across disease stages was examined 
through PedsQLTM MFS scores stratified by age group (Table 4.5) and ambulatory status 
(Table 4.6). Older children tended to report greater total fatigue compared with young 
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children and adolescents. Older children and adolescents tended to report greater general 
fatigue and sleep/rest fatigue compared with young children. Young children and older 
children tended to report greater cognitive fatigue compared with adolescents. Ambulant 
and non-ambulant patients reported similar total fatigue and sleep/rest fatigue. Non-
ambulant patients tended to report greater general fatigue compared with ambulant 
patients. Ambulant patients tended to report greater cognitive fatigue compared with non-
ambulant patients.     
4.2.2 PedsQLTM Multidimensional Fatigue Scale by Parent Proxy-Report 
PedsQLTM MFS scores by child self-report were significantly correlated with 
PedsQLTM MFS scores by parent proxy-report across domains (Table 4.7): total fatigue 
(ρ=0.69; P<0.001), general fatigue (ρ=0.63; P<0.001), sleep/rest fatigue (ρ=0.50; P<0.001) 
and cognitive fatigue (ρ=0.68; P<0.001). However, parents perceived their child’s level of 
general fatigue to be worse than that perceived by the patient. Children and adolescents 
with DMD experienced greater fatigue (lower scores) by parent proxy-report compared 
with healthy children and adolescents from published data across all domains, irrespective 
of age group or ambulatory status [117,118]. The average total fatigue score by parent 
proxy-report was 70.8  16.0 (mean  standard deviation). General fatigue scores by parent 
proxy-report were 64.2  20.1 (mean  standard deviation). Median sleep/rest fatigue score 
by parent proxy-report was 79.2 with an interquartile range of 66.7–91.7. Median cognitive 
fatigue score by parent proxy-report was 75, with an interquartile range of 54.2–91.7. The 
trajectory of parent proxy-reported fatigue across disease stages was examined through 
PedsQLTM MFS scores stratified by age group (Table 4.5) and ambulatory status (Table 
4.6). Parents reported that older children tended to experience greater total fatigue 
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compared with young children and adolescents. According to parents, older children and 
adolescents tended to experience greater general fatigue and sleep/rest fatigue compared 
with young children. Young children and older children tended to experience greater 
cognitive fatigue with adolescents. Ambulant and non-ambulant patients experienced 
similar total fatigue. Non-ambulant patients tended to experience greater general fatigue 
and sleep/rest fatigue compared with ambulant patients. Ambulant patients tended to 
experience greater cognitive fatigue compared with non-ambulant patients.            
4.3 Objective 2: To explore associations of patient characteristics with child self-
report and parent parent-proxy report measures of subjective fatigue in 
children and adolescents with DMD. 
4.3.1 Age 
 Age was assessed as a categorical variable (young children, older children, 
adolescents) and a continuous variable. Age group was not significantly associated with 
any child self-report or parent proxy-report measure of fatigue (Table 4.5). Similarly, age 
(years) was not significantly correlated with any measure of fatigue by child self-report 
(Table 4.8) or parent proxy-report (Table 4.9).  
4.3.2 Musculoskeletal Characteristics  
 No significant differences were observed between ambulant and non-ambulant 
patients for total fatigue, general fatigue, sleep/rest fatigue or cognitive fatigue by child 
self-report or parent proxy-report (Table 4.6). 
 Among non-ambulant patients, no significant differences were observed between 
patients who lost ambulation less than one year ago compared with patients who lost 
ambulation one year ago or more for total fatigue by child self-report (Z=-0.85; P=0.40) or 
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parent proxy-report (Z=-0.22; P=0.82); general fatigue by child self-report (Z=-1.18; 
P=0.24) or parent proxy-report (Z=-0.69; P=0.49); sleep/rest fatigue by child self-report 
(Z=0.34; P=0.73) or parent proxy-report (Z=0.39; P=0.70); and cognitive fatigue by child 
self-report (Z=-0.58; P=0.56) or parent proxy-report (Z=-0.31; P=0.76). 
 No significant differences were observed among patients who never, intermittently 
or permanently use a wheelchair for total fatigue by child self-report (2=0.37; P=0.83) or 
parent proxy-report (2=3.15; P=0.21); general fatigue by child self-report (2=2.73; 
P=0.26) or parent proxy-report (2=4.24; P=0.12); sleep/rest fatigue by child self-report 
(2=0.54; P=0.76) or parent proxy-report (2=4.48; P=0.11); and cognitive fatigue by child 
self-report (2=1.89; P=0.39) or parent proxy-report (2=2.06; P=0.36). 
 No significant differences were observed among patients without scoliosis, with 
surgically corrected scoliosis, or with uncorrected scoliosis for total fatigue by child self-
report (2=0.75; P=0.69) or parent proxy-report (2=4.11; P=0.13); general fatigue by child 
self-report (2=0.86; P=0.65) or parent proxy-report (2=1.94; P=0.38); sleep/rest fatigue 
by child self-report (2=0.03; P=0.98) or parent proxy-report (2=1.33; P=0.51); and 
cognitive fatigue by child self-report (2=1.87; P=0.39) or parent proxy-report (2=4.25; 
P=0.12). 
 Ten patients (14.1%) in our sample were not currently receiving glucocorticoid 
therapy. However, current glucocorticoid use was not associated with total fatigue by child 
self-report (Z=-0.04; P=0.97) or parent proxy-report (Z=-0.02; P=0.98); general fatigue by 
child self-report (Z=1.77; P=0.08) or parent proxy-report (Z=0.74; P=0.46); sleep/rest 
fatigue by child self-report (Z=-0.84; P=0.40) or parent proxy-report (Z=0.98; P=0.33); and 
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cognitive fatigue by child self-report (Z=-0.95; P=0.34) or parent proxy-report (Z=-0.65; 
P=0.53). 
4.3.3 Respiratory Characteristics  
 Greater forced vital capacity was significantly associated with less general fatigue 
by child self-report (ρ=0.34; P=0.03). Forced vital capacity was not associated with other 
domains of fatigue by child self-report (Table 4.8) or parent-proxy report (Table 4.9). 
Kruskal-Wallis test demonstrated a significant difference in parent proxy-reported 
sleep/rest fatigue between patients not treated with non-invasive ventilation (NIV; N=66), 
patients treated with part-time NIV (N=2) and patients treated with full-time NIV (N=2; 
2=7.02; P=0.03). Post-hoc analysis using Dunn’s test with Bonferroni adjustment 
demonstrated that parent proxy-reported sleep/rest fatigue was stochasticity greater for 
patients treated with part-time NIV compared with children not treated with NIV (P=0.03). 
Sleep/rest fatigue scores of the two patients receiving part-time NIV were 8.3 and 54.2 by 
parent proxy-report, and 8.3 and 66.7 by child self-report. In comparison, the median 
sleep/rest fatigue score of the entire sample was 79.2 by parent proxy-report and 75 by 
child self-report. Total fatigue scores of the two patients receiving part-time NIV were 63.9 
and 58.3 by parent proxy-report, and 44.4 and 63.9 by child self-report. In comparison, the 
mean total fatigue score of the entire sample was 70.8 by parent proxy-report and 71.6 by 
child self-report.  
 NIV status was not associated with total fatigue by child self-report (2=0.4.25; 
P=0.12) or parent proxy-report (2=0.98; P=0.61); general fatigue by child self-report 
(2=2.38; P=0.30) or parent proxy-report (2=2.58; P=0.27); sleep/rest fatigue by child 
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self-report (2=2.95; P=0.23); and cognitive fatigue by child self-report (2=1.80; P=0.41) 
or parent proxy-report (2=0.40; P=0.82). 
4.3.4 Cardiac Characteristics  
 Left ventricular ejection fraction was not associated with any measure of fatigue by 
child self-report (Table 4.8) or parent-proxy report (Table 4.9). Patients with 
cardiomyopathy (N=5) had stochastically less cognitive fatigue compared with patients 
without cardiomyopathy (N=59) by child self-report (Z=-2.39; P=0.02) and parent proxy-
report (Z=-2.11; P=0.04). Cardiomyopathy status was not associated with total fatigue by 
child self-report (Z=-0.22; P=0.83) or parent proxy-report (Z=-1.13; P=0.26); general 
fatigue by child self-report (Z=1.01; P=0.31) or parent proxy-report (Z=0.71; P=0.48); and 
sleep/rest fatigue by child self-report (Z=0.33; P=0.74) or parent proxy-report (Z=0.31; 
P=0.76).  
4.3.5 Neuropsychiatric Characteristics 
   Diagnosis with one or more neuropsychiatric disorder was not associated with total 
fatigue by child self-report (t=0.85; P=0.40) or parent proxy-report (t=1.93; P=0.06); 
general fatigue by child self-report (t=1.50; P=0.14) or parent proxy-report (t=0.92; 
P=0.36); sleep/rest fatigue by child self-report (t=0.47; P=0.64) or parent proxy-report 
(t=1.87; P=0.07); and cognitive fatigue by child self-report (t=-0.05; P=0.96) or parent 
proxy-report (t=1.82; P=0.07). 
4.3.6 Physical Activity Level  
Physical activity level was measured using the Physical Activity Questionnaire for 
Children and Adolescents (PAQ-C/A). Possible PAQ-C/A scores range from 1 (low 
physical activity) to 5 (high physical activity) [187]. Median PAQ-C/A score was 1.7, with 
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an interquartile range of 1.3–2.3 and range of 1–3.7. Greater physical activity was 
significantly associated with less general fatigue (ρ=0.27; P=0.04) by child self-report. 
Physical activity level was not associated with other domains of fatigue by child self-report 
(Table 4.8) or parent-proxy report (Table 4.9).  
4.3.7 Functional Ability  
 Overall functional ability was measured using the Duchenne Muscular Dystrophy 
Functional Ability Self-Assessment Tool (DMDSAT). Possible DMDSAT scores range 
from 0 (low functional ability) to 23 (high functional ability) [191]. Median DMDSAT 
score was 18, with an interquartile range of 9–21 and range of 3–23. Lower functional 
ability was significantly associated with greater total fatigue by parent proxy-report only 
(ρ=0.26; P=0.03); with greater general fatigue by child self-report (ρ=0.30; P=0.02) and 
parent proxy-report (ρ=0.30; P=0.01); and with greater sleep/rest fatigue by parent proxy-
report only (ρ=0.35; P=0.003). Functional ability was not associated with cognitive fatigue 
by child self-report (Table 4.8) or parent proxy-report (Table 4.9). 
4.3.8 Depressive Symptoms  
 Depressive symptoms were measured using the Center for Epidemiological Studies 
Depression Scale for Children (CES-DC). Possible CES-DC scores range from 0–60 with 
higher scores indicating greater depressive symptoms [193,207]. Median CES-DC score 
was 7.5, with an interquartile range of 4–15 and range of 0–45. More depressive symptoms 
were significantly associated with greater total fatigue by child self-report (ρ=-0.46; 
P<0.001) and parent proxy-report (ρ=-0.45; P<0.001); with greater general fatigue by child 
self-report (ρ=-0.30; P=0.02) and parent proxy-report (ρ=-0.37; P=0.002); with greater 
sleep/rest fatigue by child self-report (ρ=-0.30; P=0.02) and parent proxy-report (ρ=-0.35; 
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P=0.005); and with greater cognitive fatigue by child self-report (ρ=-0.46; P<0.001) and 
parent proxy-report (ρ=-0.32; P=0.009). 
4.3.9 Sleep Disturbances Symptoms 
 Sleep disturbance symptoms were measured using the Sleep Disturbance Scale for 
Children (SDSC), composed of six sleep disturbance factors: disorders of initiating and 
maintaining sleep, sleep-related breathing disorders, disorders of arousal, sleep-wake 
transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis. Factor 
scores and total scores were computed. Possible SDSC total scores range from 26–130, 
with higher scores indicating greater sleep disturbance symptoms [201]. Median SDSC 
total score was 38, with an interquartile range of 33–41 and range of 28–81. More sleep 
disturbance symptoms were significantly associated with greater total fatigue by child self-
report (ρ=-0.42; P=0.003) and parent proxy-report (ρ=-0.51; P<0.001); with greater 
general fatigue by child self-report (ρ=-0.32; P=0.03) and parent proxy-report (ρ=-0.45; 
P=0.001); with greater sleep/rest fatigue by child self-report (ρ=-0.30; P=0.04) and parent 
proxy-report (ρ=-0.48; P<0.001); and with greater cognitive fatigue by child self-report 
(ρ=-0.33; P=0.03) and parent proxy-report (ρ=-0.34; P=0.01). Spearman’s rank correlation 
coefficients for each SDSC factor score and PedsQLTM MFS scores by child self-report and 
parent proxy-report are presented in Table 4.8 and Table 4.9, respectively. Significant 
correlations with fatigue were most frequently observed for disorders of initiating and 
maintaining sleep, disorders of arousal, sleep/wake transition disorders, and disorders of 
excessive somnolence. 
 Exploratory multivariable linear regression analyses were performed to test the 
association between total sleep disturbance symptoms with child self-reported fatigue and 
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parent proxy-reported fatigue, while adjusting for physical activity level, functional ability 
and depressive symptoms (Figure 4.1). Because bivariate analyses did not consistently 
demonstrate significant associations between objective measures of musculoskeletal, 
respiratory and cardiac function and fatigue, overall functional ability may be more related 
to fatigue than any single musculoskeletal, respiratory or cardiac characteristic. Thus, 
functional ability measured using the DMDSAT was included as a covariate in the 
multivariable linear regression analyses, rather than single measures of musculoskeletal, 
respiratory and cardiac function. Although cardiac function is not reflected in the 
DMDSAT score, it was not included as a covariate because clinical manifestation of 
cardiac dysfunction that may impact fatigue are more likely to present in adulthood than in 
childhood or adolescence [94].   
 
Figure 4.1. A model of fatigue in children and adolescents with Duchenne muscular 
dystrophy tested using multivariable linear regression analyses.  
 Linear regression analyses with listwise deletion are presented in Tables 4.10 and 
4.11 for child self-reported and parent proxy-reported fatigue, respectively (N=41). More 
sleep disturbance symptoms were significantly associated with greater child self-reported 
total fatigue (=-0.84; P=0.001), general fatigue (=-0.97; P=0.003) and cognitive fatigue 
(=-1.24; P=0.006), but not with child self-reported sleep/rest fatigue (=-0.28; P=0.31), 
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while adjusting for physical activity level, functional ability and depressive symptoms 
(Table 4.10). Sleep disturbance symptoms, physical activity level, functional ability and 
depressive symptoms explained 38% of the variability in child self-reported total fatigue, 
39% of the variability in child self-reported general fatigue, and 22% of the variability in 
child self-reported cognitive fatigue. More sleep disturbance symptoms were significantly 
associated with parent proxy-reported total fatigue (=-0.91; P<0.001), general fatigue 
(=-1.08; P=0.002), sleep/rest fatigue (=-0.62; P=0.01) and cognitive fatigue (=-1.03; 
P=0.02), while adjusting for physical activity level, functional ability and depressive 
symptoms (Table 4.11). Sleep disturbance symptoms, physical activity level, functional 
ability and depressive symptoms explained 44% of the variability in parent proxy-reported 
total fatigue, 32% of the variability in parent proxy-reported general fatigue, 32% of the 
variability in parent proxy-reported sleep/rest fatigue, and 18% of the variability in parent 
proxy-reported cognitive fatigue. 
Linear regression analyses with multiple imputation using chained equations 
performed to examine the impact of missing data are presented in Tables 4.12 and 4.13 for 
child self-reported and parent proxy-reported fatigue, respectively (N=71). This sensitivity 
analysis yielded similar results for child self-reported and parent proxy-reported fatigue 
compared with the analysis using listwise deletion. More sleep disturbance symptoms were 
significantly associated with greater child self-reported total fatigue (=-0.62; P=0.008), 
general fatigue (=-0.73; P=0.03) and cognitive fatigue (=-0.94; P=0.005), but not with 
child self-reported sleep/rest fatigue (=-0.17; P=0.60), while adjusting for physical 
activity level, functional ability and depressive symptoms (Table 4.12). More sleep 
disturbance symptoms were significantly associated with parent proxy-reported total 
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fatigue (=-0.66; P=0.03), general fatigue (=-0.74; P=0.04), but not with sleep/rest 
fatigue (=-0.39; P=0.27) or cognitive fatigue (=-0.73; P=0.10), while adjusting for 
physical activity level, functional ability and depressive symptoms (Table 4.13). Although 
the associations between sleep disturbance symptoms and parent proxy-reported sleep/rest 
fatigue and cognitive fatigue were no longer significant, the direction of the regression 
coefficients remained the same with more sleep disturbance symptoms being associated 
with greater fatigue.  
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Table 4.1. Comparison of clinical characteristics retrieved from the Canadian 
Neuromuscular Disease Registry between participating and non-participating patients  
 Participating 
Patients 
(N=71) 
Non-Participating 
Patients 
(N=122) 
P-Valuea 
Region    0.18 
British Columbia 13 (18.3%) 36 (29.5%)  
Alberta 10 (14.1%) 15 (12.3%)  
Ontario 40 (56.4%) 65 (53.3%)  
Quebec 8 (11.3%) 6 (4.9%)  
Age  11.6  3.6  
(5, 17) 
12.0  3.3  
(5, 17) 
0.56 
Genetic Mutation   0.32 
Deletion 43 (60.6%) 82 (67.2%)  
Duplication 12 (16.9%) 10 (8.2%)  
Point Mutation 12 (16.9%) 19 (15.6%)  
None Detected 1 (1.4%) 3 (2.5%)  
Unreported 3 (4.2%) 8 (6.6%)  
Musculoskeletal Characteristics 
Unsupported ambulation    0.45 
Ambulant 42 (59.2%) 84 (68.9%)  
Non-ambulant 28 (39.4%) 31 (25.4%)  
Unreported 1 (1.4%) 7 (5.7%)  
Unsupported sitting ability   0.75 
No 4 (5.6%) 6 (4.9%)  
Yes 57 (80.3%) 104 (83.3%)  
Unreported  10 (14.1%) 12 (9.8%)  
Wheelchair use    0.50 
Never  30 (42.3%) 47 (38.5%)  
Intermitted  16 (22.5%) 38 (31.1%)  
Permanent 17 (23.9%) 27 (22.1%)  
Unreported 8 (11.3%) 10 (8.2%)  
Scoliosis    0.92 
No 46 (64.8%) 82 (67.2%)  
Surgically corrected  1 (1.4%) 1 (0.8%)  
Uncorrected  9 (12.7%) 19 (15.6%)  
Unreported 15 (21.1%) 20 (16.4%)  
Corticosteroid therapy   0.25 
Never 9 (12.7%) 8 (6.6%)  
Past  1 (1.4%) 2 (1.6%)  
Current 52 (73.2%) 101 (82.8%)  
Unreported 9 (12.7%) 11 (9.0%)  
Corticosteroid type   0.60 
Deflazacort  47 (90.4%) 95 (96.0%)  
Prednisone  2 (3.9%) 2 (2.0%)  
Unreported  3 (5.8%) 2 (2.0%)  
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 Participating 
Patients 
(N=71) 
Non-Participating 
Patients 
(N=122) 
P-Valuea 
Respiratory Characteristics 
Forced vital capacity  85.2  18.3  
(50, 127) 
80.6  23.0  
(16, 135) 
0.28 
Non-invasive ventilatory 
support    
  0.15 
No 66 (93.0%) 105 (86.1%)  
Part-time 2 (2.8%) 6 (4.9%)  
Full-time 2 (2.8%) -  
Unreported 1 (1.4%) 11 (9.0%)  
Invasive ventilatory support    - 
No 62 (87.3%) 109 (89.3%)  
Part-time - -  
Full-time - -  
Unreported 9 (12.7%) 13 (10.7%)  
Cardiac Characteristics 
Left ventricular ejection fraction  63.3  7.0  
(48, 76) 
62.9  9.9  
(17.4, 80) 
0.85 
Cardiomyopathy    0.50 
No 59 (83.1%) 106 (86.9%)  
Yes 5 (7.0%) 5 (4.1%)  
Unreported 7 (9.9%) 11 (9.0%)  
Cardiac medications   0.78 
No 46 (64.8%) 91 (74.6%)  
Yes 13 (18.3%) 23 (18.9%)  
Unreported 12 (16.9%) 8 (6.6%)  
  Research 
Clinical trial participation   0.31 
Never 35 (49.3%) 70 (57.4%)  
Past 1 (1.4%) 7 (5.7%)  
Current 15 (21.1%) 21 (17.2%)  
Unreported  20 (28.2%) 24 (19.7%)  
Data are mean  standard deviation (range) or frequency (percentage) 
aUnpaired t-tests were used for continuous variables, and 2 tests or Fisher’s exact tests 
were used for categorical variables to assess differences between respondents and non-
respondents. Unreported values were not included in analyses.    
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Table 4.2. Patient medical information by parent-report (respondents only, N=71) 
 Frequency Percentage 
Motor Function 
Ambulant 42 59.2% 
Non-ambulant 28 39.4% 
Lost ambulation less than one year ago 7 25.0% 
Lost ambulation one year ago or more  20 71.4% 
Neuropsychiatric Disorders 
Developmental delay  16 22.5% 
Learning disability  24 33.8% 
Attention Deficit Disorder or Attention Deficit Hyperactivity 
Disorder 
11 15.5% 
Autism spectrum disorder 1 1.4% 
Oppositional defiant disorder 4 5.6% 
Conduct disorder 2 2.8% 
Depression 5 7.0% 
Anxiety  9 12.7% 
One or more neuropsychiatric disorder 38 53.5% 
Therapies 
Pharmacotherapy or psychotherapy for behavioural problems    
Ever needed 14 19.7% 
Ever received 12 16.9% 
Pharmacotherapy or psychotherapy for emotional problems    
Ever needed 12 16.9% 
Ever received 11 15.5% 
Occupational therapy   
Ever needed 44 62.0% 
Ever received 42 59.2% 
Speech language therapy    
Ever needed  26 36.6% 
Ever received  26 36.6% 
School Information 
Special education (individualized education plan, special 
needs classroom, tutoring, etc.)  
  
Ever needed  50 70.4% 
Ever received  47 66.2% 
Research 
Current clinical trial or other research participation    31 44.9% 
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Table 4.3. Sociodemographic information by parent-report (respondents only, N=71)  
 Frequency Percentage 
Primary Caregivera 
Age  44.6  6.3b (29, 56)b 
Sex    
Male 9 12.8% 
Female 60 84.5% 
Relationship to Child   
Biological parent  67 94.4% 
Adoptive parent - - 
Step parent  - - 
Foster parent  2 2.8% 
Guardian  - - 
Highest educational attainment    
Less than secondary school graduation  5 7.1% 
Secondary school diploma or equivalent  13 18.3% 
Vocational training  7 9.9% 
College or university diploma or degree 38 53.5% 
Graduate degree  5 7.0% 
Employment status    
Unemployed  17 24.0% 
Employed (part-time or full-time) 43 60.6% 
Stay-at-home parent  8 11.3% 
Student - - 
Marital status   
Married or living common law  51 71.8% 
Widowed  1 1.4% 
Separated 6 8.5% 
Divorced  5 7.0% 
Single 6 8.5% 
Spouse or Partner of Primary Caregiver 
Highest educational attainment    
Less than secondary school graduation  7 9.9% 
Secondary school diploma or equivalent  9 12.7% 
Vocational training  7 9.9% 
College or university diploma or degree 27 38.0% 
Graduate degree  7 9.9% 
Employment status    
Unemployed  5 7.0% 
Employed (part-time or full-time) 49 69.0% 
Stay-at-home parent  3 4.2% 
Student - - 
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 Frequency Percentage 
Household 
Household size 4 (3, 5)c (2, 9)c 
Annual household income before taxes (CAD)   
$14,999 and under   1 1.4% 
$15,000 to $34,999 7 9.9% 
$35,000 to $49,999 7 9.9% 
$50,000 to $74,999 9 12.7% 
$75,000 to $99,999 14 19.7% 
$100,000 and over 24 33.8% 
aPrimary caregiver describes the parent who completed the questionnaire 
bData are mean  standard deviation; (range) 
cData are median (interquartile range); (range) 
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Table 4.4. Descriptive statistics for the Pediatric Quality of Life InventoryTM (PedsQLTM) 
Multidimensional Fatigue Scale by child self-report and parent proxy-report  
 Duchenne Muscular Dystrophy Sample Healthy Samplea 
 
N Mean  
SD 
Median (IQR) Range N 
Mean  
SD 
Child Self-Report 
Total fatigue 66 71.6  15.2 69.4 (62.5, 81.9) (25, 100) 
157 
82.2  12.3 
General fatigue 66 70.2  19.7  70.8 (58.3, 83.3) (0, 100) 86.4  13.1 
Sleep/rest fatigue 66 74.0  17.5 75 (64.6, 87.5) (8.3, 100) 77.4  15.4 
Cognitive fatigue 65 70.9  23.0 70.8 (54.2, 91.7) (0, 100) 82.8  16.3 
Parent Proxy-Report 
Total fatigue 69 70.8  16.0 69.4 (58.3, 84.7) (37.5, 100) 
157 
87.2  10.9 
General fatigue 69 64.2  20.1 62.5 (45.8, 79.2) (25, 100) 88.4  11.7 
Sleep/rest fatigue 69 76.9  18.0 79.2 (66.7, 91.7) (8.3, 100) 86.7  12.6 
Cognitive fatigue 69 69.7  24.6 75 (54.2, 91.7) (0, 100) 86.6  16.4 
Abbreviations: N, sample size; SD, standard deviation; IQR, interquartile range. 
aFrom published data: Varni JW et al. Int J Ped Obes 2010;5:34–42. 
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Table 4.5. Descriptive statistics for the Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional Fatigue Scale by age group 
 Age Groupa N Mean  SD Median (IQR) Range P-Valueb 
Child Self-Report 
Total fatigue 
Young children 10 72.5  21.4 72.2 (63.9, 88.9) (25, 100) 
0.66 Older children 23 69.9  14.9 69.4 (56.9, 81.9) (45.8, 98.6) 
Adolescents 33 72.5  13.6 69.4 (65.3, 81.9) (44.4, 97.2) 
General fatigue 
Young children 10 75.0  28.9 83.3 (75, 91.7) (0, 100) 
0.23 Older Children 23 70.3  19.0 66.7 (54.2, 87.5) (25, 100) 
Adolescents 32 68.6  17.1 70.8 (56.3, 81.3) (25, 100) 
Sleep/rest fatigue 
Young children 10 80.0  16.3 79.2 (66.7, 91.7) (50, 100) 
0.45 Older children 23 72.9  15.3 70.8 (62.5, 83.3) (41.7, 100) 
Adolescents 33 72.9  19.4 75 (62.5, 87.5) (8.3, 100) 
Cognitive fatigue 
Young children 10 62.5  31.2 62.5 (41.7, 91.7) (0, 100) 
0.12 Older children 23 66.9  20.8 62.5 (50, 87.5) (29.2, 100) 
Adolescents 33 76.1  21.1 75 (62.5, 95.8) (8.3, 100) 
Parent Proxy-Report 
Total fatigue 
Young children 12 74.8  23.8 84.0 (51.4, 95.8) (37.5, 100) 
0.32 Older children  25 67.3  16.3 62.5 (56.9, 79.2) (40.3, 100) 
Adolescents 32 71.9 11.8 71.5 (64.6, 81.3) (51.4, 93.1) 
General fatigue 
Young children 12 75.0  25.6 77.1 (54.2, 100) (25, 100) 
0.13 Older children  25 60.7  19.8 58.3 (45.8, 75) (25, 100) 
Adolescents 32 62.9  17.1 62.5 (47.9, 75) (25, 91.7) 
Sleep/rest fatigue 
Young children 12 84.7  16.3 89.6 (68.8, 100) (58.3, 100) 
0.21 Older children  25 77.0  16.6 75 (62.5, 87.5) (45.8, 100) 
Adolescents 32 73.9  19.2 77.1 (64.6, 89.6) (8.3, 100) 
Cognitive fatigue 
Young children 12 64.6  34.2 70.8 (37.5, 100) (0, 100) 
0.28 Older children 25 64.3  26.8 58.3 (45.8, 91.7) (0, 100) 
Adolescents  32 75.8  16.8 75 (62.5, 89.6) (33.3, 100) 
Abbreviations: N, sample size; SD, standard deviation; IQR, interquartile range. 
aYoung children, ages 4–7 years; older children, ages 8–12 years; adolescents, age 13–17 years.  
bKruskal-Wallis tests were used to assess differences between age groups. 
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Table 4.6. Descriptive statistics for the Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional Fatigue Scale by ambulatory 
status 
 Ambulatory Status N Mean  SD Median (IQR) Range P-Valuea 
Child Self-Report 
Total fatigue 
Ambulant 39 71.6  16.3 72.2 (59.7, 83.3) (25, 100) 
0.92 
Non-ambulant 26 71.9  13.9 69.4 (65.3, 81.9) (44.4, 97.2) 
General fatigue 
Ambulant 39 72.8  21.0 75 (62.5, 87.5) (0, 100) 
0.12 
Non-ambulant 25 66.7  17.5 70.8 (54.2, 75) (25, 100) 
Sleep/rest fatigue 
Ambulant 39 73.7  17.2 75 (62.5, 87.5) (33.3, 100) 
0.75 
Non-ambulant 26 73.9  18.5 75 (66.7, 83.3) (8.3, 100) 
Cognitive fatigue 
Ambulant 39 68.6  23.3 70.8 (50, 91.7) (0, 100) 
0.21 
Non-ambulant 26 75.3  22.2 70.8 (58.3, 91.7) (8.3, 100) 
Parent Proxy-Report 
Total fatigue 
Ambulant 42 71.0  18.0 70.8 (58.3, 84.9) (37.5, 100) 
0.84 
Non-ambulant 27 70.3  12.7 68.1 (58.3, 81.9) (51.4, 93.1) 
General fatigue 
Ambulant 42 65.8  22.1 62.5 (45.8, 87.5) (25, 100) 
0.55 
Non-ambulant 27 61.7  16.7 62.5 (45.8, 75) (25, 87.5) 
Sleep/rest fatigue 
Ambulant 42 79.4  15.1 81.3 (66.7, 91.7) (45.8, 100) 
0.27 
Non-ambulant 27 72.9  21.4 75 (62.5, 91.7) (8.3, 100) 
Cognitive fatigue 
Ambulant 42 67.9  27.9 72.9 (50, 91.7) (0, 100) 
0.72 
Non-ambulant 27 72.5  18.3 75 (58.3, 87.5) (33.3, 100) 
Abbreviations: N, sample size; SD, standard deviation; IQR, interquartile range. 
aWilcoxin Rank Sum tests were used to assess differences between ambulant and non-ambulant individuals. 
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Table 4.7. Correlation analyses between child self-report and parent proxy-report Pediatric Quality of Life InventoryTM (PedsQLTM) 
Multidimensional Fatigue Scale scores  
 
 
 
 Spearman’s Rank Correlation Coefficient (ρ) 
N 
P-Value 
  Child Self-Report 
P
a
re
n
t 
P
ro
x
y
-R
ep
o
r
t 
 Total fatigue General fatigue Sleep/rest fatigue Cognitive fatigue 
Total fatigue 
0.69 
64 
<0.001 
   
General fatigue  
0.63 
63 
<0.001 
  
Sleep/rest fatigue   
0.50 
64 
<0.001 
 
Cognitive fatigue    
0.68 
64 
<0.001 
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Table 4.8. Correlation analyses between child characteristics and Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional 
Fatigue Scale scores by child self-report  
 Spearman’s Rank Correlation Coefficient (ρ) 
N 
P-Value 
 Total  
fatigue 
General  
fatigue 
Sleep/rest 
fatigue 
Cognitive 
fatigue 
Clinical Characteristics 
Age (years) 
0.01 
66 
0.92 
-0.19 
65 
0.14 
-0.06 
66 
0.62 
0.23 
66 
0.07 
Forced vital capacity (%) 
0.29 
40 
0.07 
0.34 
39 
0.03 
0.15 
40 
0.35 
0.03 
40 
0.87 
Left ventricular ejection fraction (%)  
0.00 
42 
0.99 
0.10 
41 
0.52 
-0.22 
42 
0.16 
0.08 
42 
0.60 
Child Self-Report or Parent Proxy-Report Measures 
Physical Activity Questionnaire for Children and Adolescents  
0.13 
58 
0.32 
0.27 
57 
0.04 
0.12 
58 
0.35 
-0.06 
58 
0.67 
Duchenne Muscular Dystrophy Functional Ability Self-
Assessment Tool 
0.05 
64 
0.67 
0.30 
63 
0.02 
-0.01 
64 
0.94 
-0.13 
64 
0.31 
Center for Epidemiological Studies Depression Scale for 
Children 
-0.46 
66 
<0.001 
-0.30 
65 
0.02 
-0.30 
66 
0.02 
-0.46 
66 
<0.001 
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Sleep Disturbance Scale for Children      
Disorders of initiating and maintaining sleep  
-0.54 
51 
<0.001 
-0.37 
50  
0.008 
-0.26 
51 
0.07 
-0.49 
51 
<0.001 
Sleep-related breathing disorders  
-0.14 
62 
0.27 
-0.33 
61 
0.009 
-0.06 
62 
0.62 
0.06 
62 
0.64 
Disorders of Arousal  
-0.35 
62 
0.005 
-0.27 
61 
0.03 
-0.13 
62 
0.32 
-0.41 
62 
0.001 
Sleep-wake transition disorders 
-0.26 
60 
0.04 
-0.26 
59 
0.05 
-0.15 
60 
0.25 
-0.14 
60 
0.28 
Disorders of excessive somnolence  
-0.34 
58 
0.009 
-0.15 
57 
0.26 
-0.33 
58 
0.01 
-0.24 
58 
0.07 
Sleep hyperhidrosis  
-0.03 
62 
0.82 
-0.12 
61 
0.37 
0.15 
62 
0.26 
-0.06 
62 
0.66 
Total sleep disturbance symptoms 
-0.42 
46 
0.003 
-0.32 
45 
0.03 
-0.30 
46 
0.04 
-0.33 
46 
0.03 
P-Values in bold are statistically significant at =0.05 two-sided level of significance. 
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Table 4.9. Correlation analyses between child characteristics and Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional 
Fatigue Scale scores by parent proxy-report  
 Spearman’s Rank Correlation Coefficient (ρ) 
N 
P-Value 
 Total  
fatigue 
General  
fatigue 
Sleep/rest 
fatigue 
Cognitive 
fatigue 
Clinical Characteristics 
Age (years) 
0.06 
69 
0.62 
-0.10 
69 
0.42 
-0.18 
69 
0.15 
0.20 
69 
0.10 
Forced vital capacity (%) 
0.12 
40 
0.48 
0.22 
40 
0.17 
0.07 
40 
0.68 
-0.01 
40 
0.93 
Left ventricular ejection fraction (%)  
0.06 
41 
0.71 
0.22 
41 
0.17 
-0.07 
41 
0.68 
0.02 
41 
0.89 
Child Self-Report or Parent Proxy-Report Measures 
Physical Activity Questionnaire for Children and Adolescents  
0.09 
57 
0.49 
0.16 
57 
0.24 
0.18 
57 
0.17 
-0.11 
57 
0.43 
Duchenne Muscular Dystrophy Functional Ability Self-
Assessment Tool 
0.26 
69 
0.03 
0.30 
69 
0.01 
0.35 
69 
0.003 
0.08 
69 
0.52 
Center for Epidemiological Studies Depression Scale for 
Children 
-0.45 
64 
<0.001 
-0.37 
64 
0.002 
-0.35 
64 
0.005 
-0.32 
64 
0.009 
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Sleep Disturbance Scale for Children      
Disorders of initiating and maintaining sleep  
-0.53 
55 
<0.001 
-0.36 
55 
0.008 
-0.40 
55 
0.003 
-0.46 
55 
<0.001 
Sleep-related breathing disorders  
-0.20 
67 
0.10 
-0.14 
67 
0.24 
-0.19 
67 
0.12 
-0.17 
67 
0.18 
Disorders of Arousal  
-0.43 
67 
<0.001 
-0.34 
67 
0.005 
-0.27 
67 
0.03 
-0.37 
67 
0.002 
Sleep-wake transition disorders 
-0.35 
65 
0.004 
-0.29 
65 
0.02 
-0.33 
65 
0.007 
-0.28 
65 
0.02 
Disorders of excessive somnolence  
-0.42 
63 
<0.001 
-0.41 
63 
<0.001 
-0.58 
63 
<0.001 
-0.12 
63 
0.35 
Sleep hyperhidrosis  
-0.16 
67 
0.20 
-0.07 
67 
0.56 
-0.11 
67 
0.39 
-0.19 
67 
0.12 
Total sleep disturbance symptoms 
-0.51 
50 
<0.001 
-0.45 
50 
0.001 
-0.48 
50 
<0.001 
-0.34 
50 
0.01 
P-Values in bold are statistically significant at =0.05 two-sided level of significance. 
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Table 4.10. Multivariable linear regression analyses with listwise deletion to predict child self-reported fatigue (N=41) 
 ?̂? 
(95% Confidence Interval) 
P-Value 
 Dependent Variable 
Independent Variables  Total fatigue General fatigue Sleep/rest fatigue Cognitive fatigue 
Sleep Disturbance Scale for Children  
-0.84 
(-1.31, -0.38) 
0.001 
-0.97 
(-1.59, -0.35) 
0.003 
-0.28 
(-0.84, 0.27) 
0.31 
-1.24 
(-2.10, -0.39) 
0.006 
Physical Activity Questionnaire for Children and 
Adolescents  
2.50 
(-3.08, 8.08) 
0.37 
3.08 
(-4.44, 10.61) 
0.41 
4.39 
(-2.28, 11.05) 
0.19 
0.35 
(-9.95, 10.64) 
0.95 
Duchenne Muscular Dystrophy Functional Ability 
Self-Assessment Tool 
-0.18 
(-0.81, 0.45) 
0.57 
0.22 
(-0.62, 1.07) 
0.59 
-0.54 
(-1.29, 0.21) 
0.15 
-0.22 
(-1.39, 0.94) 
0.70 
Center for Epidemiological Studies Depression Scale 
for Children 
-0.32 
(-0.94, 0.30) 
0.31 
-0.70 
(-1.55, 0.14) 
0.10 
-0.01 
(-0.75, 0.73) 
0.97 
-0.33 
(-1.47, 0.82) 
0.56 
R2 (Adjusted)  0.38 0.39 0.02 0.22 
P-Values in bold are statistically significant at =0.05 two-sided level of significance.  
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Table 4.11. Multivariable linear regression analyses with listwise deletion to predict parent proxy-reported fatigue (N=41) 
 ?̂? 
(95% Confidence Interval) 
P-Value 
 Dependent Variable 
Independent Variable Total fatigue General fatigue Sleep/rest fatigue Cognitive fatigue 
Sleep Disturbance Scale for Children  
-0.91 
(-1.36, -0.46) 
<0.001 
-1.08 
(-1.74, -0.42) 
0.002 
-0.62 
(-1.11, -0.13) 
0.01 
-1.03 
(-1.85, -0.21) 
0.02 
Physical Activity Questionnaire for Children and 
Adolescents  
-1.37 
(-6.78, 4.04) 
0.61 
1.00 
(-6.93, 8.93) 
0.80 
1.52 
(-4.34, 7.38) 
0.60 
-6.64 
(-16.53, 3.24) 
0.18 
Duchenne Muscular Dystrophy Functional Ability 
Self-Assessment Tool 
0.68 
(0.07, 1.29) 
0.03 
0.43 
(-0.46, 1.33) 
0.34 
0.83 
(0.17, 1.49) 
0.02 
0.78 
(-0.34, 1.90) 
0.17 
Center for Epidemiological Studies Depression Scale 
for Children 
-0.28 
(0.88, 0.32) 
0.36 
-0.38 
(-1.26, 0.50) 
0.39 
-0.15 
(-0.80, 0.50) 
0.64 
-0.30 
(-1.40, 0.79) 
0.58 
R2 (Adjusted) 0.44 0.32 0.32 0.18 
P-Values in bold are statistically significant at =0.05 two-sided level of significance.  
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Table 4.12. Multivariable linear regression analyses with multiple imputation using chained equations to predict child self-reported 
fatigue (N=71)  
 ?̂? 
(95% Confidence Interval) 
P-Value 
 Dependent Variable 
Independent Variable Total fatigue General fatigue Sleep/rest fatigue Cognitive fatigue 
Sleep Disturbance Scale for Children  
-0.62 
(-1.06, -0.18) 
0.008 
-0.73 
(-1.38, -0.09) 
0.03 
-0.17 
(-0.83, 0.49) 
0.60 
-0.94 
(-1.58, -0.30) 
0.005 
Physical Activity Questionnaire for Children and 
Adolescents  
1.94 
(-2.95, 6.83) 
0.43 
2.82 
(-3.40, 9.04) 
0.37 
3.22 
(-3.53, 9.96) 
0.34 
0.07 
(-8.22, 8.35) 
0.99 
Duchenne Muscular Dystrophy Functional Ability 
Self-Assessment Tool 
0.29 
(-0.26, 0.83) 
0.29 
0.84 
(0.10, 1.58) 
0.03 
0.17 
(-0.60, 0.94) 
0.66 
-0.13 
(-0.99, 0.73) 
0.76 
Center for Epidemiological Studies Depression Scale 
for Children 
-0.77 
(-1.17, -0.38) 
<0.001 
-0.80 
(-1.32, -0.28) 
0.003 
-0.60 
(-1.17, -0.03) 
0.04 
-0.93 
(-1.54, -0.32) 
0.004 
P-Values in bold are statistically significant at =0.05 two-sided level of significance.  
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Table 4.13. Multivariable linear regression analyses with multiple imputation using chained equations to predict parent proxy-reported 
fatigue (N=71) 
 ?̂? 
(95% Confidence Interval) 
P-Value 
 Dependent Variable 
Independent Variables  Total fatigue General fatigue Sleep/rest fatigue Cognitive fatigue 
Sleep Disturbance Scale for Children  
-0.66 
(-1.26, -0.06) 
0.03 
-0.74 
(-1.45, -0.03) 
0.04 
-0.39 
(-1.13, 0.34) 
0.27 
-0.73 
(-1.61, 0.15) 
0.10 
Physical Activity Questionnaire for Children and 
Adolescents  
-1.55 
(-7.23, 4.12) 
0.58 
0.08 
(-6.45, 6.62) 
0.989 
-0.47 
(-6.90, 5.95) 
0.88 
-4.17 
(-14.24, 5.91) 
0.41 
Duchenne Muscular Dystrophy Functional Ability 
Self-Assessment Tool 
0.79 
(0.21, 1.38) 
0.001 
1.11 
(0.35, 1.86) 
0.005 
1.19 
(0.49, 1.90) 
0.001 
0.47 
(-0.54, 1.48) 
0.36 
Center for Epidemiological Studies Depression Scale 
for Children 
-0.82 
(-1.27, -0.37) 
0.001 
-0.91 
(-1.44, -0.38) 
0.001 
-0.71 
(-1.26, -0.16) 
0.01 
-0.98 
(-1.79, -0.18) 
0.02 
P-Values in bold are statistically significant at =0.05 two-sided level of significance.  
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Chapter 5  
5 Discussion 
To our knowledge, this is the first study to describe fatigue in children and adolescents 
with Duchenne muscular dystrophy (DMD), from the perspective of patients and their 
parents. Additionally, we have proposed a novel conceptual model of factors associated 
with fatigue in children and adolescents with DMD, and tested associations of patient 
characteristics with fatigue in this population. Our results demonstrated fatigue to be a 
significant issue in children and adolescents with DMD, across age groups from early 
childhood to adolescence, and across disease stages from the early ambulatory to late non-
ambulatory stages, highlighting the need for fatigue to be addressed in the routine clinical 
care of affected boys. We have identified several factors associated with fatigue, which 
have contributed to our understanding of the subjective experience of fatigue as a complex, 
multi-causal and multidimensional phenomenon in paediatric DMD. Our findings 
demonstrated greater sleep disturbance symptoms, greater depressive symptoms and lower 
functional ability related to activities of daily living to be associated with greater fatigue in 
children and adolescents with DMD. These findings warrant further investigation in the 
development of evidence-based therapeutic strategies aimed at reducing fatigue and 
improving health-related quality of life. This chapter discusses our results in the context of 
existing literature and interprets key findings pertaining to each objective, while 
highlighting their clinical and research implications.  
5.1 Sample Characteristics  
 Our sample was composed of 71 children and adolescents with DMD between the 
ages of 5–17 years, and included patients with DMD across all disease stages: early 
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ambulatory, late ambulatory, early non-ambulatory and late non-ambulatory. Over half of 
the patients in our sample were ambulatory and most were without known severe 
respiratory or cardiac complications, which may cause concern about non-response bias 
and whether participating patients were at a less severe disease stage than non-participating 
patients. However, comparison of registry data of participating and non-participating 
patients demonstrated that there were no significant differences between participating and 
non-participating patients. Our sample was representative of DMD patients registered in 
the Canadian Neuromuscular Disease Registry (CNDR) with respect to both clinical 
characteristics (age, genetic mutation, musculoskeletal, respiratory and cardiac 
characteristics, and clinical trial participation) and geographic region in Canada.    
5.2 Objective 1: To describe subjective fatigue in children and adolescents with 
DMD from patients’ and parents’ perspectives  
 Children and adolescents with DMD in our study experienced greater fatigue than 
healthy children and adolescents from published data, from both patients’ and parents’ 
perspectives [117,118,179]. Child self-reported and parent proxy-reported total and general 
fatigue scores of boys with DMD in our study were comparable to previously published 
scores of a multicentre cohort of ambulant boys with DMD of ages 5–13 years in Italy [58]. 
Moreover, child self-reported and parent proxy-reported fatigue for children and 
adolescents with DMD in our study were comparable to those for children and adolescents 
with cancer from published data—for whom fatigue is recognized as a frequent and 
debilitating symptom, warranting the development of the term cancer-related fatigue and 
its diagnostic criteria [13,179,208–211].  
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 In our study, child self-reports and parent proxy-reports of fatigue were similar, 
except for general fatigue, in which parents perceived their child’s level of general fatigue 
to be worse than that perceived by the patient. The general fatigue domain of the PedsQLTM 
Multidimensional Fatigue Scale (MFS) has been reported to be more related to patient 
functional ability [58]. Parents may therefore attribute their child’s fatigue to functional 
ability more so than patients themselves do. This is supported by our finding that patient 
functional ability was more strongly associated with parent proxy-reported fatigue than 
with child self-reported fatigue. Our results comparing patients’ and parents’ perceptions 
of fatigue are in contrast with the literature, which demonstrate poor agreement between 
child self-reported and parent proxy-reported fatigue. In previous studies of children and 
adolescents with chronic health conditions, parents typically underestimated their child’s 
level of fatigue [118,212–215]. Imperfect agreement between child self-reported and 
parent proxy-reported internalizing symptoms, such as fatigue, has consistently been 
documented across paediatric patient populations [216]. Discrepancies between patients’ 
and parents’ perceptions of fatigue may impact treatment decisions and ultimately, clinical 
outcomes. Gaultney et al. reported greater discrepancy between child self-reported and 
parent proxy-reported fatigue to be associated with more depressed mood in patients with 
juvenile idiopathic arthritis [212].  
Although our results demonstrated similar perceptions of fatigue by patients and 
their parents, it is unclear whether this finding would translate to a clinical setting, where 
parallel child self-report and parent proxy-report fatigue rating scales may not be used. 
Hinds et al. demonstrated that paediatric oncology patients and their parents often use 
different language to define and describe fatigue in a clinical setting [213], reaffirming the 
  
97 
need for clinicians to assess both patients’ and parents’ perspectives of fatigue when 
making treatment decisions [118,212]. It may be that in the case of a condition involving 
progressive motor impairment with onset as young as infancy, like DMD, parents have a 
greater appreciation of their child’s fatigue as they are more vigilant about their child’s 
mobility and conscious of potential difficulties their son may encounter keeping up with 
peers [217]. Parents’ expectations and observations of muscle weakness interfering with 
their child’s daily activities may therefore foster a shared understanding of fatigue severity 
between patients with DMD and their parents. Additional studies are required to draw firm 
conclusions regarding agreement between child self-reported and parent proxy-reported 
fatigue in the paediatric DMD population. Studies involving qualitative interviews and 
focus groups with children and adolescents with DMD, and their parents, can enhance our 
understanding of similarities and discrepancies between patients’ and parents’ perceptions 
of fatigue [213].  
 We used age and ambulatory status to describe fatigue in children and adolescents 
with DMD across different disease stages. No statistically significant differences in fatigue 
were observed between young children (5–7 years of age), older children (8–12 years of 
age) and adolescents (13–17 years of age), or between ambulant and non-ambulant 
patients, by child self-report or parent proxy-report. Patients with DMD in our study 
consistently experienced greater fatigue than their healthy peers when compared to 
published data, by child self-report and parent proxy-report, across age groups and 
ambulatory status [117,118,179]. Therefore, fatigue may be a prominent issue in paediatric 
patients with DMD at all disease stages.  
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Although not statistically significant, child self-reported and parent proxy-reported 
total fatigue was greater for older children, compared with young children and adolescents. 
Older children are typically in an ambulatory decline phase and may therefore experience 
greater fatigue due to continued participation in physical activities that are becoming 
progressively more challenging and exhausting over time. In a previous study, patients with 
DMD using a wheelchair intermittently were more fatigued than patients not using a 
wheelchair, suggesting that the time around transitioning to wheelchair use during the 
ambulatory decline phase may be associated with greater fatigue [3]. In our study, 
intermittent wheelchair users were also more fatigued than non-wheelchair users, although 
differences were not statistically significant.  
General fatigue and sleep/rest fatigue, which are reflective of the physical 
component of fatigue [16], were more severe among older children and adolescents 
compared with young children, whereas cognitive fatigue, which is reflective of the mental 
component of fatigue [16], was more severe among young children and older children 
compared with adolescents. Hinds et al. reported that children with cancer of ages 7–12 
years emphasized physical fatigue, whereas adolescents with cancer of ages 13–18 years 
emphasized a dynamic combination of physical and mental fatigue when describing their 
fatigue during focus groups [213]. Greater general and sleep/rest fatigue in older children 
and adolescents with DMD may be attributable to greater disease severity—particularly 
muscle weakness and reduced functional ability, which are known risk factors for fatigue 
in adult neuromuscular disorders [47,57]. Items in the cognitive fatigue domain of the 
PedsQLTM MFS focus on problems with working memory, information retrieval and 
attention—all of which improve with age [179,218]. Adolescents have better working and 
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long term memory, shorter information processing speeds and longer attention spans 
compared with young children and older children [218]. Greater cognitive fatigue in young 
children and older children with DMD compared with adolescents may therefore be 
attributable to normal age-related cognitive development. Similar trends were observed for 
non-ambulant patients who are at a more severe disease stage and typically older than 
ambulant patients, such that non-ambulant patients experienced greater general and 
sleep/rest fatigue, and less cognitive fatigue than ambulant patients with DMD.  
These findings have implications for potential therapeutic strategies for fatigue in 
DMD, such that younger patients at early disease stages may benefit from therapies 
targeting mental fatigue and older patients at late disease stages may benefit from therapies 
targeting physical fatigue. However, to our knowledge, the minimal clinically important 
differences for child self-reported and parent proxy-reported PedsQLTM MFS scores have 
not yet been defined. Therefore, the clinical significance of trends described from our 
findings are speculative and require further investigation.      
5.3 To explore associations of patient characteristics with child self-report and 
parent proxy-report measures of subjective fatigue in children and adolescents 
with DMD. 
 Of the patient characteristics explored in our study, sleep disturbance symptoms 
and depressive symptoms emerged as the strongest correlates of child self-reported and 
parent proxy-reported fatigue. Functional ability emerged as a correlate of parent proxy-
reported fatigue more so than child self-reported fatigue. Physical activity level and clinical 
characteristics including age, and musculoskeletal, respiratory and cardiac function were 
not consistently associated with child self-reported or parent proxy-reported fatigue.  
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 Because sleep disturbances are frequent in children and adolescents with DMD 
[72,219], and variations exist in the diagnostic assessment and management of sleep 
disturbances in DMD across Canada [73], we hypothesized sleep disturbance symptoms to 
be a potentially modifiable factor associated with fatigue. Our findings demonstrate that 
greater sleep disturbance symptoms were significantly associated with greater fatigue from 
both patients’ and parents’ perspectives. To our knowledge, the relationship between sleep 
disturbances and fatigue has not been studied in paediatric neuromuscular disorders. 
However, a link between sleep disturbances and fatigue has been established in adults with 
myotonic dystrophy or multiple sclerosis, and other childhood chronic health conditions, 
such as cancer [7,74–82].  
Sleep-related breathing disorders, of both non-obstructive and obstructive origin, 
are the most commonly documented sleep disturbances in DMD [71,72,111,219]. In our 
study, symptoms of sleep-related breathing disorders did not emerge as a correlate of 
fatigue. However, the accuracy of parent-reported symptoms of sleep-related breathing 
disorders compared with objective sleep measurements is unclear [72]. Moreover, 
symptoms such as restless sleep, nightmares, morning confusion and excessive daytime 
sleepiness may be related to sleep-related breathing disorders, but were scored as items of 
other domains in the Sleep Disturbance Scale for Children [201]. Therefore, the lack of 
association between sleep disordered breathing and fatigue should be interpreted 
cautiously.  
Further examination of the relationship between sleep disordered breathing and 
fatigue is warranted. The relationship between sleep disordered breathing and fatigue may 
additionally be explored by examining the level of fatigue experienced by patients 
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receiving non-invasive ventilation (NIV) for the management of  respiratory failure, which 
initially presents as nocturnal hypoventilation [53]. In our study, the two patients receiving 
part-time (nocturnal) NIV experienced greater total fatigue, general fatigue and sleep/rest 
fatigue compared with non-ventilated patients. However, this finding was only statistically 
significant for parent proxy-reported sleep/rest fatigue. No clear relationship between full-
time (nocturnal and diurnal) NIV and fatigue was observed. Because the optimal time to 
initiate NIV is still under debate [50], the absence of NIV may not accurately identify 
patients without sleep disordered breathing. Therefore, no firm conclusions can be drawn 
regarding the relationship between sleep-related breathing disorders or NIV and fatigue. 
Moreover, our study was underpowered to detect differences in fatigue between ventilated 
and non-ventilated patients. Symptoms related to disorders of initiating and maintaining 
sleep, disorders of arousal, sleep-wake transition disorders and disorders of excessive 
somnolence demonstrated the strongest associations with fatigue. Bloetzer et al. previously 
reported disorders of initiating and maintaining sleep and disorders of excessive 
somnolence to be prevalent in 29.7% and 10.9% of children and adolescents with DMD, 
respectively [72]. Thus, clinical sleep evaluations in children and adolescents with DMD 
should not be limited to detecting sleep-related breathing disorders, as other sleep 
disturbances may be present and impact fatigue.  
Consensus-based recommendations for sleep evaluations in DMD are included in 
respiratory care recommendations by the American Thoracic Society and the international 
DMD Care Considerations Working Group convened by the Centers for Disease Control 
and Prevention [1,68,220]. The optimal time to screen for sleep disordered breathing in 
DMD has not been determined, however annual polysomnography, or overnight pulse 
  
102 
oximetry with continuous carbon dioxide monitoring (capnography) if polysomnography 
is not available, is recommended starting from loss of ambulation and/or when clinically 
indicated (i.e. at the onset of daytime symptoms of sleep disordered breathing or abnormal 
pulmonary function tests) [68]. Polysomnography is a multi-parametric test used as a 
diagnostic tool in sleep medicine to record physiological changes during sleep. The 
polysomnogram monitors cerebral cortical activity (electroencephalogram), cardiac 
activity (electrocardiogram), muscle activity (electromyogram), eye movements 
(electrooculogram), respiratory airflow, thoracoabdominal movements, oximetry and 
capnography [50].  
Because oximetry with capnography has limited utility for detecting sleep 
disturbances not associated with hypoxemia or hypercapnia, and because there is poor 
correlation between daytime symptoms, abnormal pulmonary function and sleep 
disturbances, a “polysomnography for all policy” has been proposed in the management of 
children and adolescents with DMD [71,111]. However, polysomnography is costly and 
not universally available across clinics [221]. In addition, because polysomnography 
requires admission to a sleep laboratory and may result in the disruption of normal sleep 
architecture and respiratory patterns, portable home monitoring has been proposed as an 
alternative diagnostic tool for sleep disturbances in DMD. However, the validity of 
portable home monitoring in paediatric neuromuscular disorders remains unclear 
[41,71,221,222]. In Canada, routine polysomnography to assess for sleep disordered 
breathing is ordered by approximately half of neurologists and respirologists caring for 
children and adolescents with DMD [73]. Polysomnography is important for indicating the 
need for timely intervention with NIV, which can reduce symptoms of sleep disordered 
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breathing and potentially confer a beneficial effect on fatigue [223]. In addition to 
determining the optimal time to screen for sleep disturbances using polysomnography, 
further research is warranted to validate more affordable screening technologies in the 
paediatric DMD population, such as portable home monitoring, and to determine sensitive 
and specific daytime predictors of sleep disordered breathing [221,224,225].  
In boys with DMD, sleep can be further complicated by disease-related, 
psychological and social factors. Muscle weakness and the subsequent need to be turned 
by a caregiver during the night has been reported to be associated with sleep disturbance 
symptoms in boys with DMD [72]. Overnight use of ankle-foot orthotics or knee-ankle-
foot orthotics may cause further discomfort during sleep for some patients [55]. Although 
the role of dystrophin in the central nervous system remains unclear, the absence of 
dystrophin has been hypothesized to alter neuronal function, which may subsequently 
impact sleep patterns [55]. Moreover, boys with DMD are at increased risk for emotional 
and behavioural problems, including anxiety, depression and attention deficit hyperactivity 
disorder (ADHD), which have been reported to contribute to sleep disturbances during 
childhood and adolescence [91,226]. Parental exhaustion, sleep deprivation and poor 
mental health, associated with caring for a child with DMD [227,228], can further 
contribute to the vulnerability of these families and interfere with the development of 
effective sleep hygiene practices in affected boys. Parents of children with DMD are at 
higher risk for experiencing depression and lower self-esteem compared with parents of 
healthy children [229]. Both maternal and paternal depression have been reported to be 
associated with sleep disturbances in children [230]. Compromised parental mental health 
may contribute to parenting inconsistency, which has been reported to be associated with 
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sleep disturbances in children with ADHD [231]. It is therefore imperative that 
recommendations for the assessment and management of sleep disturbances in children 
and adolescents with DMD are interdisciplinary and extend beyond sleep disordered 
breathing to include other sleep disorders, as well as disease-related, psychological and 
social factors.  
Cognitive behavioural therapy (CBT) has been proposed as a treatment for 
disorders of initiating and maintaining sleep. Concomitant treatment of sleep disturbances 
and fatigue using CBT has been evaluated in adults with facioscapulohumeral dystrophy, 
multiple sclerosis, chronic fatigue syndrome and traumatic brain injury, demonstrating 
beneficial effects on sleep disturbances and fatigue, as well as comorbid depression 
[103,143,232,233]. CBT has also been reported to reduce fatigue in adolescents with 
chronic fatigue syndrome [234–236].   
Our study demonstrated an association between greater depressive symptoms and 
greater fatigue in children and adolescents with DMD from both patients’ and parents’ 
perspectives. This finding is consistent with studies that have examined the relationship 
between depression and fatigue in other paediatric patient populations, such multiple 
sclerosis, chronic fatigue syndrome and cancer [45,237–240]. Studies examining emotional 
disturbances in children and adolescents with DMD are limited. However, there is evidence 
to suggest boys with DMD are at increased risk for depression compared with their healthy 
peers or other paediatric patient populations with physical disabilities, with older boys at 
greater risk than young boys [55,91,241]. In a cross-sectional study of adults with DMD, 
Pangalila et al. reported fatigue and affective disorders (depression and/or anxiety) to co-
exist in 24.1% of patients [120]. However, this finding is equivocal, as diagnoses of fatigue 
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and affective disorders were made by dichotomizing self-reported scores of the Fatigue 
Severity Scale and Hospital Anxiety and Depression Scale, respectively, as either 
indicative or not indicative of clinical significance [120,242,243]. In addition to concerns 
regarding sensitivity and specificity of these measures and the potential of misclassification 
bias, dichotomization of continuous variables results in loss of information, produces 
associations of lower magnitude and reduces statistical power [244–248].  
Despite a strong association between depression and fatigue in chronic health 
conditions, the causal relationships between depression and fatigue remain to be elucidated 
[99,249]. Three causal hypotheses have been proposed in the literature relating to cancer-
related fatigue: (1) fatigue is caused by the illness, and treatment of the illness causes 
depression, (2) fatigue develops in patients because of depression, or (3) no causal 
relationship exists, and a third factor is the cause of both depression and fatigue. However, 
demonstrating these relationships has proven to be a methodological challenge [249]. 
Understanding the causal relationship between fatigue and depression has clinical 
implications for developing effective therapeutic strategies for fatigue. If depression and 
fatigue are causally associated, a predominant effect in one direction may support a strategy 
that targets either depression or fatigue first. Alternatively, a bidirectional causal 
relationship may support a strategy that treats depression and fatigue as a symptom cluster. 
For example, physical exercise has been proposed as a symptomatic therapy for both 
depression and fatigue in patient populations, including children and adolescents with 
physical disabilities [250,251]. Physical exercise has been evaluated as a treatment for 
fatigue in children and adolescents with cancer with inconclusive results [252]. The 
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feasibility of physical exercise as a treatment for fatigue may be limited in non-ambulant 
boys with DMD due to functional limitations.   
In our study, physical activity level was not associated with fatigue in children and 
adolescents with DMD from patients’ or parents’ perspectives. This contrasts with findings 
by Maher et al. in children and adolescents with physical disabilities, which included 
neuromuscular disorders such as Charcot-Marie-Tooth disease, myotonia congenita and 
myotubular myopathy [251]. Using an accelerometer to objectively measure physical 
activity level, Maher et al. reported physical inactivity to be associated with fatigue in 
children and adolescents with physical disabilities. Similarly, lower physical activity has 
been reported to be associated with greater fatigue in children and adolescents with 
multiple sclerosis [195]. It is possible that the Physical Activity Questionnaire for Children 
and Adolescents used in our study did not adequately capture variability in the physical 
activity level of children and adolescents with DMD [187]. Limited variability in the data 
may have reduced the magnitude of correlation coefficients between physical activity level 
and fatigue in our study [253].  
Because most measures of physical activity level are intended for use in typically 
developing children, there is a need for the development of feasible, valid and reliable 
measures to assess physical activity level in children and adolescents with neuromuscular 
disorders, which quantify both lower limb and upper limb activity [184]. The combined 
use of subjective and objective measures has been recommended to achieve a better 
understanding of physical activity level in children and adolescents with neuromuscular 
disorders, as no single instrument can quantify all dimensions of physical activity [185]. 
Physical activity level is, at least in part, determined by functional ability in children and 
  
107 
adolescents with DMD [184]. In our study, objective measures of musculoskeletal, 
respiratory and cardiac function did not emerge as correlates of fatigue. Although 
cardiomyopathy was associated with less cognitive fatigue from both patients’ and parents’ 
perspectives, this association may have been confounded by age. Onset of cardiomyopathy 
in DMD typically occurs during adolescence and in our study, adolescents experienced less 
cognitive fatigue compared with young children and older children. Lower functional 
ability related to activities of daily living, however, was associated with greater fatigue 
from parents’ perspective. Thus, parents may be more likely to perceive their child’s 
fatigue as an outcome of or contributor to the progressive functional decline associated 
with DMD more so than the patients themselves.  
5.4 Strengths and Limitations  
 A strength of our study was that our sample was composed of children and 
adolescents with DMD across disease stages. Moreover, the use of a national registry to 
recruit patients facilitated the inclusion of patients from multiple clinics and regions within 
Canada, thereby further enhancing the generalizability of our results. To our knowledge, 
descriptive data of fatigue in paediatric DMD have only previously been published for 
ambulant boys of ages 5–13 years in Italy, and only for total and general fatigue scores 
measured using the PedsQLTM MFS [58].  
The use of the PedsQLTM MFS was an additional strength of our study. A recently 
published systematic review of instruments to assess fatigue in paediatric chronic health 
conditions identified the PedsQLTM MFS to have the best evidence for strong psychometric 
properties (reliability, content validity and hypothesis testing) in a range of paediatric 
chronic health conditions across childhood, and as the only subjective fatigue measure with 
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robust evidence for use in young children [14]. Additionally, the use of a generic 
instrument, the PedsQLTM MFS, enabled comparison of fatigue in children and adolescents 
with DMD with healthy children and other patient populations to better comprehend the 
severity of fatigue in paediatric DMD.  
The assessment of fatigue from both patients’ and parents’ perspectives is also 
considered to be strength of our study. A lack of agreement between child self-reported 
and parent proxy-reported fatigue previously observed in other paediatric chronic health 
conditions underscores the need to consider both patients’ and parents’ perspectives to 
characterize fatigue during childhood and adolescence [14]. Understanding how parents’ 
perspectives compare with patients’ perspectives of fatigue is particularly important in a 
clinical setting when a child is too young, too cognitively impaired or too ill to express 
health concerns to their practitioner.  
Our results should be interpreted considering several limitations. The cross-
sectional design of our study does not allow for temporality or causality to be established 
regarding the associations explored between patient characteristics and fatigue in children 
and adolescents with DMD. Additionally, a response rate of 36.8% and sample size of 71 
may have resulted in a lack of statistical power to detect associations between some clinical 
characteristics and fatigue. Although the Tailored Design Method was employed to 
maximize our response rate to questionnaires, we were unable to implement a key 
component of the Tailored Design Method due to privacy and confidentiality protocols of 
the CNDR: personalization of contacts with eligible patients [177]. Personalization of 
questionnaires and letters with a person’s name has been demonstrated to increase the 
response rate of mailed paper questionnaires [177,254]. Personalization can reduce the 
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social distance between the researcher and eligible patient, reduce the likelihood of a survey 
request being ignored using the rationale that others will respond, establish authenticity of 
the researcher and the study being conducted, and ultimately, establish trust between the 
researcher and eligible patient—all of which should increase the response rate [177]. 
However, the CNDR does not allow for identification of eligible patients or for 
investigators to contact eligible patients directly.  
 No differences in registry data were observed between participating and non-
participating patients, demonstrating that our sample was representative of children and 
adolescents with DMD registered in the CNDR with respect to clinical characteristics and 
geographical region. However, the CNDR only included patients from British Columbia, 
Albert, Ontario and Quebec, with Ontario contributing most patients to the registry. 
Therefore, it is unclear whether children and adolescents with DMD registered in the 
CNDR are representative of all children and adolescents with DMD across Canada, 
particularly in remote regions. This has important implications in the study of fatigue given 
the variations in clinical practices that exist across Canada for the screening and 
management of sleep disordered breathing in children and adolescents with DMD [73]. 
Moreover, it is unclear whether patients enrolled in the CNDR systematically differ from 
patients with DMD not enrolled in the CNDR with respect to clinical characteristics. 
Epidemiological data on DMD in Canada is limited. To our knowledge, no Canadian 
population-based descriptive studies on DMD have been published to allow for 
comparison. Selection bias may have been introduced if patients at a more severe disease 
stage were more likely to decline invitations to enroll in the CNDR. Nevertheless, the use 
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of the CNDR allowed for a more representative sample than would have been achieved 
through patient recruitment from our neuromuscular clinic only.  
In addition to discrepancies in care practices or clinical characteristics between 
patients enrolled in the CNDR and patients with DMD not enrolled in the CNDR, selection 
bias and non-response bias may have been introduced from behavioural, socioeconomic or 
cultural factors. For example, patients and parents who are more knowledgeable and 
vigilant about their health may be more motivated to enroll in the registry and participate 
in research studies. Similarly, higher educational attainment and income are associated 
with greater health literacy [255], which may ultimately result in greater motivation to 
enroll in the registry and participate in research studies. Factors that may prevent patients 
and parents from responding to questionnaires include difficulties reading and writing or 
cognitive impairment. Patients’ and parents’ past experiences in research studies, whether 
positive or negative, may have also influenced both enrollment in the registry and 
participation in the current study.  
An additional limitation associated with the CNDR is the possibility of outdated 
patient medical histories in the registry database. Most clinical data included in the registry 
were obtained from clinic visits between 2013 and 2016. However, the inclusion of a 
patient medical information section in the parent questionnaire allowed us to cross-
reference registry data and parent-reported data related to major disease milestones, such 
as loss of ambulation and initiation of NIV. Discrepancies between registry and parent-
reported ambulatory status and ventilatory status were observed for five and four 
participating patients, respectively.    
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 It is also possible that child self-report and parent proxy-report measures were 
subject to a degree of response bias, such as recall bias or social-desirability bias. In our 
study, fatigue was assessed over a one-month recall period, as previous research evaluating 
the accuracy of fatigue ratings across recall periods demonstrated that momentary 
assessments of fatigue were often more highly correlated with ratings from a one-month 
recall period compared with a seven-day recall period [256]. Given the difficulty of 
recalling many days, as in the case of a one-month recall period, patients with a chronic 
illness refer to beliefs based on their extensive experience with symptoms, which provide 
a reasonably accurate estimate of average symptom levels. When asked to construct a rating 
to represent the past seven days, patients may attempt to retrieve memories from the past 
week, which are subject to cognitive heuristics that give disproportionate weight to peak 
and most recent symptoms experienced, thereby decreasing accuracy [256]. Lastly, 
because questionnaires were not completed in a supervised setting, we cannot be certain 
that patients and parents independently completed their respective questionnaires, or that 
parents did not interpret questions or answers for their child if assistance was provided.  
 Due to similarities between the constructs of sleep disturbance symptoms and 
depressive symptoms, it is possible that the multivariable regression analyses conducted 
were affected by multicollinearity. Multicollinearity occurs when two or more independent 
variables in a multivariable regression model are moderately to highly correlated. 
Multicollinearity can reduce the precision of regression coefficient estimates, as 
demonstrated by large standard errors and wide confidence intervals, and consequently 
increase the risk of a type II error (failure to reject a false null hypothesis) [257]. 
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5.5 Implications of Findings and Future Directions  
 Our results have implications in both clinical and research settings. Our findings 
contribute to the limited literature on fatigue in a broader paediatric patient population of 
children and adolescents with neuromuscular disorders. We have identified fatigue to be a 
prominent issue in children and adolescents with DMD across disease stages, from both 
patients’ and parents’ perspectives. This finding emphasizes the need for healthcare 
providers to become more familiar with fatigue in children and adolescents with DMD and 
to engage in dialogue about fatigue with DMD patients and their caregivers. Regular 
assessment of fatigue at routine clinic visits may provide clinicians with insight about the 
onset and patterns of fatigue in relation to other clinical manifestations or changes in 
function, and aid in the identification of individualized therapeutic targets for fatigue. For 
example, an increase in fatigue may be observed around the time of transition into 
wheelchair use, as affected boys struggle to maintain independent ambulation. To reduce 
fatigue, clinicians may encourage more flexible wheelchair use by focusing on the potential 
benefit of improved fatigue, and aim to shift patient and parent attitudes about the negative 
milestone of wheelchair use by emphasizing wheelchair use as a rehabilitative practice for 
improving mobility, rather than a loss of independence [258].  
We developed a conceptual model of factors associated with fatigue in paediatric 
DMD, and tested the associations between factors included in the model and fatigue. In 
doing so, we have identified several factors that may be associated with fatigue in 
paediatric DMD, which warrant further investigation. Although causal conclusions cannot 
be made regarding the associations of sleep disturbance symptoms, depressive symptoms, 
physical activity level, functional ability and clinical characteristics with fatigue, our study 
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serves as a hypothesis-generating starting point in this novel area of research in paediatric 
DMD. Our results identified sleep disturbance symptoms, depressive symptoms and 
functional ability as potentially modifiable risk factors associated with fatigue, warranting 
further attention in clinical settings and in future research aimed at developing evidence-
based interventions for the management of fatigue in paediatric DMD. Studies evaluating 
interventions for the treatment of fatigue in paediatric patient populations are limited and 
have primarily been conducted in paediatric chronic fatigue syndrome or cancer 
populations. CBT may be worth exploring as a therapy for fatigue in children and 
adolescents with DMD as it can simultaneously target fatigue, sleep disturbance symptoms 
and depressive symptoms. Moreover, it has demonstrated promising effects on fatigue in 
adult neuromuscular disorders and paediatric chronic fatigue syndrome [143,233–236]. 
In designing and conducting our study, we have identified several methodological 
challenges of studying fatigue and factors associated with fatigue in children and 
adolescents with DMD. Here, we provide insights on how these obstacles can be addressed 
or ameliorated in future studies. Although registries are intended to be representative of 
certain patient populations and reflective of the clinical practices of healthcare providers 
in certain geographical regions, registries are often associated with challenges, such as 
difficulties with patient recruitment and retention, that can have profound consequences on 
the validity of registry data [259]. The representativeness of our sample to our target 
population of children and adolescents across Canada may have been improved with the 
recruitment of additional neuromuscular clinics to the CNDR. At the registry level, 
providing innovative nonfinancial incentives that meet the needs of decision-makers at 
potential recruitment sites has been demonstrated to increase patient enrollment and 
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subsequently improve the validity and generalizability of research facilitated through 
registries [259].   
 Additional large-scale prospective cohort studies are required to characterize the 
trajectory of fatigue in paediatric DMD and to determine causal relationships of sleep 
disturbance symptoms, depressive symptoms, physical activity level, functional ability and 
clinical characteristics with fatigue. In our study, sleep disturbance symptoms and 
depressive symptoms were identified as potentially modifiable factors associated with 
fatigue in children and adolescents with DMD, as these symptoms may be overlooked in 
the routine management of DMD. Child self-report and parent proxy-report symptom-
based measures are easy to administer, and are associated with low participation burden. 
However, measures of sleep disturbance symptoms and depressive symptoms provide 
limited information on the associations of formal diagnoses of sleep disturbances and 
depression with fatigue. To further understand these relationships, polysomnographic data 
and psychiatric evaluations conducted by clinicians are required in future studies.  
 In the early research of cancer-related fatigue, many qualitative studies were 
conducted to better comprehend the complex, multi-causal and multidimensional 
subjective experience of fatigue [260–263]. A qualitative study of fatigue in children and 
adolescents with DMD can provide unprecedented insight on the origin, severity, patterns 
and impact of fatigue. Moreover, qualitative interviews with DMD patients and their 
parents may facilitate our understanding of similarities and differences of how patients and 
their parents define and perceive fatigue. A qualitative study of fatigue in children and 
adolescents with DMD may also facilitate the identification of additional factors, and 
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potential therapeutic targets, associated with fatigue that were not included in our proposed 
model.   
5.6 Conclusions  
 This is the first study to comprehensively describe fatigue in children and 
adolescents with DMD from patients’ and parents’ perspectives, and to explore 
associations of patient characteristics with fatigue in this population. Children and 
adolescents with DMD experienced greater fatigue compared with their healthy peers, and 
experience comparable levels of fatigue as children and adolescents with cancer, across all 
disease stages from both patients’ and parents’ perspectives. Our findings underscore 
fatigue as a prominent issue in paediatric DMD, which may be overlooked in the current 
management of children and adolescents with DMD because of the lack of literature 
describing the presentation and implications of fatigue in this population. Greater sleep 
disturbance symptoms were associated with greater fatigue from patients’ and parents’ 
perspectives. Sleep disturbance symptoms may be overlooked in the management of 
children and adolescents with DMD [71], and therefore warrant further investigation as a 
potentially modifiable risk factor for fatigue in this population. Moreover, greater 
depressive symptoms were associated with greater fatigue from patients’ and parents’ 
perspectives, and lower functional ability was associated with greater fatigue from parents’ 
perspective. Additional large-scale prospective cohort studies are required to establish 
causality between these patient characteristics and fatigue in children and adolescents with 
DMD, to facilitate the development of targeted therapeutic strategies to effectively reduce 
fatigue and subsequently improve health-related quality of life.  
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Appendices 
Appendix A: Literature Review Search Strategy Terminology and Syntax 
 
Table A.1. Database-specific terminology and syntax used in literature search strategy   
Concept MEDLINE  EMBASE CINAHL PsychINFO Keywords 
Muscular 
Dystrophies/Spinal 
Muscular Atrophy 
exp 
Muscular 
dystrophies/ 
or exp 
Muscular 
atrophy, 
spinal/  
 
muscular dystrophy/ 
or becker muscular 
dystrophy/ or 
duchenne muscular 
dystrophy/ or 
dystrophinopathy/ or 
emery dreifuss 
muscular dystrophy/ 
or 
facioscapulohumeral 
muscular dystrophy/ 
or limb girdle 
muscular dystrophy/ 
or progressive 
muscular dystrophy/ 
or exp spinal 
muscular atrophy/ 
(MH 
“Muscular 
Dystrophy”) 
or or (MH 
“Muscular 
Dystrophy, 
Duchenne+”) 
or (MH 
“Muscular 
Atrophy, 
Spinal+”) 
SU.EXACT(“Muscular 
Dystrophy”) or 
SU.EXACT(“Muscular 
Disorders”) 
Muscular dystroph* 
or dystrophinopath* 
or duchenne muscular 
dystrophy or becker 
muscular dystrophy or 
emery dreifuss 
muscular dystrophy or 
facioscapulohumeral 
muscular dystrophy or 
limb girdle muscular 
dystrophy or spinal 
muscular atrophy or 
spinal muscle atrophy 
Fatigue exp fatigue/  fatigue/ (MH “Mental 
Fatigue”) OR 
(MH 
“Fatigue”) 
SU.EXACT(“Fatigue”) Fatigue or fatigability 
or tired*  
Search Limits - Full text  
Human  
English Language  
- - - 
Total Citations  404 356 47 209 1,016 
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Appendix B: Literature Review Study Selection 
 
 
Figure B.1. Flowchart of study selection for literature review 
  
  
153 
Appendix C: Research Ethics Board Approval Notice 
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Appendix D: Canadian Neuromuscular Disease Registry Affiliate Clinics 
 
Table D.1. Current and former paediatric neuromuscular clinics participating in the 
Canadian Neuromuscular Disease Registry 
City Clinical Sites Academic Affiliation 
Current 
Vancouver, BC  British Columbia Children’s 
Hospital  
University of British 
Columbia  
Calgary, AB  Alberta Children’s Hospital  University of Calgary  
Toronto, ON Holland Bloorview Kids 
Rehabilitation Hospital  
University of Toronto 
London, ON Thames Valley Children’s Centre  Western University  
Ottawa, ON Children’s Hospital of Eastern 
Ontario  
University of Ottawa  
Kingston, ON Child Development Centre, Hotel 
Dieu Hospital  
Queen’s University  
Montreal, QC Montreal Children’s Hospital  McGill University  
Halifax, NS IWK Health Centre  Dalhousie University 
Former 
Mississauga, 
ON 
ErinoakKids Centre for Treatment 
and Development  
McMaster University  
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Appendix E: Letter of Information 
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Appendix F: Assent Letter 
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Appendix G: Thank-You Postcard 
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Appendix H: Follow-up Reminder Letter 
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Appendix I: PedsQLTM Multidimensional Fatigue Scale (Child Self-Report) 
 
In the past ONE month, how much of a problem has this been for you… 
 
GENERAL FATIGUE  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. I feel tired 0 1 2 3 4 
2. I feel physically weak (not strong) 0 1 2 3 4 
3. I feel too tired to do things that I like to do 0 1 2 3 4 
4. I feel too tired to spend time with my friends 0 1 2 3 4 
5. I have trouble finishing things 0 1 2 3 4 
6. I have trouble starting things 0 1 2 3 4 
 
SLEEP/REST FATIGUE  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. I sleep a lot 0 1 2 3 4 
2. It is hard for me to sleep through the night 0 1 2 3 4 
3. I feel tired when I wake up in the morning 0 1 2 3 4 
4. I rest a lot 0 1 2 3 4 
5. I take a lot of naps 0 1 2 3 4 
6. I spend a lot of time in bed 0 1 2 3 4 
 
COGNITIVE FATIGUE  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1. It is hard for me to keep my attention on 
things 
0 1 2 3 4 
2. It is hard for me to remember what people 
tell me 
0 1 2 3 4 
3. It is hard for me to remember what I just 
heard 
0 1 2 3 4 
4. It is hard for me to think quickly 0 1 2 3 4 
5. I have trouble remembering what I was just 
thinking 
0 1 2 3 4 
6. I have trouble remembering more than one 
thing at a time 
0 1 2 3 4 
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Appendix J: PedsQLTM Multidimensional Fatigue Scale (Parent Proxy-Report) 
 
In the past ONE month, how much of a problem has this been for your child… 
 
GENERAL FATIGUE  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
7. Feeling tired 0 1 2 3 4 
8. Feeling physically weak (not strong) 0 1 2 3 4 
9. Feeling too tired to do things that he/she 
likes to do 
0 1 2 3 4 
10. Feeling too tired to spend time with his/her 
friends 
0 1 2 3 4 
11. Trouble finishing things 0 1 2 3 4 
12. Trouble starting things 0 1 2 3 4 
  
SLEEP/REST FATIGUE  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
7. Sleeping a lot 0 1 2 3 4 
8. Difficulty sleeping through the night 0 1 2 3 4 
9. Feeling tired when he/she wakes up in the 
morning 
0 1 2 3 4 
10. Resting a lot 0 1 2 3 4 
11. Taking a lot of naps 0 1 2 3 4 
12. Spending a lot of time in bed 0 1 2 3 4 
  
COGNITIVE FATIGUE  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
7. Difficulty keeping his/her attention on things 0 1 2 3 4 
8. Difficulty remembering what people tell 
him/her 
0 1 2 3 4 
9. Difficulty remembering what he/she just 
heard 
0 1 2 3 4 
10. Difficulty thinking quickly 0 1 2 3 4 
11. Trouble remembering what he/she was just 
thinking 
0 1 2 3 4 
12. Trouble remembering more than one thing 
at a time 
0 1 2 3 4 
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Appendix K: Physical Activity Questionnaire for Children 
 
We are trying to find out about your level of physical activity from THE LAST 7 DAYS (IN THE 
LAST WEEK). This includes sports or dance that make you sweat or make your legs or arms feel 
tired, or games that make you breathe hard, like tag, skipping, running, climbing, and others.  
 
We understand that the mobility and strength of children with Duchenne muscular dystrophy may 
be limited and may prevent you from participating in physical activities to the same extent as your 
peers. However, we are interested in any and all activities that you consider to be physically active. 
 
Remember:  
1. There are no right and wrong answers—this is not a test 
2. Please answer all the questions as honestly and accurately as you can—this is very 
important. 
 
 
1. Physical activity in your spare time: Have you done any of the following activities in the past 7 
days (last week)? If yes, how many times? (Check only one box per row.) 
 No 1–2 3–4 5–6 
7 times 
or more 
Skipping      
Rowing/canoeing      
In-line skating      
Tag      
Walking for exercise      
Bicycling      
Jogging or running      
Aerobics      
Swimming      
Baseball, softball      
Dance      
Football      
Badminton      
Skateboarding      
Soccer      
Street hockey      
Basketball      
Ice skating      
Cross-country skiing      
Ice hockey/ringette      
Other:      
____________________      
____________________      
 
2. In the last 7 days, during your physical education (PE) classes, how often were you very active 
(playing hard, running, jumping, throwing)? (Check one only.)  
 I don’t do PE 
 Hardly ever 
 Sometimes 
 Quite often 
 Always 
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3. In the last 7 days, what did you do most of the time at recess? (Check one only.)  
 Sat down (talking, reading, doing schoolwork) 
 Stood around or walked around 
 Ran or played a little bit 
 Ran around or played quite a bit 
 Ran or played hard most of the time 
 
4. In the last 7 days, what did you normally do at lunch (besides eating lunch)? (Check one only.)  
 Sat down (talking, reading, doing schoolwork) 
 Stood around or walked around 
 Ran or played a little bit 
 Ran around or played quite a bit 
 Ran or played hard most of the time 
 
5. In the last 7 days, on how many days right after school, did you do sports, dance, or play games 
in which you were very active? (Check one only.)  
 None 
 1 time last week 
 2 or 3 times last week 
 4 times last week 
 5 times last week 
 
6. In the last 7 days, on how many evenings did you do sports, dance, or play games in which you 
were very active? (Check one only.)  
 None 
 1 time last week 
 2 or 3 times last week 
 4 or 5 times last week 
 6 or 7 times last week 
 
7. On the last weekend, how many times did you do sports, dance, or play games in which you 
were very active? (Check one only.) 
 None 
 1 time  
 2 or 3 times  
 4 or 5 times  
 6 or more times  
8. Which one of the following describes you best for the last 7 days? Read all five statements before 
deciding on the one answer that describes you.  
   
 
All or most of free time was spent doing things that involve little physical 
effort 
 
I sometimes (1–2 times last week) did physical things in my free time 
(e.g. played sports, went running, swimming, bike riding, did aerobics) 
 I often (3–4 times last week) did physical things in my free time 
 I quite often (5–6 times last week) did physical things in my free time 
 
I very often (7 or more times last week) did physical things in my free 
time 
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9. Mark how often you did physical activity (like playing sports, games, doing dance, or any other 
physical activity) for each day last week.  
 None Little bit Medium Often 
Very 
often 
Monday      
Tuesday      
Wednesday      
Thursday      
Friday      
Saturday      
Sunday      
 
10. Were you sick last week, or did anything prevent you from doing your normal physical activities? 
(Check one.)  
 No  
 Yes 
 
If yes, please specify in the box below: 
 
 
 
  
 
 
11. Think about the past 7 days (last week) in comparison to other usual weeks. Were you more 
physically activity last week than you normally would be in a typical week? 
 No 
 Yes 
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Appendix L: Duchenne Muscular Dystrophy Functional Ability Self-Assessment 
Tool 
 
Please complete this section with your child. The questions below describe levels of activity for 
arm function, mobility, transfers, and need for ventilatory support. The activities are intended to be 
in order of difficulty and we would like you to check the box that best applies to your child’s current 
level of function.  
 
Question 1: Arm function Select one 
Can put an item, such as a book, onto a shelf above shoulder height  
Can eat a meal without any help  
Needs help to cut up food, but can feed and drink independently  
Needs help to drink or feed self  
Can pick objects up e.g. pen/money  
Can move fingers e.g. press on mobile or other electronic device  
Cannot move fingers  
 
Question 2: Mobility Select one 
Walks independently long distances outdoors (more than 1 km)  
Walks independently medium distances outdoors (less than 1 km)  
Walks outdoors for short distances e.g. to car with or without help from a person  
Walks indoors with or without help from a person, but requires wheelchair for 
outdoors 
 
Uses wheelchair indoors and outdoors  
Uses wheelchair indoors and outdoors, but unable in some situations e.g. cold 
weather or unable to control wheelchair without help 
 
 
Question 3 to 7: Transfers 
Can do 
independently 
Can do 
with help 
Needs to be lifted or 
hoisted or cannot 
Get on and off the floor    
Get in and out of a chair    
Get in and out of bed    
Get on and off the toilet    
Go up and down stairs    
 
Question 8: Ventilatory support Not ventilated 
Ventilated 
at night 
Ventilated during day 
and night 
Ventilatory status    
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Appendix M: Center for Epidemiological Studies Depressive Scale for Children 
 
INSTRUCTIONS: Below is a list of the ways you might have felt or acted. Please check how much 
you have felt this way during the past week. 
 
DURING THE PAST WEEK 
Not At 
All 
A 
Little 
Some A Lot 
1. I was bothered by things that usually don’t bother me.     
2. I did not feel like eating, I wasn’t very hungry.     
3. I wasn’t able to feel happy, even when my family or 
friends tried to help me feel better. 
    
4. I felt like I was just as good as other kids.     
5. I felt like I couldn’t pay attention to what I was doing.     
  
DURING THE PAST WEEK 
Not At 
All 
A 
Little 
Some A Lot 
6. I felt down and unhappy.     
7. I felt like I was too tired to do things.     
8. I felt like something good was going to happen.     
9. I felt like things I did before didn’t work out right.     
10. I felt scared.     
 
DURING THE PAST WEEK 
Not At 
All 
A 
Little 
Some A Lot 
11. I didn’t sleep as well as I usually sleep.     
12. I was happy.     
13. I was more quiet than usual.     
14. I felt lonely, like I didn’t have any friends.     
15. I felt like kids I know were not friendly or that they 
didn’t want to be with me.  
    
 
DURING THE PAST WEEK 
Not At 
All 
A 
Little 
Some A Lot 
16. I had a good time.      
17. I felt like crying.     
18. I felt sad.     
19. I felt people didn’t like me.     
20. It was hard to get started doing things.     
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Appendix N: Sleep Disturbance Scale for Children 
 
INSTRUCTIONS: This questionnaire will allow to your doctor to have a better understanding of the 
sleep-wake rhythm of your child and of any problems in his/her sleep behavior. Try to answer 
every question; in answering, consider each question as pertaining to the past 6 months of the 
child’s life. Please answer the questions by circling the number 1 to 5. Thank you very much for 
your help. 
 
1. How many hours of sleep 
does your child get on most 
nights? 
1 
9-11 hrs 
2 
8-9 hrs 
3 
7-8 hrs 
4 
5-7 hrs 
5 
Less than 
5 hrs 
2. How long after going to bed 
does your child usually fall 
asleep? 
1 
Less than 
15 min 
2 
15-30 min 
3 
30-45 min 
4 
45-60 min 
5 
More than 
60 min 
 
5 Always (daily) 
4 Often (3 or 5 times per week)  
3 Sometimes (once or twice per week)   
2 Occasionally (once or twice per month or less)    
1 Never     
3. The child goes to bed reluctantly 1 2 3 4 5 
4. The child has difficulty getting to sleep at night 1 2 3 4 5 
5. The child feels anxious or afraid when falling asleep 1 2 3 4 5 
6. The child startles or jerks parts of the body while falling asleep 1 2 3 4 5 
7. The child shows repetitive actions such as rocking or head banging while 
falling asleep 
1 2 3 4 5 
8. The child experiences vivid dream-like scenes while falling asleep 1 2 3 4 5 
9. The child sweats excessively while falling asleep 1 2 3 4 5 
10. The child wakes up more than twice per night 1 2 3 4 5 
11. After waking up in the night, the child has difficulty to fall asleep again 1 2 3 4 5 
12. The child has frequent twitching or jerking of legs while asleep or often 
changes position during the night or kicks the covers off the bed. 
1 2 3 4 5 
13. The child has difficulty in breathing during the night 1 2 3 4 5 
14. The child gasps for breath or is unable to breathe during sleep 1 2 3 4 5 
15. The child snores 1 2 3 4 5 
16. The child sweats excessively during the night 1 2 3 4 5 
17. You have observed the child sleepwalking 1 2 3 4 5 
18. You have observed the child talking in his/her sleep 1 2 3 4 5 
19. The child grinds teeth during sleep 1 2 3 4 5 
20. The child wakes from sleep screaming or confused so that you cannot 
seem to get through to him/her, but has no memory of these events the 
next morning 
1 2 3 4 5 
21. The child has nightmares which he/she doesn’t remember the next day 1 2 3 4 5 
22. The child is unusually difficult to wake up in the morning 1 2 3 4 5 
23. The child awakes in the morning feeling tired 1 2 3 4 5 
24. The child feels unable to move when waking up in the morning 1 2 3 4 5 
25. The child experiences daytime somnolence 1 2 3 4 5 
26. The child falls asleep suddenly in inappropriate situations 1 2 3 4 5 
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Appendix O: Patient Medical Information Section 
 
We would like to ask you a few questions ask about some other health experiences your child 
may have had. 
 
1. Has your child ever been formally diagnosed with any of the following developmental 
disorders? 
 
 
No Yes 
Developmental Delay   
A Learning Disability   
Attention Deficit Disorder (ADD) or Attention Deficient Hyperactivity Disorder 
(ADHD) 
  
Autism, Pervasive Developmental Disorder (PDD) or Asperger’s Syndrome   
Oppositional Defiant Disorder   
Conduct Disorder   
Depression   
Anxiety     
 
2. Does your child have any of the following health conditions? 
 No Yes 
Asthma   
Cystic Fibrosis   
Diabetes   
Cerebral Palsy   
Epilepsy   
Cancer   
Any other long-term health conditions. Please specify:   
 
 
  
 
3. For each of the following, please provide 2 answers. Whether your child has a) ever needed 
and b) ever received: 
 a) Ever 
Needed 
b) Ever 
Received 
No Yes No Yes 
Extra help with schoolwork (e.g. tutoring, working with a special 
education resource teacher, having an Individualized Educational 
Program). Please specify: 
 
 
    
Placement in a special class for children with learning difficulties.     
Speech-language therapy     
Occupational therapy     
Medication or therapy for behaviour problems. Please specify: 
 
 
    
Medication or therapy for emotional problems (e.g. depression). 
Please specify: 
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4. Is your child currently involved in any clinical trials or other research studies for his Duchenne 
muscular dystrophy? 
 No 
 Yes 
 
5. Is your child able to walk?  
 No                       
 Yes 
 
If no, when did your child stop walking? 
 Less than 1 year ago                      
 More than 1 year ago 
 
6. Have there been any major changes in your child’s health within the last year (e.g. major 
illness, hospitalization, etc.)?  
 No  
 Yes 
 
If yes, please specify in the box below: 
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Appendix P: Sociodemographic Information Section 
1. Are you:  
 Male 
 Female 
 
2. Who currently lives with your child? Please do not use any people’s names when completing 
the table below:  
 
Person 
Their relationship to your child (e.g. Mom, Dad, 
brother, sister, grandparent, aunt, uncle, friend, 
roommate, partner/spouse)  
Their 
Age 
Their Sex 
1 
 
 
 
 Male  Female 
2 
 
 
 
 Male  Female 
3 
 
 
 
 Male  Female 
4 
 
 
 
 Male  Female 
5 
 
 
 
 Male  Female 
6 
 
 
 
 Male  Female 
7 
 
 
 
 Male  Female 
8 
 
 
 
 Male  Female 
 
3. Which of the following best describes your current work status? Check one box only. 
 
      
Not working 
due to my 
child’s health 
Not working 
for “other” 
reasons 
Looking for 
work outside 
the home 
Working full- 
or part-time 
(either 
outside the 
home or at a 
home-based 
business) 
Full time 
homemaker 
Student 
 
4. What is your relationship to this child? Check one box only. 
 
      
Biological 
parent 
Step parent Foster parent Adoptive 
parent 
Guardian Other (please 
explain on 
the line 
below) 
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5. What is the highest grade of school you have completed?  
 Less than 8 years 
 8 to 12 years 
 Completed high school 
 Completed vocational/technical training 
 Completed college/university 
 Completed graduate school 
 Prefer not to disclose 
 
6. What is your age?  
 
7. What is your current marital status? Check one box only.  
 
      
Married Widowed Divorced Separated Remarried Never 
married 
 
8. Are you currently living with a spouse or partner?  
 No  If no, skip to question 11.    
 Yes 
 
If yes, proceed to question 9. 
 
9. Which of the following best describes your spouse’s/partner’s current work status? Check one 
box only. 
 
      
Not working 
due to my 
child’s health 
Not working 
for “other” 
reasons 
Looking for 
work outside 
the home 
Working full- 
or part-time 
(either 
outside the 
home or at a 
home-based 
business) 
Full time 
homemaker 
Student 
 
10. What is the highest grade of school your spouse/partner has completed?  
 Less than 8 years 
 8 to 12 years 
 Completed high school 
 Completed vocational/technical training 
 Completed college/university 
 Completed graduate school 
 Prefer not to disclose 
 
 
 
 
  
172 
11. In which category is your total yearly household income before taxes? Check one box only.  
 Less than $5,000 
 $5,000 to $9,999 
 $10,000 to $14,999 
 $15,000 to $19,999 
 $20,000 to $24,999 
 $25,000 to $ 34,999 
 $35,000 to $49,999 
 $50,000 to $74,999 
 $75,000 to $99,999 
 $100,000 to $149,999 
 $150,000 to $200,000 
 Over $200,000 
 I don’t know 
 
12. Thinking about your total family income, from which sources did your family receive income 
during the past year? Check all that apply. 
 Wages and salaries 
 Income from self-employment 
 Family allowance (baby bonus) 
 Unemployment insurance or strike pay 
 Worker’s compensation 
 
Old Age Security, Guaranteed Income Supplement, Canada or Quebec 
Pension Plan, Retirement Pension Plan, Superannuation 
 Dividends and interest on bonds, deposits and saving certificates  
 Other government sources such as welfare, mother’s allowance, etc. 
 Other source(s). Please specify: ___________________________ 
 Prefer not to disclose 
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